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Abstract 
Enteropathogenic (EPEC) and enterohaemorrhagic (EHEC) Escherichia coli cause severe 
disease with symptoms ranging from mild diarrhoea to haemolytic uremic syndrome. During 
infection of the gut, these bacteria provoke attaching and effacing lesions (A/E lesions), 
characterised by intimate bacterial attachment and effacement of microvilli from the surface 
of enterocytes. A type III secretion system (T3SS), encoded by the locus of enterocyte 
effacement (LEE), allows EPEC and EHEC to inject more than twenty effector proteins into 
the host cell cytoplasm and to manipulate a large number of cellular processes. 
The non-LEE encoded effector proteins EspI and NleH1 are involved in inhibition of 
vesicular transport and apoptosis, respectively. The effector protein Map induces filopodia 
formation by activating the Rho GTPase Cdc42. Persistence of filopodia on the host cell 
surface depends on the interaction of Map with Na
+
/H
+
 Exchanger Regulatory Factor 1 
(NHERF1) and activation of RhoA. NHERF proteins are PDZ domain-containing proteins 
involved in addressing, recycling and regulating numerous proteins such as ion channels in 
epithelial cells. 
Using a PDZ proteomic array and biochemical interaction assays, we confirmed that Map and 
EspI interact with both NHERF1 and NHERF2 through their C-terminal PDZ binding motifs. 
In addition, we identified NleH1 as a new binding partner of NHERF2. Employing a newly 
generated HeLa-NHERF2 stable cell line, we found that overexpression of NHERF2 in HeLa 
cells affected distribution and function of these three effectors: the transit of EspI from the 
bacterial attachment site to the Golgi apparatus was accelerated; Map-dependent filopodia 
during EPEC infection were stabilised and NleH1-mediated inhibition of apoptosis was 
reduced. 
The investigation of NHERF recruitment by diarrhoeagenic E. coli showed that EPEC, EHEC 
and Citrobacter rodentium, the mouse model for EPEC and EHEC, recruited NHERF1 and 
NHERF2 at the site of bacterial adherence. We revealed that both EPEC and EHEC could 
recruit NHERF2 by a mechanism which required the T3SS translocated intimin receptor (Tir), 
but did not involve Tir-induced actin polymerisation pathways. Furthermore, EPEC recruited 
NHERF2 by a T3SS-independent mechanism which, in contrast to the T3SS-dependent 
pathway, relied on the NHERF2 ezrin-binding domain (EBD). 
This work demonstrates that NHERF proteins are recruited by several diarrhoeagenic 
Escherichia coli and are able to modulate function of at least three effector proteins from A/E 
pathogens. The data strongly points to a model in which NHERFs act as central hubs 
regulating the temporal and spatial localisation and function of effector proteins in the host 
cell and indicates that they might play an essential role in the process of intestinal epithelium 
colonisation by these pathogens. 
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1. Introduction 
1.1. Diarrhoeagenic Escherichia coli 
1.1.1. Classification 
1.1.1.1. Escherichia coli-associated diarrhoea 
Escherichia coli are facultative anaerobe Gram-negative bacteria which belong to the 
Enterobacteriaceae family and are present among the commensal flora of the human gut 
(Nataro and Kaper, 1998). The human intestine is the site of digestion and transport of 
nutrients, water and electrolyte exchange as well as hormone production. It also defines a 
physical barrier between the host and the external environment (Sansonetti, 2004). Most of 
the bacterial species living in the intestine are commensals: they colonise their host and elicit 
an immune response without provoking any damage (Casadevall and Pirofski, 2000). The 
human immune system tightly regulates the bacterial load in the gut, resulting in a state of 
microbial tolerance (Sansonetti, 2004). However, pathogenic Enterobacteriaceae, such as 
Salmonella and Escherichia coli strains, are able to rupture and cause inflammatory 
destruction of the intestinal epithelia (Sansonetti, 2004; Nataro and Kaper, 1998). These 
pathogens developed mechanisms to outcompete the commensals, colonise the human gut and 
provoke clinical symptoms ranging from mild diarrhoea to severe gastroenteritis, 
haemorrhagic colitis and potentially fatal haemolytic uremic syndrome (HUS) (Ohl and 
Miller, 2001; Nataro and Kaper, 1998). 
Infectious diarrhoea is one of the most common causes of death worldwide and affects mainly 
infants in developing countries (Lopez et al., 2006). The origin of diarrhoea comes from an 
imbalance of absorption and secretion of ions which provokes water accumulation in the gut. 
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Repetitive episodes of diarrhoea are responsible for major developmental disabilities such as 
reduced growth and fitness impairment (Petri et al., 2008). Even though diarrhoea could be 
considered as a host defence mechanism, enteric pathogens benefit from diarrhoea in the way 
that it increases their dissemination into the environment (Viswanathan et al., 2009). 
Diarrhoeagenic Escherichia coli species are commonly classified into six patho-groups: 
diffuse adherent (DAEC), enteroaggregative (EAEC), enterotoxigenic (ETEC), 
enteropathogenic (EPEC), enterohaemorrhagic (EHEC) and enteroinvasive (EIEC) (Nataro 
and Kaper, 1998). 
 
1.1.1.2. Enteropathogenic Escherichia coli 
Enteropathogenic Escherichia coli (EPEC), which colonise the human small intestine while 
remaining extracellular, are a major threat for infants in the developing world (Chen and 
Frankel, 2005). EPEC strains are classified into two sub-categories: typical EPEC, which 
carries the chromosomic locus of enterocyte effacement (LEE) and the EPEC adherence 
factor (EAF) plasmid, and atypical EPEC, which carries the LEE but lacks the EAF plasmid 
(Trabulsi et al., 2002). Typical EPEC strains are further divided into two evolutionary 
lineages known as EPEC 1 and EPEC 2 that differ by their flagellar serotype and adhesin 
intimin subtype (Adu-Bobie et al., 1998; Whittam et al., 1993; Orskov et al., 1990); the 
prototypical EPEC strain E2348/69 belongs to the EPEC 1 lineage (Lacher et al., 2007). 
Initial adhesion of typical EPEC to cultured intestinal epithelial cells is mainly mediated 
through the type IV bundle-forming pilus (BFP) encoded by the EAF plasmid (Giron et al., 
1991; Baldini et al., 1983) while atypical EPEC strains possess several adherence factors 
distinct from BFP (Hernandes et al., 2006). Binding of the outer-membrane adhesin intimin to 
β1 integrins (Frankel et al., 1996b) and nucleolin (Sinclair and O'Brien, 2002) might also 
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participate in the initial bacteria-host interaction. The BFP fimbriae also provoke 
autoaggregation of typical EPEC leading to the formation of microcolonies and localised 
adherence (LA) on cultured epithelial cells (Tobe and Sasakawa, 2001; Knutton et al., 1999; 
Giron et al., 1991). 
EPEC pathogenesis leads to the formation of attaching and effacing (A/E) lesions 
(Donnenberg and Kaper, 1992; Knutton et al., 1989) which are characterised by intimate 
attachment of EPEC to the surface of enterocytes and effacement of microvilli from their 
surface (Figure 1.1). The genes required for A/E lesion formation are carried on a 
chromosomic 35-kb pathogenicity island called the locus of enterocyte effacement (LEE) 
(McDaniel and Kaper, 1997). The LEE comprises of 41 open-reading frames, and is divided 
into 5 polycistronic regions (LEE1 to 5) (Garmendia et al., 2005). Importantly, the LEE 
encodes the genes required to assemble a type 3 secretion system (T3SS) (Elliott et al., 1998). 
For clarity, the structure and function of this complex will be further described in chapter 
1.1.3.1. In addition to the structural T3SS components, the LEE encodes regulator proteins 
(Ler, GrlR and GrlA), chaperones (CesAB, CesD, CesD2, CesF and CesT), secreted 
translocator proteins (EspA, EspB and EspD), the adhesin intimin, the translocated intimin 
receptor (Tir) and effector proteins (Map, EspF, EspG, EspH and SepZ) (Garmendia et al., 
2005; Goosney et al., 1999; Elliott et al., 1998). Intimate attachment of EPEC to the plasma 
membrane of the host cell is followed by the formation of an actin-rich structure called a 
pedestal (Rosenshine et al., 1996). 
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Figure 1.1: Electron micrograph of human enterocytes infected with EPEC E2348/69 
EPEC intimately adhere to the surface of enterocytes, inducing actin accumulation underneath 
adherent bacteria (arrows) and effacement of microvilli. E: EPEC, MV: microvilli. 
Adapted from Knutton et al., 1987. 
 
1.1.1.3. Enterohaemorragic Escherichia coli 
Enterohaemorrhagic Escherichia coli (EHEC) are thought to colonise the large human 
intestine and are the causative agent of severe food-related gastroenteritis in developed 
countries (Nataro and Kaper, 1998). EHEC are commensal bacteria in cattle and other 
ruminants and can contaminate humans through ingestion of undercooked meat or food 
contaminated with bovine faeces (Yoon and Hovde, 2008; Robinson et al., 2006). Most 
outbreaks are due to serotype O157:H7, although serogroups O26, O111 and O145 are also 
prevalent (Frankel and Phillips, 2008). EHEC infection can cause symptoms ranging from 
mild diarrhoea to life-threatening haemorrhagic colitis and haemolytic uremic syndrome 
(HUS) (Paton and Paton, 1998). The main virulence factors of EHEC are the phage-encoded 
cytotoxins Stx1 and Stx2 (Nataro and Kaper, 1998).The toxins share high homology with the 
Shiga toxin from Shigella dysenteriae and possess an N-glycosidase activity that triggers 
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inhibition of protein synthesis in host cells (Sandvig, 2001). Initial adherence of EHEC to the 
human large bowel is mediated by a large number of fimbriae, the plasmid encoded ToxB and 
the outer membrane protein OmpA (Xicohtencatl-Cortes et al., 2007; Low et al., 2006; Torres 
and Kaper, 2003; Tatsuno et al., 2001). Interaction between the adhesin intimin and nucleolin 
has also been suggested to participate in adherence of EHEC O157:H7 to cultured cells 
(Sinclair and O'Brien, 2002). 
Similar to EPEC, EHEC also belong to the family of A/E pathogens and adhere intimately to 
enterocytes, forming actin-rich pedestals underneath attached bacteria (Frankel et al., 1998). 
Even though LEEs from EHEC and EPEC share the same organisation, the expression of their 
genes are differently regulated (Mellies et al., 1999). In contrast to the EPEC LEE, 
introduction of the EHEC LEE in the laboratory strain K12 does not confer an ability to 
provoke actin polymerisation in cultured cells (Elliott et al., 1999). The different pathways 
used by these pathogens to form pedestals will be discussed in chapter 1.1.3.3. 
 
1.1.1.4. Diffuse adherent Escherichia coli 
The role of diffuse adherent Escherichia coli (DAEC) in diarrhoea is still controversial 
(Knutton et al., 2001; Forestier et al., 1996). Diffuse adherent E. coli are characterised by 
diffuse adherence (DA) to Hep2 and HeLa cells (Cravioto et al., 1991). DAEC can be 
classified in two categories. The first, DAEC1, is closely related to enteroaggregative 
Escherichia coli (EAEC) and expresses afimbrial, fimbrial and nonfimbrial adhesins (Servin, 
2005). DAEC1 strains have been shown to trigger microvilli elongation, actin disassembly, 
and provoke cellular projections around adhering bacteria on cultured Caco2 cells (Peiffer et 
al., 2000; Peiffer et al., 1998; Bernet-Camard et al., 1996). In this in vitro model, tight 
adhesion of DAEC1 strains, and formation of cellular projections around bacteria, have been 
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shown to be elicited by the interactions between Afa/Dr and F1845 adhesins with decay-
accelerating factor (DAF) CD55 and carcinoembryogenic antigen CD66e (Korotkova et al., 
2008; Korotkova et al., 2006; Berger et al., 2004; Guignot et al., 2000). Belonging to the 
DAEC1 family, prototypical intestinal C1845 and urinary tract-colonising IH11128 strains do 
not possess a T3SS (Servin, 2005). The second class of DAEC, DAEC2, expresses an adhesin 
(AIDA-I) involved in diffuse adherence (Benz and Schmidt, 1989). These strains secrete 
proteins closely related to EPEC secreted proteins (Esp) and trigger actin rearrangements and 
protein phosphorylation beneath adherent bacteria (Wachter et al., 1999; Beinke et al., 1998). 
 
1.1.1.5. Enteroaggregative Escherichia coli 
Enteroaggregative Escherichia coli (EAEC) are considered emergent enteric pathogens that 
cause diarrhoeal outbreaks in developed and developing countries (Huang et al., 2006b; 
Nataro et al., 1998). EAEC are able to bind human jejunal, ileal and colonic epithelia and 
provoke vesiculation of microvilli as well as increased production of thick mucus in the colon 
(Hicks et al., 1996). In vivo and in vitro, the bacteria form the characteristic “stacked brick” 
aggregative pattern (Nataro and Kaper, 1998; Hicks et al., 1996). Pathogenesis of EAEC 
occurs in three stages: fimbriae-mediated aggregative adherence (AAF) to enterocytes, 
biofilm formation at the surface of enterocytes and toxin release leading to an inflammatory 
response (Huang et al., 2006a; Harrington et al., 2005). EAEC adherence to intestinal mucosa 
requires three AAFs and other adherence factors (Huang et al., 2006a). Expression of AAF/I 
and AAF/II, which are part of the Dr family of adhesins, is regulated by the transcriptional 
activator AggR (Czeczulin et al., 1997; Savarino et al., 1994). A third adhesin, AFA/III, has 
also been shown to be involved in adherence of EAEC to enterocytes (Bernier et al., 2002). 
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Other adherence factors, such as outer-membrane proteins, can play a role in EAEC 
adherence to enterocytes (Spencer et al., 1998). 
The second stage of EAEC pathogenesis is poorly characterised and involves production of a 
thick mucus layer at the surface of enterocytes where the bacteria persist (Huang et al., 
2006a). The last stage of pathogenesis starts with the release of several toxins that elicit an 
inflammatory response by the intestinal mucosa (Nataro et al., 1998). Among the molecules 
secreted, the best characterised are the plasmid-encoded toxin Pet, EAEC heat-stable 
enterotoxin EAST1 and Shigella enterotoxin 1 ShET1 (Huang et al., 2006a). 
 
1.1.1.6. Enterotoxigenic Escherichia coli 
Enterotoxigenic Escherichia coli (ETEC) affects children in the developing world and is the 
main causative agent of traveller’s diarrhoea (Nataro and Kaper, 1998). Bacteria classified in 
the ETEC group colonise the small intestine and possess at least one of the two heat-labile 
(LT) or heat-stable (ST) toxins (Wolf, 1997). LT possess approximately 80 % homology with 
the cholera toxin (CT) and displays the same ADP rybosylase activity (Spangler, 1992). ST 
form a family of peptides less than 20 amino acids in length, which are present in 75 % of 
ETEC isolates (Wolf, 1997). Adherence of ETEC to cells is mediated through two loci, tia 
and tib, and a wide range of colonisation factors (CFA) (Fleckenstein et al., 1996; Gaastra and 
Svennerholm, 1996; Elsinghorst and Weitz, 1994). 
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1.1.1.7. Enteroinvasive Escherichia coli 
The pathogenic features of enteroinvasive Escherichia coli (EIEC) are identical to those of 
Shigella spp: both bacteria are responsible for shigellosis in humans, characterised by 
destruction of the colonic epithelium (Parsot, 2005). Both organisms possess a virulence 
plasmid of approximately 220 kb that encodes determinants for invasion and dissemination in 
the colonic epithelium (Parsot, 2005; Nataro and Kaper, 1998). EIEC and Shigella are unable 
to invade enterocytes apically and therefore enter the basolateral colonic epithelium via M 
cells (or microfold cells, present in the epithelium of Peyer’s patches) and macrophages 
(Torres et al., 2005). These bacteria use their plasmid-encoded T3SS to translocate effector 
proteins inside these cells to induce endocytosis (Nhieu and Sansonetti, 1999). Once 
endocytosed, they lyse their vacuole, multiply intracellularly and spread from cell to cell 
within the epithelial cell layer (Philpott et al., 2000). 
1.1.1.8. Animal models 
Atypical Citrobacter freundii biotype 4280 and mouse pathogenic E. coli (MPEC) were 
classified under the species Citrobacter rodentium (Wiles et al., 2005; Luperchio and 
Schauer, 2001). This bacterium is a natural mouse pathogen that provokes colitis and 
transmissible colonic hyperplasia (Luperchio et al., 2000; Schauer and Falkow, 1993b). 
Similar to EPEC and EHEC, the bacterium possesses the LEE, which is required for the 
formation of A/E lesions in the colon of infected mice (McDaniel et al., 1995; Schauer and 
Falkow, 1993b; Schauer and Falkow, 1993a). Since EPEC and EHEC are unable to infect 
laboratory mice (Mundy et al., 2006; Frankel et al., 1996a), C. rodentium became a highly 
valuable bacterium to model the infection mechanisms of EPEC and EHEC in vivo. Mouse 
strains C57Bl/6 and NIH Swiss show little or no mortality when infected with C. rodentium, 
whereas the bacteria are fatal for C3H/Hej mouse strain (Mundy et al., 2005).  
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1.1.2. Secretion systems 
Secretion of proteins by Gram negative bacteria is central to pathogenesis and is achieved 
through 6 distinct secretion systems, namely the type I, II, III, IV, V and VI secretion systems 
(Figure 1.2). A seventh has recently been discovered in Mycobacteria (Tseng et al., 2009; 
Abdallah et al., 2007). The type I secretion system is composed of an assembly of three 
proteins (an outer membrane protein, an ATP-binding protein and an adaptor protein) forming 
a channel that allows direct secretion of proteins through the inner and outer membrane of the 
bacteria (Delepelaire, 2004). Proteins secreted through the type II secretion system are first 
transported to the periplasm via either the Sec or the two-arginine (Tat) pathways. The Sec 
machinery recognises N-terminal secretion signals on unfolded secreted proteins and requires 
energy derived from ATP for transport while the Tat pathway recognises an N-terminal 
double arginine motif on folded proteins and uses the proton motive force to translocate 
proteins into the periplasm (Papanikou et al., 2007; Muller, 2005). Proteins following the type 
II secretion pathway exit the bacteria through secretin subunits embedded in the bacterial 
outer membrane (Tseng et al., 2009). Type V-secreted substrates are first transported to the 
periplasm via the Sec pathway; they are autotransporters classified in three categories (Va, Vb 
and Vc) and are composed of a pore-forming β domain that inserts in the outer membrane and 
a passenger domain that is either transported with the β domain or cleaved from it at the 
bacterial cell surface (Henderson et al., 2004). The type IV secretion system is unique among 
the other secretion systems due to its ability to transport nucleic acids as well as proteins 
(Cascales and Christie, 2003). Horizontal transfer of DNA among bacteria is mediated 
through conjugative T4SS (cT4SS) while pathogenic T4SS (pT4SS) injects virulence factors 
inside eukaryotic host cells (de Paz et al., 2005). The type VI secretion system (T6SS) can 
potentially inject effector proteins into the cytoplasm of host cells (Tseng et al., 2009). It 
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plays an important role in virulence in human and animal pathogens (Filloux et al., 2008) as 
well as in biofilm formation (Bordi et al., 2010). 
 
 
Figure 1.2: Secretion systems in Gram negative bacteria 
Simplified sketches of the 6 secretion systems known in Gram negative bacteria. The type I 
secretion system (T1SS) is composed of an inner membrane embedded ATP Binding Cassette 
(ABC) and an outer membrane structure connected by a transperiplasmic channel. The Sec 
and Tat- pathways belong to the type II secretion system (T2SS) which allows transport of 
proteins through the inner membrane into the periplasm. Type II substrates are exported to the 
extracellular media through OM-embedded secretin units. The type III secretion system 
(T3SS) is composed of two proteic rings spanning the inner and outer membranes that are 
extended by a needle-like structure. ATPases provide the energy necessary for translocation 
of proteins from the bacterial cytoplasm to the host cell cytoplasm through the T3SS. The 
type IV secretion system is energised by ATPases such as VirB11 to translocate proteins and 
DNA into the cytoplasm of host cells. Type V autotransported substrates use the T2SS for 
transport into the periplasm and then insert themselves into the OM for secretion. The type VI 
secretion system is energised by ATPases such as ClpB to translocate proteins into the 
cytoplasm of host cells. 
 
HM: host plasma membrane, OM: outer membrane, IM: inner membrane, OMP: outer 
membrane protein, MFP: membrane fusion protein. 
Adapted from Tseng et al., 2009. 
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The type III secretion system (T3SS), also called the injectisome, shares an evolutionary 
origin with the flagellar apparatus (Cornelis, 2006). Similar to the T4SS, the T3SS delivers its 
substrates across the bacterial and host membrane, in a process called translocation, to subvert 
cell functions such as actin dynamics, endocytosis, apoptosis and inflammation (Gauthier et 
al., 2003). Some Gram negative bacteria may harbour more than one T3SS, such as 
Salmonella enterica which possess two T3SS required for invasion (SPI-1) and persistence 
(SPI-2) in host cells (Waterman and Holden, 2003; Zhou and Galan, 2001). EPEC and EHEC 
encode a T3SS essential for colonisation of the human gut. 
 
1.1.3. EPEC and EHEC T3SS and its implication in infection 
1.1.3.1. Structure of the T3SS 
The T3SS is a multiproteic complex of about 20 gene products that forms a needle-like 
structure embedded in the bacterial cell membrane (Figure 1.3) (Garmendia et al., 2005). The 
T3SS core is known as the needle complex (NC). First, the membrane-embedded protein rings 
composing the base of the NC are exported via the Sec pathway. Then, the elements 
constituting the tip of the needle are exported in a Sec-independent way through the 
previously assembled needle base. T3SSs are used by bacteria to export flagellar proteins and 
to translocate effector proteins into the cytoplasm of host cells (Galan and Wolf-Watz, 2006; 
Dreyfus et al., 1993). In A/E pathogens, the T3SS is elongated with a filamentous conduct 
similar in structure to the flagellum, composed of polymerised EspA subunits (Daniell et al., 
2001; Knutton et al., 1998). The EspA filament is believed to be capped by a multimeric 
complex of EspB/D that forms a translocation pore in the host cell membrane (Ide et al., 
2001). The energy necessary to translocate proteins through the secretion system is provided 
by the cytoplasmic ATPase EscN (Garmendia et al., 2005). 
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Figure 1.3: The type III secretion system of EPEC and EHEC 
The basal body of the T3SS is composed of two membrane-embedded inner (EscR, EscS, 
EscT, EscU and EscV) and outer (EscC) ring structures linked by the lipoprotein EscJ. EscF 
forms the needle on top of which EspA polymerises to form a hollow filament. EspB and 
EspD insert into the host cell plasma membrane, thus connecting the bacterial cytoplasm to 
the host cell cytoplasm. Energy for translocation of effector proteins is provided by EscN, 
which hydrolyses ATP into ADP. Correct folding of effector proteins, such as Map or Tir, is 
mediated by the CesT chaperone. Cyto: cytoplasm.  
Adapted from Garmendia et al., 2005. 
 
1.1.3.2. Translocated effector proteins 
EPEC and EHEC use their T3SS to inject a battery of LEE and non-LEE encoded effector 
proteins that subvert host signalling. The number of translocated effector proteins vary from 
one strain to another: EPEC O127:H6 E2348/69 injects 21 effectors (Iguchi et al., 2009) 
while EHEC O157:H7 Sakai translocates 50 effector proteins (Tobe et al., 2006). All the 
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EPEC E2348/69 effectors are also present in C. rodentium, which encodes a total of 29 
effectors (Petty et al., 2010). While some effectors (e.g. Tir) are essential for colonisation, 
other effectors are believed to provide A/E pathogens with an advantage. Deletion of single 
effector genes does not abolish colonisation but instead leads to reduced fitness and these 
mutants are outcompeted by wild-type bacteria in mixed infections (Hemrajani et al., 2008; 
Wickham et al., 2007; Gruenheid et al., 2004; Mundy et al., 2004). 
Effector proteins target different cellular compartments and often possess multiple cellular 
partners in eukaryotic cells (Garmendia et al., 2005). The function of the effectors can be 
divided into several categories: (i) subversion of the host cell cytoskeletal microtubule, 
intermediate filament and actin microfilament networks (Tir, Map, EspG, EspH, EspB) 
(Matsuzawa et al., 2004; Tu et al., 2003; Kenny et al., 2002), (ii) disruption of intestinal 
barrier function and decrease of the transepithelial resistance (Map, EspF, EspI) 
(Thanabalasuriar et al., 2010; Simpson et al., 2006; McNamara et al., 2001), (iii) loss of 
mitochondria membrane potential indicative of mitochondria swelling and damage (Map, 
EspF) (Nougayrede and Donnenberg, 2004; Kenny et al., 2002), (iv) inhibition of cell cycle 
G2/M phase transition (Cif) (Taieb et al., 2006), (v) inhibition of vesicular transport between 
the Golgi apparatus and the endoplasmic reticulum (EspI) (Kim et al., 2007), and (vi) 
inhibition of phagocytosis (EspB, EspF, EspJ,) (Marches et al., 2008; Iizumi et al., 2007). 
EPEC and EHEC can also translocate pro-apoptotic proteins (e.g. EspF) (Crane et al., 2001) 
and anti-apoptotic proteins (e.g. NleH) (Hemrajani et al., 2010). 
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1.1.3.3. EPEC and EHEC pedestal formation and regulation 
The term pedestal refers to the actin-rich pseudopodal structure formed underneath attached 
A/E pathogens (Frankel et al., 1998; Kenny et al., 1997). Even though actin is the major 
component of the pedestal, this structure appears to contain several other cytoskeletal and 
signalling proteins (Table 1.1) (Goosney et al., 2001). 
Table 1.1: Host proteins present in EPEC and EHEC pedestals 
Protein 
Presence in EPEC 
pedestals 
Presence in EHEC 
pedestals 
Actin-associated proteins 
  
Arp2/3 + + 
Cortactin + + 
Ezrin + + 
N-WASP + + 
Talin + + 
Tropomyosin + + 
Vinculin + + 
Zyxin + + 
 
  
Membrane protein 
  
CD44 + + 
   
Adaptor proteins 
  
CrkII + - 
Grb2 + - 
Shc + + 
 
+: protein recruited to the site of bacterial adherence. -: protein not recruited during infection. 
Adapted from Goosney et al., 2001. 
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Formation of pedestals is strictly dependent on the interaction between translocated Tir and 
the outer membrane bacterial adhesin intimin (Kenny et al., 1997). Tir contains two 
transmembrane domains; upon translocation it is integrated into the plasma membrane where 
it adopts a hairpin loop topology. The loop, formed by the central domain, is exposed on the 
cell surface and functions as an intimin receptor (de Grado et al., 1999; Hartland et al., 1999; 
Kenny, 1999; Liu et al., 1999). 
Phosphorylation of C-terminal TirEPEC tyrosine Y474 is essential for efficient actin 
polymerisation and pedestal formation (Figure 1.4) (Bommarius et al., 2007; Campellone and 
Leong, 2005; Swimm et al., 2004; Kenny, 1999). Phosphorylated tyrosine Y474 recruits the 
adaptor proteins Nck1 and 2 (commonly referred to as Nck) which in turn activates the neural 
Wiskott-Aldrich syndrome protein (N-WASP), leading to recruitment of Arp2/3 and induction 
of strong actin polymerisation (Campellone et al., 2002; Gruenheid et al., 2001). In addition, 
TirEPEC possesses an Asn-Pro-Tyr (NPY) motif (comprising Y454) which triggers a weak 
Nck-independent actin polymerisation beneath adherent bacteria, probably through interaction 
with the insulin receptor substrate p53 (IRSp53) and/or IRTKS (Weiss et al., 2009; 
Campellone and Leong, 2005). 
In contrast to EPEC, EHEC pedestal formation occurs independently of Nck and does not 
require Tir phosphorylation (Figure 1.4) (DeVinney et al., 1999). Although TirEHEC does not 
possess Y474, it still has the NPY motif, containing Y458, which recruits IRTKS and/or 
IRSp53 (Vingadassalom et al., 2009; Weiss et al., 2009). Pedestal formation by EHEC is 
dependent on another translocated effector protein, Tir cytoskeleton coupling protein (TccP, 
also known as EspFu) (Campellone et al., 2004; Garmendia et al., 2004), which links IRTKS 
and IRSp53 to N-WASP (Vingadassalom et al., 2009; Weiss et al., 2009). TccP activates N-
WASP by interacting with its GTPase binding domain (GBD), thus allowing it to recruit 
Arp2/3 to produce localised strong actin polymerisation (Garmendia et al., 2006). 
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Figure 1.4: Pedestal formation by EPEC and EHEC 
Interaction of intimin with TirEPEC or TirEHEC is essential for pedestal formation. Following 
insertion into the host cell membrane, TirEPEC is phosphorylated on tyrosine Y474. Nck 
interacts with the phosphorylated tyrosine Y474 and links Tir to the N-WASP and Arp2/3 
complex to trigger actin polymerisation. Tyrosine Y454 triggers weak actin polymerisation, 
probably through interaction with IRSp53. 
In contrast, TirEHEC is not phosphorylated. IRTKS and IRSp53 link tyrosine Y458 to another 
translocated protein, TccP, in order to recruit N-WASP and Arp2/3, which leads to actin 
polymerisation. 
Both TirEPEC and TirEHEC possess an N-terminal PPR region which is involved in regulation of 
pedestal length. 
PPR: polyproline region, P.M.: plasma membrane, cyto: cytoplasm. 
Adapted from Garmendia et al., 2005. 
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Both TirEPEC and TirEHEC possess a short N-terminal polyproline region (PPR). This motif in 
TirEPEC is required for recruitment of host tyrosine kinase that phosphorylates Y474, 
(Bommarius et al., 2007) while in TirEHEC, this PPR motif has been shown to regulate pedestal 
length (Campellone et al., 2006). 
Tir from EPEC and EHEC can also be serine phosphorylated: host kinases recruited by 
TirEPEC trigger phosphorylation of serines S434 and S463, which induces a conformational 
change in Tir and results in pedestal elongation (Race et al., 2007; Warawa and Kenny, 2001). 
Equivalent serine residues S436 and S437 on TirEHEC have been shown to be phosphorylated 
by protein kinase A but this did not affect pedestal formation or elongation (Allen-Vercoe et 
al., 2006). 
Recently, TirEPEC tyrosine residues Y483 and Y511 have been shown to be important for 
recruitment of the inositol phosphatase SHIP2 and for regulation of the pedestal length and 
shape. However, the role of corresponding tyrosines Y490 and Y519 in TirEHEC still remains 
to be determined since mutations of these residues did not affect EHEC pedestal length 
(Smith et al., 2010). 
Finally, TirEPEC residue R521 was hypothesised to be part of a putative GTPase-activating 
protein (GAP) motif which could be involved in pedestal length regulation (Kenny et al., 
2002). However, GAP activities of R521 in TirEPEC and the corresponding R529 residue in 
TirEHEC still remain to be confirmed (Jepson et al., 2003). 
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1.1.3.4. Protein-protein interactions during infection 
Some effector proteins from A/E pathogens have evolved in such a way that they now achieve 
a high degree of mimicry to host cell proteins that allows them to exploit the host molecular 
pathways. Several interactions between translocated effector proteins and cellular proteins 
have been identified (Table 1.2). While most of the interactions still need to be defined on the 
molecular level, some bacterial effectors contain specific motifs which target eukaryotic 
protein domains. 
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Table 1.2: Cellular proteins interacting with EPEC and EHEC effectors 
Effector Cellular partner Function Reference 
    TirEPEC Nck Adaptor protein (Gruenheid et al., 2001) 
 IRSp53 Adaptor protein (Weiss et al., 2009) 
 Cortactin Adaptor protein (Nieto-Pelegrin and Martinez-Quiles, 
2009) 
    
TirEHEC IRTKS Adaptor protein (Vingadassalom et al., 2009) 
 IRSp53 Adaptor protein (Weiss et al., 2009) 
 Cortactin Adaptor protein (Cantarelli et al., 2007) 
    
TccP N-WASP Adaptor protein (Garmendia et al., 2004) 
 IRTKS Adaptor protein (Vingadassalom et al., 2009) 
 IRSp53 Adaptor protein (Vingadassalom et al., 2009) 
    
NleH Bax inhibitor 1 ER associated protein (Hemrajani et al., 2010) 
 RSP3 Ribosomal protein (Gao et al., 2009) 
    
EspB Myosin 1c Cytoskeleton (Iizumi et al., 2007) 
    
EspF actin, profilin, ZO1, 
ZO2, Arp2/3, N-WASP 
Cytoskeleton, adaptor 
protein 
(Peralta-Ramirez et al., 2008) 
 Abcf2 ABC transporter (Nougayrede et al., 2007) 
 Cytokeratin 18 Cytoskeleton (Viswanathan et al., 2004) 
 SNX9 Adaptor protein (Marches et al., 2006) 
    
Map Tom22/40 Mitochondrial protein (Papatheodorou et al., 2006) 
 Cdc42 Rho GTPase (Huang et al., 2009) 
 NHERF1 Adaptor protein (Alto et al., 2006; Simpson et al., 
2006) 
    
EspL2 Annexin 2 Adaptor protein (Tobe, 2010) 
    
EspM2 RhoA Rho GTPase (Arbeloa et al., 2009) 
    
EspZ CD 98 Membrane protein (Shames et al., 2010) 
    
EspI/NleA Sec24 Vesicule associated 
protein 
(Lee et al., 2008; Kim et al., 2007) 
    
EspH Rho-GEFs GEF (Dong et al., 2010) 
    
EspG Tubulin Cytoskeleton (Shaw et al., 2005) 
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Src homology 2 (SH2) are small interaction domains of 110 amino acids that recognise 
phosphorylated tyrosines in a particular sequence context (Kuriyan and Cowburn, 1997). The 
adaptor protein Nck is composed of three SH3 domains and one SH2 domain, the latter being 
able to interact with phosphorylated receptor kinases (Buday et al., 2002; Schlessinger, 2000; 
Galisteo et al., 1996). Phosphorylation of tyrosine 474 on TirEPEC is essential for interaction 
with Nck SH2 domain (Gruenheid et al., 2001). 
Src homology 3 (SH3) domains are interaction domains of approximately 60 amino acids that 
interact specifically with proline-rich motifs such as P-X-X-P (where X represents any amino 
acid) (Kuriyan and Cowburn, 1997). Similarly to SH2 domains, SH3 domains participate in 
scaffolding multimolecular signalling complexes (Li, 2005). The EPEC and EHEC EspF and 
the EHEC TccP possess prolin-rich repeats (PRR) that have been shown to interact with SH3 
domain-containing host cell proteins: EspF interacts with the SH3 domain of sorting nexin 9 
(SNX9) to induce membrane remodelling (Alto et al., 2007; Marches et al., 2006), while 
interaction of TccP with the SH3 domain of IRSp53 and/or IRTKS allows the bridging of 
TirEHEC to activated N-WASP (Morita-Ishihara et al., 2009; Vingadassalom et al., 2009; 
Weiss et al., 2009). Furthermore, TccP has been shown to disrupt the autoinhibition of N-
WASP through interaction of its first 17 amino acids with the GTPase-binding domain of N-
WASP (Sallee et al., 2008). 
Recently, genomic analysis of EHEC Sakai revealed that several effector proteins contain 
potential interacting domains such as ankyrin repeats or leucine-rich repeats (Tobe et al., 
2006). However, host cell partners of these effector proteins still remain to be identified 
experimentally. 
PSD-95/Disk-large/ZO-1 (PDZ) domains are wide-spread in nature and are found in more 
than 300 proteins in the eukaryotic and prokaryotic proteomes (Shenolikar et al., 2004; 
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Ponting, 1997). PDZ domains are structures of approximately 90 amino acids composed of 6 
beta-sheets and 2 alpha helixes (Figure 1.5) (Sheng and Sala, 2001). They commonly bind C-
terminal motifs which can be classified in 3 groups (PDZ binding motifs I to III) according to 
their sequence. Class I PDZ domains bind C-terminal sequences corresponding to the 
consensus X-S/T-X-ɸ (where X is any amino acid and ɸ is an hydrophobic amino acid), class 
II domains bind the sequence X- ɸ -X- ɸ and class III domains interact with X-X-C (Harris 
and Lim, 2001). PDZ domains can also interact with β-hairpins, which mimic C-terminal ends 
(Hillier et al., 1999; Yun et al., 1998). 
 
Figure 1.5: Structure of a PDZ domain 
Ribbon diagram of PSD-95 PDZ domain 3 (red) in complex with the C-terminal end of a 
peptide (KQTSV, in blue). 
Adapted from Harris and Lim, 2005. 
 
It has been shown that the EPEC effector protein Map interacts with PDZ-containing Na
+
/H
+
 
exchange regulator factor 1 (NHERF1) and that this interaction modulates Map-induced 
filopodia formation (Berger et al., 2009; Alto et al., 2006; Simpson et al., 2006). Other EPEC 
effector proteins, such as EspI, NleH1 and NleH2, possess a C-terminal PDZ-binding motif, 
and could potentially interact with PDZ domain-containing proteins (Lee et al., 2008). As the 
interaction of translocated effector proteins with eukaryotic PDZ domains is unique, we aimed 
to explore the role it plays in the intracellular activity of Map, EspI and NleH1. 
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1.1.3.5. NleH1 
NleH1 and NleH2 are two non-LEE encoded effector proteins present in EPEC and EHEC 
(Iguchi et al., 2009). Sharing 84% identity, NleH1 differs from NleH2 by the insertion of a 
central 10 amino acid sequence (Gao et al., 2009). Both effectors are homologous to OspG, a 
Shigella effector, which plays a role in inflammation by preventing activation of NF-κB (Kim 
et al., 2005). NleH1 and 2 are also able to modulate NF-B expression by interacting with the 
Ribosomal Protein S3 (RPS3): NleH1 downregulates NF-B expression while NleH2 
upregulates it (Gao et al., 2009). NleH1 and NleH2 participate in inhibition of apoptosis by 
blocking caspase-3 activation, nuclear condensation and cell detachment in vitro (Hemrajani 
et al., 2010). Apoptosis occurs via two pathways: a mitochondria-associated intrinsic 
pathway, and a receptor-associated extrinsic pathway (Figure 1.6) (Elmore, 2007). Both 
pathways converge on the execution pathway, which is initiated by the activation of cysteine 
proteases caspase-3, -6 and -7, and results in DNA fragmentation, degradation of cytoskeletal 
and nuclear proteins, and formation of apoptotic bodies (Cohen, 1997). 
NleH1 has been shown to interact with an ER-associated protein, Bax inhibitor 1 (BI-1) 
(Hemrajani et al., 2010). BI-1 inhibits Bax activation and translocation to the mitochondria, 
thus impeding the release of cytochrome C (Chae et al., 2004). 
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Figure 1.6: Intrinsic and extrinsic apoptotic pathways  
Caspases are present in an inactive proenzyme form in the cytoplasm. Once activated, 
caspases can then activate other procaspases, leading to a proteolytic cascade. 
In the extrinsic pathway, binding of a pro-apoptotic ligand to its cognate death receptor 
triggers activation of initiator caspases-8 and -10 which will in turn cleave and activate 
executioner caspases-3, -6 and -7, leading to apoptosis. 
In the intrinsic pathway, cell stress increases the intracellular levels of p53 which influences 
the expression of apoptotic protease activating factor 1 (Apaf-1) and Bax. The latter increases 
the permeability of the mitochondria and thus the release of cytochrome C in the cytoplasm. 
Apaf-1, cytochrome C and caspase-9 form the apoptosome which activates executioner 
caspases-3, -6 and -7, leading to apoptosis. 
The Bcl-2 superfamily regroups anti-apoptotic and pro-apoptotic proteins. 
P.M.: plasma membrane, cyto: cytoplasm. 
Adapted from Elmore, 2007. 
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1.1.3.6. Map 
Mitochondrion-associated protein (Map) displays three distinct and independent functions. It 
induces transient formation of filopodia-like extensions during the initial stages of EPEC 
infection and contributes to brush border effacement (Simpson et al., 2006; Dean and Kenny, 
2004). It also alters tight junctions, disrupts the intestinal barrier and induces mitochondrial 
swelling and damage (Ma et al., 2006). Mitochondrial damage has been linked to the N-
terminal 44 amino acids of Map, which are not only essential for translocation but also 
contain a mitochondrial targeting sequence (MTS) (Kenny and Jepson, 2000). Map, along 
with EspM2, EspT and Shigella effector proteins IpgB1 and 2, possess a common Trp-xxx-
Glu (WxxxE) motif and are able to mimic the active Rho GTPases Cdc42, Rac1 and RhoA 
(Bulgin et al., 2009; Arbeloa et al., 2008; Alto et al., 2006) which are ubiquitous proteins 
expressed in yeast, plants and mammals. However, Map is unique in the family of WxxxE 
effectors as it possesses a C-terminal class I PDZ-binding motif (-TRL) and is able to interact 
with NHERF1 (Alto et al., 2006; Simpson et al., 2006). 
Rho GTPases regulate actin polymerisation, microtubules dynamics, morphogenesis and 
migration (Etienne-Manneville and Hall, 2002). They are molecular switches that alternate 
between an activated GTP-loaded state and an inactive GDP-loaded state (Figure 1.7) 
(Bustelo et al., 2007). Two types of regulatory proteins regulate this cycling: Guanine 
nucleotide Exchange Factors (GEFs) trigger the transition from inactive GDP-bound Rho 
GTPase to active GTP-bound Rho GTPase, while GTPase activating proteins (GAPs) 
promote hydrolysis of GTP to GDP, thus inactivating the GTPase (Rossman et al., 2005). 
GTP-bound Rho GTPases are able to interact with a large variety of molecular partners 
leading to the stimulation of signalling cascades. Posttranscriptional addition of a lipid moiety 
(farnesyl, geranyl, palmitoyl, or methyl) to their C-terminal end allows GTPases to be 
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targeted to different membranous compartments (Roberts et al., 2008). Guanine dissociation 
inhibitors (GDI) participate in maintaining Rho GTPases in an inactive form in the cytoplasm 
by reversibly masking their prenyl group and impeding the release of GDP (Bustelo et al., 
2007; Dransart et al., 2005). 
 
Figure 1.7: Rho GTPase activation/deactivation cycle 
Guanine nucleotide exchange factors (GEF) promote the exchange of GDP for GTP in the 
Rho GTPase molecules leading to their activation. Active Rho GTPases interact with 
molecular partners to activate signalling cascades. GTPase activating factors (GAP) hydrolyse 
GTP to return Rho GTPases to their inactive GDP-bound state. Guanine dissociation 
inhibitors (GDI) interact with inactive Rho GTPases to keep them in the cytoplasmic 
compartment. Pi: inorganic phosphate. 
 
Among EPEC translocated effector proteins, EspM2 has been shown to act as a GEF for 
RhoA (Arbeloa et al., 2009) while EspT could activate both Rac1 and Cdc42 (Bulgin et al., 
2009). Recently, Map has been shown to display a GEF activity, suggesting that Map 
activates rather than mimics Cdc42 (Huang et al., 2009).  
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1.1.3.7. EspI 
EspI is a non-LEE encoded effector protein which, upon translocation, colocalises with Golgi 
markers mannosidase II, Golgin-17 and GM130 (Lee et al., 2008; Creuzburg et al., 2005; 
Gruenheid et al., 2004). Even though the protein is not required for pedestal formation, it 
plays a critical role in virulence during C. rodentium infection (Gruenheid et al., 2004; Mundy 
et al., 2004). The protein, which does not contain classical Golgi-targeting motifs, interacts 
with Sec23/24 to inhibit the COPII-mediated vesicular transport between the endoplasmic 
reticulum (ER) and the Golgi apparatus (Lee et al., 2008; Kim et al., 2007).  
Anterograde transport of vesicles between the ER and the Golgi apparatus is mediated by 
COPII coat proteins, while retrograde transport of vesicles is operated by COPI coat proteins 
(Figure 1.8) (Lee et al., 2004). Composition of the coating complexes greatly differ and is 
essential for the correct targeting of vesicles: COPII vesicles are composed of Sec23/24 
heterodimers and Sec13/31 heterotetramers while COPI vesicles consist of an assembly of 7 
subunits (β,γ,α,β’,δ,δ,ε) (Lee et al., 2004). Alternatively, COPII vesicles can be diverted to the 
ER Golgi intermediate compartment (ERGIC) and either be delivered to the Golgi in a 
microtubule-dependent manner or recycled back to the ER (Lee et al., 2004). 
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Figure 1.8: Representation of ER-Golgi transport 
COPII vesicles are coated with the Sec23/24 and Sec13/31 complexes. They are transported 
either directly to the Golgi or to the ER Golgi intermediate compartment (ERGIC). From the 
latter compartment, these vesicles are either targeted to the Golgi apparatus or recycled back 
to the ER. COPI vesicles are coated with the COPI heptamer and operate the retrograde 
transport of vesicles from the Golgi to the ER. VTC: vesicular tubular cluster. 
Adapted from Lee et al., 2004. 
 
EspI does not block formation of COPII vesicles at the ER but rather stabilises COPII vesicles 
at the Golgi, thus impeding secretion of proteins from this organelle (Kim et al., 2007). A 
recent study has shown that EspI participates in tight junction disruption, this phenotype was 
linked to its effect on vesicular transport (Thanabalasuriar et al., 2010). Even though EspI 
structure remains to be elucidated, the protein possesses a C-terminal PDZ-binding motif (-
TRV). This motif appeared to be essential for interaction with 15 host cell partners, including 
NHERFs (Lee et al., 2008). 
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1.2. NHERF proteins 
1.2.1. NHERF and ERM structural domains 
NHERFs form a family of four proteins (Donowitz et al., 2005). NHERF1 and NHERF2 are 
composed of 2 PDZ domains as well as a C-terminal ezrin/radixin/moesin (ERM)-binding 
domain (EBD) (Figure 1.9 A) (Yun et al., 1998; Reczek et al., 1997; Weinman et al., 1995). 
NHERF3 and NHERF4 are composed of 4 PDZ domains but have no EBD domain (Figure 
1.9 A) (Scott et al., 2002; Kocher et al., 1998). ERM proteins are composed of an N-terminal 
ERM association domain (N-ERMAD) which interacts with the EBD of NHERFs and a 
variety of plasma membrane proteins, and a helical C-terminal ERM association domain (C-
ERMAD) which binds filamentous actin, thus defining a structure that allows them to act as 
molecular cross-linkers. (Figure 1.9 B) (Tsukita and Yonemura, 1997). The C-ERMAD and 
N-ERMAD of ERM can interact with each other (Gary and Bretscher, 1995). As a result, 
ERM molecules are present in an auto-inhibited state in the cytoplasm of mammalian cells, 
which can be relieved by phosphorylation of specific threonine residues in the C-ERMAD 
(Ivetic and Ridley, 2004). The last 30 aa of NHERF1 and 2 are able to interact with the N-
ERMAD domain of ezrin, radixin and moesin (Reczek and Bretscher, 1998). 
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Figure 1.9: Structure of NHERF and ERM proteins 
A: The NHERF family is composed of 4 members, NHERF1 to 4. NHERF1 and 2 possess 2 
PDZ domains and an ezrin/radixin/moesin (ERM)-binding domain (EBD). NHERF3 and 4 
have 4 PDZ domains and no EBD. 
B: Structure of ERM. The protein is composed of an N-terminal domain (N-ERMAD) which 
interacts with EBD-containing proteins and a C-terminal domain (C-ERMAD) which binds 
filamentous (F) actin. Activation of ERM occurs through threonine phosphorylation (P). 
FERM: band Four point one Ezrin Radixin Moesin, NHE3: Na
+
/H
+
 exchanger 3. 
Adapted from Harris and Lim, 2001. 
 
1.2.2. Distribution and cellular partners of NHERF proteins 
NHERF proteins are mainly expressed in polarised epithelia such as in the kidney, lung and 
intestine (Ingraffea et al., 2002; Yun et al., 1997) and display different localisations in these 
epithelia: NHERF1 and 3 are mainly present in the brush border (BB) whereas NHERF2 
localises predominantly in the intermicrovillar clefts below the brush border (Donowitz and 
Li, 2007). NHERF4 has minimal BB localisation and is mainly found in the cytoplasm 
(Thelin et al., 2005). Moderate expression of NHERF proteins has also been reported in the 
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brain, spleen, stomach, liver and skeletal muscles of vertebrates, while they are absent from 
their thymus and leukocytes (Yun et al., 1997). More than 40 NHERF cellular partners have 
been identified so far (Table 1.3) (Shenolikar et al., 2004). 
 
Table 1.3: Cellular targets of NHERF proteins 
Target NHERF isoform Reference 
Ion transporters 
  
NHE3 NHERF1, 2 and 3 (Donowitz et al., 2005) 
CFTR NHERF1, 2 and 3 (Singh et al., 2009) 
TRP4 and 5 NHERF1 (Tang et al., 2000) 
Npt2a NHERF1, 2 and 3 (Weinman et al., 2005b) 
TRPV5 and 6 NHERF4 (van de Graaf et al., 2006) 
Dra NHERF2 (Lamprecht et al., 2002) 
   
GPCRs 
  
β2-AR NHERF1 and 2 (Hall et al., 1998b) 
P2Y1R NHERF1 and 2 (Hall et al., 1998a) 
   
Signalling proteins 
  
PLCβ3 NHERF2 (Hwang et al., 2000) 
PKD1 and 2 NHERF1 (Kunkel et al., 2009) 
iNOS NHERF1 (Glynne et al., 2002) 
PKA NHERF1 and 2 (Weinman et al., 2000) 
LPA2 NHERF2 (Oh et al., 2004) 
  
 Scaffold proteins 
 
 α-actinin-4 NHERF2 (Kim et al., 2002) 
ezrin NHERF1 and 2 (Lamprecht et al., 1998) 
  
 Nuclear proteins 
 
 SRY-1 NHERF2 (Thevenet et al., 2005) 
TAZ NHERF2 (Kanai et al., 2000) 
 
NHE: Na
+
/H
+
 exchanger, Npt2a: Na
+
 -phosphate transporter 2a, TRP: transient receptor 
potential Ca
2+
 channel, Dra: down regulated in adenoma, GPCR: G-protein coupled receptor, 
β2-AR: β2 adrenergic receptor, P2Y1R: purinergic receptor, PLC β3: phospholipase C β3, 
PKD: protein kinase D, iNOS: inducible nitric oxide synthase, PKA: protein kinase A, LPA2: 
lysophosphatidic acid receptor 2, SRY: sex-determining region of the Y chromosome, TAZ: 
transcriptional co-activator with PDZ-binding motif. 
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Adapted from Shenolikar et al., 2004. 
NHERF proteins appear to play an important role not only in regulation of ion channels but 
also in signalling transduction (Table 1.3). Even though PDZ domains of NHERF proteins 
share a high degree of identity (up to 72% identity between the first PDZ domains of 
NHERF1 and 2), NHERF1, 2 and 4 proteins possess unique interacting partners (Shenolikar 
et al., 2004; Takeda et al., 2001). NHERF1 binds specifically to the inducible nitric oxide 
synthase (iNOS) and Ca
2+
 channels TRP4 and 5 (Glynne et al., 2002; Tang et al., 2000). 
NHERF2 has specific binding partners that do not interact with other NHERF proteins (α 
actinin-4, phospholipase C β3, cGMP kinase I and II) (Lamprecht and Seidler, 2006; Cha et 
al., 2005; Kim et al., 2002) and NHERF4 interacts with the intestinal receptor guanylyl 
cyclase C (Scott et al., 2002). 
 
1.2.3. Regulation of CFTR and NHE3 activities by NHERF proteins 
Electrogenic intestinal anion (Cl
-
 and HCO3
-
) secretion is predominantly mediated by the 
cystic fibrosis transmembrane conductance regulator (CFTR), and isoforms of the Na
+
/H
+
 
exchanger (NHE) family are responsible for electroneutral NaCl absorption in the intestine 
and kidney (Lamprecht and Seidler, 2006). NHERF1, 2 and 3 interact with both CFTR and 
NHE3 and regulate their activity in the intestinal epithelia (Hillesheim et al., 2007; Sun et al., 
2000; Kurashima et al., 1999; Yun et al., 1998). NHE3 activity is modulated by trafficking, 
phosphorylation, protein-protein interactions and transcriptional regulation (He and Yun, 
2010). Both NHERF1 and 2 trigger cAMP-mediated down-regulation of NHE3 (Lamprecht et 
al., 1998). Thanks to their multiple binding domains, NHERF1 and 2 form a complex with 
ezrin, NHE3 and protein kinase A (PKA) (Figure 1.10 A). Ezrin acts as a cAMP kinase 
anchoring protein (AKAP), which allows cAMP-activated PKA to serine phosphorylate 
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NHE3, leading to inhibition of its activity (Weinman et al., 2005a; Wong and Scott, 2004). 
NHERF2, but not NHERF1, is able to interact with cGMP-dependent protein kinase type II 
(cGKII) and is responsible for cGMP inhibition of the ion transporter (Cha et al., 2005). 
Another mechanism implicated in NHE3 down-regulation is mediated solely by NHERF2 
(Figure 1.10 B). Through interaction with α-actinin and protein kinase C α (PKC α), NHERF2 
induces an endocytic signal cascade which depletes NHE3 from the plasma membrane 
(Figure 1.10 B) (Lee-Kwon et al., 2003; Kim et al., 2002). While NHERF1 and 2 participate 
mainly in inhibition of NHE3, they participate in activation of CFTR by two main pathways 
(Figure 1.10 C and D). Firstly, NHERF-mediated formation of CFTR dimers increases the 
probability of the channel being open and, as a result, the export of chloride ions in the 
intestinal lumen (Figure 1.10 C) (Raghuram et al., 2001). Secondly, the complex formed by 
NHERF1/2-ezrin-PKA induces phosphorylation of the CFTR regulatory domain, leading to 
stimulation of ion transport (Figure 1.10 D) (Winter and Welsh, 1997). 
The several interacting domains of NHERFs allow them to act as adaptor proteins, bringing 
different molecular partners in a restricted area. Therefore, NHERFs participate in the 
regulation and recycling of ion channels. 
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Figure 1.10: Regulation of NHE3 and CFTR by NHERF1 and 2 
A: NHERF1 and 2 link NHE3 to Protein Kinase A (PKA) via ezrin, thus increasing 
phosphorylation of NHE3 and inhibiting its activity.  
B: NHERF2 bridges NHE3, PKCα and α-actinin-4 thus increasing endocytosis of NHE3. 
C: One molecule of NHERF1or 2 can interact with two CFTR molecules, forming an active 
dimer and stimulating chloride transport. 
D: NHERF1 and 2 localise PKA close to CFTR regulatory domain (R) to stimulate chloride 
transport. 
Cyto: cytoplasm, P.M.: plasma membrane, F actin: filamentous actin, R: regulatory domain. 
Adapted from Lamprecht and Seidler, 2006. 
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1.2.4. Role of NHERF proteins in receptor trafficking 
NHERF1 and 2 can be connected to the actin cytoskeleton through interaction with ERM 
proteins and increasing evidence demonstrates that they play a role in trafficking of 
membrane proteins (Shenolikar and Weinman, 2001). The role of NHERF proteins in 
membrane protein sorting can be classified into two categories: (i) addressing and stabilising 
membrane proteins at the plasma membrane, and (ii) recycling of these membrane proteins 
from the plasma membrane to cytoplasmic compartments (Weinman, 2001).  
The parathyroide hormone (PTH) 1 receptor (PTH1R) is a GPCR involved in mineral ion 
homeostasis in bone and kidney (Mannstadt et al., 1999). It interacts with NHERF1 and 2 via 
its C-terminal PDZ-binding motif -ETVM (Sneddon et al., 2003; Mahon et al., 2002). It was 
recently shown that NHERF1 delays endocytosis and inhibits recycling of PTH1R in CHO 
cells in a PDZ-binding motif-dependent manner (Wang et al., 2007; Wheeler et al., 2007). 
NHERF1 and 2 are able to anchor CFTR at the plasma membrane (Favia et al., 2006; Short et 
al., 1998). In early endosomes and the trans-Golgi network (TGN), NHERF1 competes with 
the CFTR-associated ligand (CAL) for CFTR (Figure 1.11) (Cushing et al., 2008). CAL 
mediates lysosomal degradation of CFTR while NHERF1 promotes membrane addressing of 
the protein (Cheng et al., 2002). Even though NHERF1 and 2 are not implicated in endocytic 
recycling of CFTR (Guggino and Stanton, 2006; Kleizen et al., 2000), they play a role in 
exocytosis and retention of the ion transporter at the plasma membrane through interaction 
with its C-terminal PDZ-binding motif (Swiatecka-Urban et al., 2002; Moyer et al., 2000). 
The fact that approximately 10% of patients suffering from cystic fibrosis present mutations 
in the CFTR C-terminal domain strongly suggests that its interaction with NHERF1 plays an 
important role in chloride homeostasis and thus diarrhoea (Voltz et al., 2001; Moyer et al., 
1999).  
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The GPCR β2-adrenergic receptor (β2AR) mediates epinephrine and norepinephrine signal 
transduction (Bunemann and Hosey, 1999). In vitro studies have demonstrated that NHERF1 
and NHERF2 could interact with β2AR (Hall et al., 1998a; Hall et al., 1998b). Further in vivo 
experiments exposed NHERF1 as an essential link in the endocytic sorting of β2AR (Figure 
1.11) (Cao et al., 1999). This study showed that deletion of the receptor PDZ-binding motif or 
expression of dominant negative NHERF1∆EBD increased lysosomal degradation of β2AR. 
 
 
Figure 1.11: Role of NHERF1 in endocytic sorting of membrane proteins 
From early endosomes, NHERF1 targets CFTR to the plasma membrane while CAL directs 
the protein to lysosomes. NHERF1 recycles GPCR such as the β2-adrenergic receptor 
between the plasma membrane and early endosomes. 
Cyto: cytoplasm, P.M.: plasma membrane, F actin: filamentous actin, EE: early endosome, 
lyso: lysosome, β2AR: β2-adrenergic receptor. 
 
The study of NHERF proteins in sorting membrane proteins highlights contradictory 
conclusions: NHERF proteins participate in anchoring CFTR and PTH1R to the plasma 
membrane, while NHERF1 is implicated in the endocytic trafficking of the β2AR, which 
suggests that other unknown regulatory mechanisms might be involved for specific membrane 
proteins. 
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1.2.5. Role of NHERF proteins in intracellular signalling 
NHERF1 and 2 were initially identified as regulators of ion transporters in polarised epithelia 
(Lamprecht et al., 1998) but further studies demonstrated their implication in other cellular 
mechanisms such as signal transduction, apoptosis and even breast cancer proliferation (Pan 
et al., 2006; Voltz et al., 2001). 
The platelet-derived growth factor (PDGF) receptor is a tyrosine kinase receptor that mediates 
mitogenic signalling in many cell types. Upon binding of its extracellular ligand PDGF, the 
receptor undergoes dimerisation and oligomerisation, leading to stimulation of its intrinsic 
tyrosine kinase activity (Heldin et al., 1998). NHERF1 and 2 have been shown not only to 
interact with the C-terminal domain of PDGFR, but also to potentiate its activity upon binding 
(Maudsley et al., 2000). This study demonstrated that oligomerisation of NHERF1 and 
PDGFR does not participate in the receptor activation but rather increases its activity, leading 
to cell proliferation. 
Further evidence that NHERF1 contributes to cellular proliferation was shown by studies on 
breast carcinomas (Pan et al., 2008; Pan et al., 2006). NHERF1 was downregulated in 
oestrogen receptor-negative breast carcinomas while it was upregulated in certain oestrogen 
receptor-positive breast carcinomas (Song et al., 2007; Stemmer-Rachamimov et al., 2001). 
In these studies, loss or overexpression of NHERF1 had a critical effect on downstream 
signalling, which highlighted the role of NHERF1 as an adaptor protein assembling signalling 
complexes (Georgescu, 2008). 
Purinergic receptors P2Y1 (P2Y1Rs) and metabotropic glutamate receptors (mGluRs) are 
GPCRs that modulate ATP-dependent and glutamate-dependent intracellular calcium levels in 
astrocytes, respectively (Agulhon et al., 2008). Two studies demonstrated that interaction of 
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P2Y1 and mGluR5 with NHERF2 could prolong and potentiate Ca
2+
-associated signalling 
cascades in these neuronal cells (Paquet et al., 2006; Fam et al., 2005).  
The GPCR family of lysophosphatidic acid (LPA) receptors are involved in diverse biological 
processes such as angiogenesis, wound healing and cell proliferation (Contos et al., 2000). 
Two independent studies showed that NHERF2 can interact specifically with LPA2 (E et al., 
2009; Oh et al., 2004). NHERF2 forms a ternary complex with LPA2 and the adaptor thyroid 
hormone receptor interacting protein 6 (TRIP6) to trigger protection against chemically-
induced apoptosis (E et al., 2009). 
 
1.2.6. Role of NHERFs in compartmentalisation of enzymatic activity 
NHERF1 is able to interact with inducible nitric oxide synthase (iNOS) through its C-terminal 
class I PDZ-binding motif (-SAL) (Glynne et al., 2002). The enzyme iNOS converts arginine 
into citrulline using NADPH and oxygen to generate the free radical NO, which is a highly 
reactive compound implicated in the innate immune response (Bogdan, 2001). Through its 
interaction with ERM proteins, NHERF1 localises iNOS in the vicinity of the phagosome 
(Davis et al., 2007). Importantly, it was also shown that macrophages stimulated with LPS 
overexpressed both NHERF1 and iNOS (Davis et al., 2007). Nitric oxide radicals have a very 
short half-life and interaction between NHERF1 and iNOS increases localised activity of the 
enzyme (Kone et al., 2003). 
Members of the protein kinase D (PKD) family are serine/threonine protein kinases involved 
in vesicle trafficking, cell proliferation and immune cell signalling (Toker, 2005). PKD can be 
activated by the second messenger diacylglycerol (DAG) and protein kinase C (PKC) 
(Spitaler and Cantrell, 2004; Rykx et al., 2003). A study demonstrated that isoforms PKD1 
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and 2 could interact with PDZ1 of NHERF1 to stabilise and increase their enzymatic activity 
at the plasma membrane (Kunkel et al., 2009). 
Activated phospholipase C beta (PLC β) proteins catalyse the hydrolysis of 
phosphatidylinositol 4,5-biphosphate (PIP2) to generate the secondary messengers 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) (Nishizuka, 1992). A study 
showed that specific interaction of PLC β3 with NHERF2 potentiates its activity (Hwang et 
al., 2000). Furthermore, a second study showed that NHERF2 was important for specific and 
efficient activation of PLC β3 by LPA2 (Oh et al., 2004). 
Even though the direct results of increased PKD and PLCβ3 enzymatic activities were not 
unveiled, they confirmed the role of NHERF1 and 2 as scaffold proteins that play a role in 
localising enzymatic activity in discrete regions of the cell. 
 
1.3. Aims 
Recent studies revealed that Map, EspI and NleH1 contain a C-terminal PDZ-binding motif 
and that Map and EspI bind NHERFs (Lee et al., 2008; Simpson et al., 2006). The aim of this 
study was to elucidate the role of the PDZ binding motifs of Map, EspI and NleH1 in host-
pathogen interaction. 
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2. Materials and methods 
2.1. Materials 
2.1.1. Chemicals 
Unless otherwise stated, all chemicals were purchased from Sigma (Sigma-Aldrich Chemie 
GmbH, Germany) or BDH (BDH laboratory Supplies, Poole, UK). Restriction enzymes, Deep 
vent polymerase, Taq polymerase, T4 DNA ligase and their corresponding buffers were 
purchased from New England Biolabs (NEB) (Hertfordshire, UK). 
2.1.2. Bacterial growth media 
All bacteria were cultured in Luria-Bertani (LB) broth or on LB agar supplemented with 
ampicillin (100 µg/ml), kanaMycin (50 µg/ml), chloramphenicol (34 µg/ml) or tetracycline 
(10 µg/ml) as required. 
2.1.3. Strains and plasmids 
The bacterial strains used in this study are listed in Appendix 1. Plasmids used in this study 
are listed in Appendix 2. 
2.1.4. Oligonucleotide primers 
All synthetic primers used in polymerase chain reactions (PCR) were synthesised by Thermo 
Electron GmbH (Ulm, Germany). Primers used in this study are listed in Appendix 3. 
Oligonucleotide primers were resuspended in deionised water to a stock concentration of 100 
pmol/µl and used at a final concentration of 10 pmol/µl. 
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2.1.5. Antibodies 
All antibodies used in this study are listed in Appendix 4. 
2.2. DNA manipulation 
2.2.1. Small and medium scale plasmid DNA purification 
Small scale, purified plasmid DNA was prepared from 1.5 ml of overnight cultures using 
Qiaprep spin miniprep plasmid purification kits. Medium scale, purified plasmid DNA was 
prepared from 100 ml of overnight cultures using Qiaprep spin midiprep plasmid purification 
kits according to the manufacturer’s protocols (QIAGEN GmbH, Germany). Briefly, bacteria 
were harvested and resuspended in an alkaline solution containing sodium dodecyl sulphate 
(SDS) and RNase. These conditions provoke the lysis of bacteria as well as the denaturation 
of genomic and plasmid DNA. Neutralisation of the solution led to re-annealing of plasmid 
DNA and precipitation of genomic DNA. Bacterial debris and precipitated DNA were then 
aggregated by centrifugation or flotation. Plasmid DNA was then purified and concentrated 
on silica-based resins. Following a washing step with 70% ethanol, plasmid DNA was eluted 
in sterile water. 
2.2.2. Polymerase Chain Reaction conditions 
PCR reactions were performed in 1X polymerase buffer (10 mM KCl, 10 mM (NH4)2SO4, 20 
mM Tris-HCl, 2 mM MgSO4, 0.1% Triton X-100 pH 8.8, supplied with the enzyme) using 50 
ng of template DNA, 1 pmol/µl of each primer, 0.25 mM of each dNTP, 3 mM MgSO4 and 
either 0.02 U/µl of Deep Vent or 0.015 U/µl of Taq polymerase (NEB). Taq polymerase was 
used for colony PCR where template DNA was replaced with a fresh bacterial colony grown 
overnight on solid agar medium. PCR was performed in a final volume of 50 µl in 200 µl 
PCR tubes using a G-Storm thermocycler (Sopachem) programmed with the following cycle: 
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initial denaturation for 10 min at 93°C; 35 cycles of denaturation at 93°C for 45 sec, 
annealing at X°C for 45 sec, elongation at 72 or 74°C for Y min; final elongation at 72 or 
74°C for 10 min. X was optimised for each PCR reaction, with a value ranging from 50 to 
70°C. Y was calculated according to the estimated size of the DNA fragment to amplify and 
the polymerisation speed of the DNA polymerase (1 min per kb on average). 
2.2.3. Agarose gel electrophoresis 
Following purification or PCR-amplification, DNA was resolved by horizontal 
electrophoresis. Gels were cast using 0.8% to 1.2% agarose gels, and a 1:10000 dilution of 
SYBR Safe™ DNA gel stain (Invitrogen) to aid visualisation. Prior to gel loading, DNA 
samples were mixed with 6X loading buffer (40% (w/v) sucrose, 0.25% (w/v) bromophenol 
blue, 0.25% (w/v) Xylene cyanol FF). Gels were run in 1x TAE buffer (40 mM Tris-acetate, 1 
mM EDTA) using a constant voltage of 120 V. DNA bands were visualised using a Safe 
Imager™ blue light transilluminator (Invitrogen) and images were acquired using an Ingenius 
Syngene BioImaging GeneSnap software (Syngene). DNA fragment size was estimated using 
a 1 kb or 2-log ladder (NEB). 
2.2.4. Restriction endonuclease digestion 
DNA restriction digest was performed overnight at 25°C or 37°C (according to the optimal 
temperature for enzymatic activity) in a final volume of 100 µl with: 1 µg of DNA template, 
10 U of each restriction enzyme (NEB), 10 µl of restriction buffer (selected according to the 
enzyme(s) used, NEB) and 1mM BSA. Digested DNA products were run on agarose gels and 
purified using a Qiagen gel extraction kit (Qiagen). 
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2.2.5. Purification of DNA 
PCR-amplified, and digested DNA was run on agarose gels and visualised using a Safe 
Imager™ blue light transilluminator (Invitrogen). The agarose plug containing the DNA was 
removed using a scalpel and DNA was purified using a Qiaquick Gel extraction kit (Qiagen) 
according to manufacturer’s protocols. Briefly, the agarose plug was melted at 55°C in a high 
salt-containing buffer and DNA was purified on silica-gel membranes to remove 
contaminants. DNA was eluted in 50 µl of sterile deionised water and processed for ligation 
or stored at -20°C. 
2.2.6. Ligation of DNA fragments 
Digested PCR fragments were ligated into digested plasmids using T4 DNA ligase and the 
supplied buffer (NEB). Ligation reactions were performed overnight at 16°C in a final volume 
of 20 µl. This comprised 1X ligation buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 10 mM 
DTT, 1 mM ATP, 25 µg/ml BSA), 40 U/µl T4 DNA ligase, and digested plasmid and insert 
DNA used at a typical vector:insert molar ratio of 1:3. 
DNA fragments generated by reverse PCR were phosphorylated using T4 polynucleotide 
kinase (PNK, NEB) prior to ligation. Phosphorylation reactions were performed at 37°C for 1 
h in a final volume of 30 µl comprising 1X ligation buffer (50 mM Tris-HCl pH 7.5, 10 mM 
MgCl2, 10 mM DTT, 1 mM ATP, 25 µg/ml BSA), 40 U/µl T4 PNK and gel-purified PCR 
product. T4 PNK was inactivated for 20 min at 65°C and 15 µl of the phosphorylated DNA 
mix was used in a ligation reaction. 
2.2.7. DNA sequencing 
DNA was sequenced using primers corresponding to the flanking regions of the DNA 
fragment of interest. Sequencing was performed by GATC Biotech (Konstanz, Germany) 
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using 30-100 ng/µl DNA and 10 pmol of primer. Sequences were analysed using BioEdit 
Sequence alignment editor (Ibis Therapeutics, Carlsbad, CA) and EMBOSS pairwise 
alignment program (http://www.ebi.ac.uk/Tools/emboss/align/). 
2.3. Protein purification and analysis 
2.3.1. Protein expression 
Protein expression was optimised for each eukaryotic and bacterial protein used in this study. 
For production of NHERF1 and 2, overnight expression in an auto-inducible culture media 
was used. This media was derived from ZYM-5052 (Studier, 2005) and contained 1% (w/v) 
N-Z amine, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM 
Na2SO4, 2 mM MgSO4, 0.5% glycerol, 0.05% glucose and 0.2% lactose. The BL21 (DE3) 
star strain containing expression plasmids was grown overnight at 37°C in 50 ml of auto-
inducible media containing the appropriate antibiotic before being harvested by centrifugation 
at 4°C at 3000 x g for 15 min. The supernatant was then discarded and bacterial pellets were 
either processed immediately for protein purification, or stored at –20°C. 
LB was used for the production of all bacterial proteins. An overnight culture of BL21 (DE3) 
star, carrying the recombinant plasmid, was diluted 1:100 into fresh LB broth containing the 
appropriate antibiotics. The culture was incubated at 37°C with shaking agitation (200 rpm) 
until an OD600 = 0.45-0.55 was obtained. Isopropyl-β-D-thiogalactopyranoside (IPTG) was 
then added to a final concentration of 1 mM. The culture was then incubated for a further 4 h 
before the bacteria were harvested by centrifugation at 3000 x g at 4°C for 15 min. The 
supernatant was then discarded and bacterial pellets were either processed immediately for 
protein purification, or stored at –20°C. 
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2.3.2. Purification of recombinant proteins 
2.3.2.1. Purification of His-tagged proteins 
For purification of His-NHERF2, the bacterial pellet was resuspended in 3 ml of binding 
buffer (50 mM Tris-HCl, pH 7.8, 500 mM NaCl, 30 mM imidazole) and lysed with 300 µl of 
Bugbuster 10x (Novagen), 250 µg of lysozyme (Sigma) and 1 Unit of DNAse (Sigma). Lysis 
was carried out in 50 ml Falcon tubes (BD Biosciences) on a rocking platform for 40 min. 
Lysed bacteria were transferred to 1.5 ml eppendorf tubes and centrifuged at 10000 x g for 15 
min at 4°C. The supernatant was cleared through a 0.22 µm filter unit (Millipore) and loaded 
into the injecting loop of an ÄKTAprime automated liquid chromatography system (GE 
Healthcare). The sample was loaded onto a HiTrap IMAC FF column (GE Healthcare), 
following the manufacturer’s protocol, and proteins were eluted in a buffered gradient of 
imidazole (50 mM Tris-HCl, pH 7.8, 500 mM NaCl, 30 to 500 mM imidazole). 
For all the other His-tagged protein purifications, the bacterial pellet was resuspended in 3 ml 
of binding buffer (50 mM Tris-HCl, pH 7.8, 500 mM NaCl, 30 mM imidazole) and lysed as 
previously described. The supernatant was loaded into a 15ml column containing 2ml Nickel-
NTA resin (NEB), pre-charged with 50 mM NiSO4 in a 15 ml column and equilibrated in 
binding buffer. Following loading of the cell lysate onto the resin, columns were washed with 
20 ml of binding buffer followed by 30 ml of washing buffer (50 mM Tris-HCl, pH 7.8, 500 
mM NaCl, 60 mM imidazole). Proteins were eluted with eluting buffer (50 mM Tris-HCl, pH 
7.8, 500 mM NaCl, 250 mM imidazole); 1 ml fractions were collected in 1.5 ml eppendorf 
tubes and stored at 4°C. 
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2.3.2.2. Purification of MBP-tagged proteins 
The bacterial pellet was resuspended in 3 ml of MBP column buffer (50 mM Tris-HCl, pH 
7.4, 200 mM NaCl, 1 mM EDTA, 1 mM DTT) and lysed as previously described. The 
supernatant was loaded onto 2ml amylose resin (Novagen) equilibrated in MBP column 
buffer, in a 15 ml column. After all the cell lysate had entered the resin, the columns were 
washed with 30 ml of MBP column buffer. Proteins were eluted with MBP column buffer 
supplemented with 10 mM maltose; 1 ml fractions were collected in 1.5 ml eppendorf tubes 
and stored at 4°C. 
2.3.2.3. Purification of GST-tagged proteins 
The bacterial pellet was resuspended in 3 ml of GST column buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, 1 mM EDTA, 1 mM DTT) and lysed as previously described. The supernatant 
was loaded onto 2ml glutathione resin (GE Healthcare), equilibrated in GST column buffer, in 
a 15 ml column. After the cell lysate had completely entered the resin, the columns were 
washed with 30 ml of GST column buffer. Proteins were eluted with GST column buffer 
supplemented with 25 mM glutathione; 1 ml fractions were collected in 1.5 ml eppendorf 
tubes and stored at 4°C. 
2.3.3. Quantification of protein concentration 
Protein concentration was estimated using the BCA (bicinchoninic acid) protein assay 
(Pierce) using the manufacturer’s protocol. Briefly, the proteins samples were added to the 
BCA reagent at a ratio of 1:1 and incubated for 30 min at 37°C. A Benchmark microtitre plate 
reader (Biorad) was used to measure absorbance at A562. Absorbance of BSA standard 
samples (0 to 500 µg/ml BSA) at A562 was assessed in parallel, to plot a standard curve and 
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determine the concentration of unknown samples. All measurements were performed in 
duplicate. 
2.3.4. SDS-PAGE 
Resolving gels were made using 12% acrylamide in a Tris-HCl/SDS buffer (0.375 M Tris-
HCl, pH 8.8, 0.1% SDS) and stacking gels were made using 4% acrylamide in a Tris-
HCl/SDS buffer (0.125 M Tris-HCl, pH 6.8, 0.1% SDS). Polymerisation of acrylamide was 
generated using 0.1% (w/v) ammonium persulfate and 0.1% (v/v) TEMED. After 
polymerisation, gels were positioned in a gel electrophoresis tank (Biorad) with 1 X running 
buffer (3 g/l Tris, 14.4 g/l glycine, 0.1% SDS). Samples were mixed with 2 X loading buffer 
(250 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 20 mM DTT, 0.01% Bromophenol blue) 
prior to loading. Gels were run under a constant voltage (routinely 120 V) until the blue dye 
front reached the bottom of the gel. The molecular weight of the samples was compared to a 
prestained broad range protein marker (NEB). 
2.3.5. Coomassie staining of SDS-PAGE 
Coomassie Blue was used to stain proteins separated by SDS-PAGE. Gels were immersed in 
Coomassie stain solution (45% (v/v) ethanol, 10% (v/v) acetic acid, 0.25% (w/v) coomassie 
R250) and incubated on a rocking platform for 1 h. Gels were then destained by successive 10 
min washes in destain solution (45% (v/v) ethanol, 10% (v/v) acetic acid) until the protein 
bands could be visualised. Gels were immersed for 1 h in distilled water before being dried on 
a Hoefer GD2000 slab gel dryer (Amersham Pharmacia Biotech, Buckinghamshire, UK) at 
50°C for 1 h. 
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2.3.6. Western blotting 
Proteins resolved by SDS-PAGE were transferred to a Polyvinylidene difluoride (PVDF) 
membrane (Millipore) using a semi-dry blotter (Biorad). Briefly, SDS-PAGE, PVDF 
membrane and Whatman paper were soaked in transfer buffer (25 mM Tris, 250 mM glycin, 
20% methanol) and stacked on the blotting apparatus. Proteins were transferred under 
constant voltage (routinely 20 V) for 1 h. PVDF membranes were then blocked at room 
temperature in 5% (w/v) skimmed milk in Tris buffer saline (TBS) containing 0.1% (v/v) 
Tween-20 (TBST) for 1 h on a rocking platform. Blocking buffer was then replaced with 
primary antibody (listed in Appendix 4) diluted in 1% skimmed milk in TBST. Membranes 
were incubated on a rocking platform for 45 min before being washed thoroughly 3 times in 
TBST. Donkey anti-mouse and anti-rabbit Horse radish peroxydase (HRP)-conjugated 
secondary antibodies (Dako) were diluted (1:3000) in TBST/1% skimmed milk and added to 
the membranes. After 45 min incubation as previously described, membranes were washed 
thoroughly 3 times in TBST. Western blots were developed using the Enhanced 
ChemiLuminescence (ECL) detection system (Amersham Pharmacia Biotech) and visualised 
using a LAS-3000 Fuji Imager. 
2.3.7. Far Western blot 
Recombinant proteins were resolved by SDS-PAGE and transferred to a PVDF membrane as 
previously described. PVDF membranes were then blocked at room temperature in 5% (w/v) 
skimmed milk in TBST for 1 h on a rocking platform before being overlaid with 10 µg/ml of 
purified proteins in 1% skimmed milk/TBST. Following incubation for 3 h at room 
temperature, or overnight at 4°C, membranes were washed thoroughly with TBST and 
processed for Western blotting as described previously. 
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2.3.8. PDZ domain array 
PDZ domain array was performed by Erin Garcia in Dr Randy Hall’s laboratory (Department 
of Pharmacology, Emory University School of Medicine, Atlanta, GA). Briefly, purified His-
tagged PDZ domain fusion proteins were spotted at 1 g per well onto Nytran SuperCharge 
96-grid nylon membranes (Schleicher & Schuell). The membranes were allowed to dry 
overnight and then blocked in blot buffer (2% non-fat dry milk, 0.1% Tween-20, 50 mM 
NaCl, 10 mM Hepes, pH 7.4) for 30 minutes at room temperature. The arrays were then 
overlaid with control GST or GST fusion proteins (100 nM in blot buffer) overnight at 4˚C. 
The overlaid arrays were washed 3 times for 5 minutes each with 20 ml blot buffer and 
incubated with anti-GST horseradish peroxidase-conjugated antibody (Amersham, 1:4000) for 
1 hr at room temperature. The arrays were washed again 3 times for 5 minutes each with 20 
ml blot buffer, and ultimately visualised via Enhanced ChemiLuminescence (ECL) detection 
system (Pierce). 
2.3.9. Secretion assay 
Overnight cultures of EPEC strains were inoculated 1:70 into 15 ml of DMEM supplemented 
with the appropriate antibiotic and incubated at 37°C with shaking at 200 rpm until OD600 
reached 0.4-0.5. Protein expression was then induced by addition of 1 mM IPTG and cultures 
were grown for a further 5 h as above. After recording the OD600 of the samples, the bacterial 
cells were pelleted by centrifugation for 10 min at 3000 x g. The supernatants were cleared 
through 0.22 µm syringe filters, loaded into Amicon Ultra-15 filters (10kDa size cut-off, 
Millipore) and concentrated 75-fold to 200 µl by centrifugation for 40 min at 3000 x g. An 
equal volume of 2x SDS loading buffer was added to the concentrated supernatants, while the 
cell pellets were resuspended in 1400 x OD600 loading buffer prior to SDS-PAGE analysis. 
Samples were stored at -20°C. 
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2.3.10. ELISA 
Each experiment was performed in triplicate and included control wells containing no 
interacting proteins or primary antibody. ELISA wells were coated with 100 µl of purified 
proteins at a concentration of 1 µM overnight at 4°C. The following day, the ELISA 
experiment was carried out using the steps described below. After each step, a cycle of 3 
washes with Phosphate buffer saline 0.1% Tween-20 (PBST) and 1 wash with PBS was 
performed. 
1) 3% BSA in PBS was added to the wells and incubated for 1 h at room temperature (RT). 
2) 100 µl of purified protein at a concentration of 2 µM in PBS/3%BSA were added to the 
wells and incubated for 1 h at RT. 
3) 100 µl of primary antibodies (diluted in PBS/3%BSA as detailed in Appendix 4) were 
added to the wells and incubated for another hour at RT. 
4) 100 µl of HRP-conjugated secondary antibodies were added to the wells (diluted in 
PBS/3%BSA as detailed in Appendix 4). 
5) Developing solution (25 mM citric acid, 50 mM Na2HPO4, O-phenylenediamine 
dihydrochloride (OPD, Sigma) tablet supplemented with 0.012% hydrogen peroxide) was 
added to the wells and the reaction was left to develop for 15 minutes at RT. The reaction was 
stopped with 15 µl of 3 M sulphuric acid. Optical density was read at 490nm in a Benchmark 
microtitre plate reader (Biorad). 
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2.3.11. Co-Immunoprecipitation 
HeLa-NHERF2 cells were grown to confluence in 25-cm
2
 cell culture flasks and infected for 
1 h as described above. Cells were washed 3 times with PBS and lysed in 500 µl of Co-IP 
buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 10% 
glycerol, protease inhibitors (Complete, Roche)) on a spinning wheel for 1 h at 4°C. The 
lysate was transferred to a pre-chilled eppendorf tube and centrifuged at 9200 x g for 10 
minutes at 4°C. The cleared lysate was transferred to a fresh pre-chilled eppendorf tube 
containing 15 µl of pre-equilibrated anti-HA agarose beads (Sigma) and incubated on a 
spinning wheel for 2 h at 4°C. The suspension was washed 3 times in Co-IP buffer by brief 
centrifugation of 10 sec at 9200 x g at 4°C after each wash. Bound proteins were eluted using 
80 µl of 100 µg/ml HA peptide (Sigma). Analysis of the samples was performed by Western 
blot as described in section 2.3.6. 
2.4. Transformation of bacteria 
2.4.1. Heat shock 
For preparation of chemically competent bacteria, an overnight bacterial culture was 
inoculated into LB broth at a dilution of 1:100 and incubated with shaking at 200 rpm at 37°C 
until the culture reached mid-log phase (OD600 = 0.45-0.55). Following a 15 min incubation 
on ice, the bacterial culture was centrifuged at 3000 x g at 4°C for 10 minutes. The 
supernatant was discarded and the bacteria were resuspended in 0.1 volumes (compared to the 
original culture volume) of ice-cold RF1 buffer (100 mM RbCl, 50 mM MnCl2, 30 mM 
potassium acetate, 10 mM CaCl2, 15% (v/v) glycerol, pH 5.8). Following 10 min of 
incubation on ice, the bacteria were pelleted by centrifugation as described above. The 
supernatant was discarded and the bacterial pellet was resuspended in 0.01 volumes 
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(compared to the original culture volume) of ice-cold RF2 buffer (10 mM MOPS, 10 mM 
RbCl, 75 mM CaCl2, 15% (v/v) glycerol, pH 6.5). 200 µl aliquots were snap-frozen in a dry 
ice/ethanol bath and stored at -80°C. 
For each heat shock transformation, 50 µl of competent bacteria were thawed on ice before 
addition of DNA (5 µg of plasmid DNA or 10 µl of ligation reaction). Bacteria were then 
incubated for 30 min on ice before being heat shocked for 1 min at 42°C. Following addition 
of 1ml of LB broth, the transformation mix was then incubated at 37°C with shaking at 200 
rpm for 1 h. Bacteria were then plated on LB agar plates containing the appropriate antibiotic 
and incubated at 37°C overnight. 
2.4.2. Electroporation 
For preparation of electrocompetent bacteria, an overnight bacterial culture was inoculated 
into LB broth at a dilution of 1:100 and incubated with shaking at 200 rpm at 37°C until the 
culture reached mid-log phase (OD600 = 0.45-0.55). Following a 30 min incubation on ice, 
bacteria were pelleted at 3000 x g at 4°C for 10 min. The bacterial pellet was resuspended in 
0.1 volumes (compared to the original culture volume) of sterile ice-cold water and 
centrifuged as described above. This step was repeated and bacteria were resuspended in 0.05 
volumes (compared to the original culture volume) of sterile ice-cold 10% glycerol before 
centrifugation at 3000 x g at 4°C for 10 min. The bacterial pellet was resuspended in 0.01 
volumes (compared to the original culture volume) of sterile ice-cold 10% glycerol before 
being aliquoted and stored as described in section 2.4.1. 
For each electroporation reaction, 50 µl of electrocompetent bacteria were thawed on ice 
before addition of 2 µg plasmid DNA. Bacteria were incubated on ice for 20 min before being 
transferred to a 0.2 cm electrode gap electroporation cuvette. Electroporation was performed 
using a BioRad gene pulser programmed to the following settings: 200 Ω, 25 µF, 2.5 V. 
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Following addition of 1 ml of LB broth, the transformation mix was incubated at 37°C for 1 
h. Bacteria were then plated on LB plates containing the appropriate antibiotic and incubated 
at 37°C overnight. 
2.5. Infection 
The expression, or priming of LEE-encoded genes, in attaching and effacing pathogens, can 
be induced by growing the bacteria in DMEM. For EPEC, overnight LB cultures were 
inoculated 1:50 into DMEM and grown statically for 3 h at 37°C in a humidified atmosphere 
of 5% CO2 prior to infection. EHEC cultures were grown in LB broth for 8 h before being 
grown statically overnight at 37°C in a humidified atmosphere of 5% CO2 at a dilution of 
1:500 in DMEM, and infection was carried out for 5 h. Recombinant protein expression was 
induced by addition of 1 mM IPTG 30 min prior to infection. 
DAEC and EAEC cultures grown overnight in LB broth were washed twice in Phosphate 
buffer saline (PBS) before being resuspended in the same culture volume of DMEM 
supplemented with 1% mannose to inhibit unspecific binding due to type 1 fimbriae. DAEC 
and EAEC infections were carried out in DMEM 1% mannose for 1 h and 3 h, respectively. 
All infections were performed at 37°C in 5% CO2, bacteria were diluted accordingly and 
added to the cell culture media to reach a multiplicity of infection (MOI) of 100. 
2.6. Eukaryotic cell methods 
2.6.1. Maintenance of cells 
Cervix epithelial HeLa cells, fibroblast Swiss 3T3 cells and colonic epithelial Caco2 cells 
were obtained from the American Type Culture Collection (ATCC) and maintained according 
to standard protocols. All media and buffer supplements were obtained from Gibco-BRL and 
Sigma. HeLa cells were cultured in low glucose (1 g/l) Dulbecco`s Modified Eagle Medium 
71 
 
(DMEM) while Swiss 3T3 and Caco2 cells were cultured in high glucose (4.5 g/l) DMEM. 
Culture media were supplemented with 15% heat inactivated foetal calf serum (FCS) and 2 
mM L-Glutamate. FCS was heat inactivated for 30 min at 56°C prior to use, aliquoted and 
stored at -20°C. Cells were cultured statically at 37°C in a humidified atmosphere of 5% CO2. 
HeLa and Swiss 3T3 cells were sub-cultured every four days by removal of the spent 
medium, followed by treatment of the confluent cells with 5 ml Hanks balanced salt solution 
(HBSS) 0.02% EDTA containing 0.05% trypsin (Sigma). The cells were harvested after 5 
minutes, followed by the addition of 5 ml of fresh DMEM. The cells were then centrifuged at 
300 x g for 5 minutes. After discarding the supernatant, the cells were resuspended in 10 ml 
DMEM of which 1 ml was sub-cultured in a final volume of 10 ml (equivalent of 1 passage). 
For infection experiments, 2x10
5
 cells/ml were seeded on glass cover slips in 24-well plates 
(Nalgene) and grown overnight. Caco2 cells were grown for 14 days in a T75 flask or on 
glass cover slips in 24-well plates (Nalgene). The culture media was changed every day and 
cells were discarded after 17 passages. 
2.6.2. Cell transfection 
HeLa cells were grown to 70% confluence on glass cover slips in 24-well plates (Nalgene) 
and transfected with lipofectamin (Invitrogen) for 4 hours according to the manufacturer’s 
indications. Briefly, HeLa cells were washed 3 times with PBS and incubated in 500 µl of 
DMEM without FCS or L-glutamate. For a 2 cm
2
 area (1 well in a 24-well plate), 1µg of 
plasmid DNA and 3 µl of lipofectamin were diluted in 100 µl Optimem (Gibco) and were 
incubated at room temperature for 30 min. The transfection mix was then added to the HeLa 
cells and the plates were gently swirled and incubated at 37°C in a humidified atmosphere of 
5% CO2 for 4 h. Transfection media was then removed and cells were incubated overnight in 
DMEM supplemented with 15 % FCS and 2 mM L-glutamate. 
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2.6.3. Generation of stable cell lines 
For generation of stable cell lines, HeLa cells were grown to confluence in a 75 cm
2
 flasks 
and transfected with pBKCMV vectors for 4 hours according to the manufacturer’s 
indications. Cell media was replaced by DMEM supplemented with 15% FCS and 2 mM L-
glutamate and cells were incubated overnight at 37°C in an atmosphere of 5% CO2. The 
following day, cells were trypsinised and 2x10
5
 cells were sub-cultured in 100 mm Petri 
dishes in DMEM media supplemented with 800 µg/ml geneticin (G418, Gibco). Cells were 
cultured for 10 days in the same Petri dish with occasional change of DMEM media for 
selection of resistant clones. Single clones were transferred manually to 96 well plates 
(Nalgene) and grown to confluence. Clones were transferred to 24-well plates containing 
cover slips for expression analysis. This was performed in duplicate and positive clones were 
trypsinised, sub-cultured in 25-cm
2
 flasks and stored at -80°C in DMEM supplemented with 
10% dimethyl sulfoxide (DMSO). 
2.6.4. Preparation of eukaryotic cell extract 
Cells were washed twice with cold PBS and resuspended in 5 ml of lysis buffer (50 mM Tris, 
pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 1 mM Na3VO4, 1 mM NaF, 6.25 mM 
NaPPi). Cell suspensions were sonicated 3 times in a Vibra-Cell VCX 750 Sonicator and 
incubated on a rolling wheel for 30 min at 4°C. Cell extracts were then centrifuged at 12000 x 
g for 20 minutes and the supernatant collected. 
2.6.5. Viability assay 
Cells were grown to 80 % confluence in 24-well plates (Nalgene) and infected for 1 h as 
described in section 2.5. Following infection, cells were washed 5 times with PBS and 
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incubated for 4 h in DMEM supplemented with 200 µg/ml gentamicin (Invitrogen). Cells 
were then washed 3 times with PBS and trypsinised in 300 µl of HBSS 0.02% EDTA 
containing 0.05% trypsin (Sigma). Trypsin was then inactivated by addition of 500 µl of 
DMEM containing 10% FCS and 2 mM L-glutamate. Cells were mixed 1:1 (v/v) with 0.05% 
Trypan Blue in PBS and counted on a Neubauer haemocytometer (Sigma-Aldrich). All counts 
were compared to the level of uninfected cells and plotted as a percentage of adherent cells. 
2.6.6. Apoptosis assay 
Cells were transfected as described in section 2.6.2. After 16 h, cells were washed 3 times 
with PBS and incubated at 37°C in a humidified atmosphere of 5% CO2 for 4 h in DMEM 
supplemented with 1 µM staurosporine (STS) (Calbiochem). Apoptotic cells were stained 
either for nuclear condensation or caspase-3 activation and counted using 
immunofluorescence microscopy as described in 2.7.1. 
2.6.7. RNA interference 
Cells were grown to 50% confluence on glass cover slips in 24-well plates (Nalgene). 
Following 3 washes with PBS, cells were incubated at 37°C in 500 µl of DMEM without FCS 
or L-glutamate. For a 2 cm
2
 area (1 well in a 24-well plate), siRNA duplexes directed against 
NHERF1 (GGAGAACAGUCGUGAAGCCUU) and control non-targeting siRNA 
(Dharmacon) were diluted to 20 nM in 50 µl of Optimem (Gibco). 3 µl of Hiperfect (Qiagen) 
was diluted in 50 µl of Optimem (Gibco), mixed with the siRNA duplexes and incubated at 
room temperature for 30 min. The siRNA mix was then added to the cells and the plates were 
gently swirled and incubated at 37°C in a humidified atmosphere of 5% CO2 for 4 h. The 
culture media containing the siRNA mix was then removed and DMEM containing 10% fetal 
calf serum (FCS) and 2 mM L-glutamate was added. Interference of target genes was 
controlled after 24, 43, 66 and 83 h by Western blot. 
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2.7. Sample processing for microscopy 
2.7.1. Cytoimmunostaining 
Non-adherent bacteria were removed and infected cells were washed 3 times with Phosphate 
Buffer Saline (PBS). Cells were fixed for 20 minutes in 500 µl of 3% paraformaldehyde-PBS. 
The fixed cells were first quenched for 20 min with PBS 50 mM NH4Cl, and then 
permeabilised for 4 min in PBS 0.25% Triton X100 and washed 3 times in PBS. Cover slips 
were incubated for 45 minutes with primary antibody diluted in 5% BSA-PBS (see Appendix 
4 for specific antibody dilutions). Cover slips were then washed 3 times with PBS and 
incubated for 45 minutes with secondary antibody diluted in 5% BSA-PBS (see Appendix 4 
for specific antibody dilutions). Following 3 washes with PBS, cover slips were mounted on 
SuperFrost glass slides using Prolong Gold antifading reagent (Invitrogen). 
2.7.2. Histoimmunostaining 
Mouse infection, tissue collection and mounting of colon sections were performed by Dr 
Francis Girard and Dr Valérie Crépin. C57 BL6 mice were infected by oral gavage with 10
8
 
CFU of wild-type Citrobacter ICC169 and colons were harvested at day 9 post-infection. 
Colons were sectioned at a thickness of 5 µm, and were then mounted on SuperFrost glass 
slides (Fisher) then dried for 20 minutes and then stored at -80°C.  
Mounted, unfixed, frozen sections were allowed to dry at room temperature for 5 minutes 
before being fixed in 3% PFA-PBS for 10 minutes. The slides were washed twice for 3 
minutes each with PBS and then blocked with PBS-0.5% BSA-2% NDS (Normal Donkey 
Serum)-0.1% Saponin for 20 minutes. Slides were incubated for 1 hour with primary antibody 
diluted in PBS-0.5% BSA-2% NDS-0.1% Saponin (see Appendix 4 for specific antibody 
dilutions). Slides were rinsed twice for 10 minutes each with PBS-0.1% Tween-20-0.1% 
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Saponin and then incubated for 30 minutes with secondary antibody diluted in PBS-0.5% 
BSA-2% NDS-0.1% Saponin (see Appendix 4 for specific antibody dilutions). Following this, 
slides were washed twice for 10 minutes with PBS-0.1% Tween-20-0.1% Saponin and 
covered with coverslips using Prolong Gold antifading reagent (Invitrogen). 
2.7.3. Scanning electron microscopy 
Transfected or infected cells were washed 3 times with PBS and fixed with 3% 
glutaraldehyde in PBS. The samples were then washed 3 times with PBS before being fixed in 
1% Osmium Tetroxide for 1 h. Following 3 washes in PBS and 15 min dehydration in graded 
ethanol solutions (50% to 100%), the samples were transferred to an Emitech K850 Critical 
Point drier and processed according to the manufacturer's instructions. The samples were 
coated in gold/palladium mix to a thickness of approximately 370Å using an Emitech Sc7620 
minisputter. 
2.8. Microscopy 
2.8.1. Fluorescence microscopy 
Observation and acquisition of cells stained with fluorescent labels were performed on a Zeiss 
Axioimager immunofluorescence microscope using the following excitation wavelengths: 
AMCA – 350nm, FITC/Cy2 – 492nm, Rhodamine/Cy3 – 550nm and Cy5 – 650nm. All 
images were analysed using the Axiovision Rel 4.5 software. 
2.8.2. Scanning electron microscopy 
Samples were examined at an accelerating voltage of 20 kV using a Jeol JSM-6390 electronic 
microscope. 
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2.9. Statistical analysis 
Results are expressed as mean values ± standard deviation. All statistical tests were performed 
using the Sigma Plot version 11.0 program using the parametric Student t-test. A P < 0.05 
was considered significant. 
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3. Results 
Results from this chapter were presented and accepted for publication in the peer-reviewed 
journal Cellular Microbiology the 6
th
 of July 2010 under the title: 
Binding to Na
+
/H
+
 exchanger regulatory factor 2 (NHERF2) affects trafficking and function 
of the enteropathogenic Escherichia coli type III secretion system effectors Map, EspI and 
NleH. (Appendix 6) 
 
3.1. Biochemical analysis of the interaction between NHERFs and the 
effector proteins Map, EspI and NleH1 
3.1.1. Map interacts with NHERF1, NHERF2 and NHERF3 
NHERF1 and NHERF2 were originally identified as potential Map binding partners in a yeast 
two-hybrid (Y2H) screen (Simpson et al., 2006). A PDZ protein array approach, performed in 
Dr Randy Hall’s laboratory, Emory University Atlanta, was used to identify additional 
partners. In collaboration with Dr Elizabeth Hartland (Melbourne University), the last 50 
amino acids of Map (MapC50) were cloned into pGEX-3X to generate an N-terminally GST-
tagged fusion protein. The protein was purified and probed against blotted PDZ domains 
(Figure 3.1, list of PDZ domains in appendix 5). As expected, MapC50 interacted with PDZ 
domains 1 and 2 of NHERF1 and 2. Interestingly, MapC50 also bound PDZ3 of NHERF3.  
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Figure 3.1: Map interacts with PDZ domains of NHERF1, NHERF2 and NHERF3 on PDZ 
array 
A: PDZ protein array overlaid with purified GST and detected with anti-GST antibodies. PDZ 
domains are listed in appendix 5. 
B: PDZ protein array overlaid with purified GST-MapC50 and detected with anti-GST 
antibodies. PDZ domains are listed in appendix 5. MapC50 interacts specifically with PDZ1 
and 2 of NHERF1 and NHERF2, as well as PDZ3 of NHERF3. 
This experiment was performed by Erin Garcia in Dr Randy Hall’s laboratory, Emory 
University Atlanta. 
 
In order to confirm these interactions, full length Map was cloned into pMal-c2X using 
primers Map-Fw1 and Map-Rv. Following expression and purification, the protein was 
overlaid on blotted His-tagged NHERF1 and NHERF2. MBP-Map interacted with both 
proteins, which supports the finding of the PDZ array (Figure 3.2 A). 
Furthermore, in order to determine which NHERF domains are targeted by Map, PDZ 
domains as well as EBDs of NHERF1 and 2 were cloned in pMal-c2X using primer pairs 
N1PDZ1-Fw/N1PDZ1-Rv, N1PDZ2-Fw/N1PDZ2-Rv, N1EBD-Fw/N1EBD-Rv, N2PDZ1-
Fw/N2PDZ1-Rv, N2PDZ2-Fw/N2PDZ2-Rv and N2EBD-Fw/N2EBD-Rv. All constructs 
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were purified as MBP fusion proteins. Far Western blot using MBP-PDZ1, PDZ2 and EBD 
from NHERF1 and 2 indicated that Map could interact specifically with PDZ1 of NHERF1 
and PDZ2 of NHERF2 (Figure 3.2 B and C). In contrast to the PDZ array, interaction between 
Map and PDZ2 of NHERF1 and PDZ1 of NHERF2 could not be detected (Figure 3.2 B and 
C), probably due to the high stringency of the far Western blot conditions. 
The importance of the Map C-terminal TRL motif has been demonstrated in its interaction 
with NHERF1 (Simpson et al., 2006). In order to investigate the role of this motif in the Map-
NHERF2 interaction, bacterial extracts from EPEC ∆map expressing Map or Map∆C3 (also 
known as Map∆TRL) were blotted and overlaid with purified His-NHERF2 (Figure 3.2 D). 
Using anti-NHERF2 antibodies, we detected NHERF2 interaction with Map but not Map∆C3, 
indicating that the last 3 amino acids of Map are also critical for the interaction with 
NHERF2. 
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Figure 3.2: Map interacts with PDZ1 of NHERF1 and PDZ2 of NHERF2 by far Western blot 
A: Purified His-NHERF1, His-NHERF2, MBP-Map and MBP were blotted and overlaid with 
MBP-Map followed by detection with anti-Map. No cross-reactivity was detected by Western 
blot using anti-Map. Equivalent loading of proteins was confirmed by Coomassie staining. 
Map interacts with NHERF1 and NHERF2. 
B: Purified MBP, MBP-Map, and MBP fusions of NHERF1 PDZ1, PDZ2 and EBD were 
blotted and overlaid with MBP-Map followed by detection with anti-Map. No cross-reactivity 
was detected by Western blot using anti-Map. Equivalent loading of proteins was confirmed 
by Coomassie staining. Map interacts with PDZ1 of NHERF1. 
C: Purified MBP fusions of NHERF2 PDZ1, PDZ2 and EBD, as well as purified MBP-Map 
and MBP were blotted and overlaid with MBP-Map followed by detection with anti-Map. No 
cross-reactivity was detected by Western blot using anti-Map. Equivalent loading of proteins 
was confirmed by Coomassie staining. Map interacts with PDZ2 of NHERF2. 
D: Bacterial extracts from EPEC ∆map complemented with either pSA10-Map or pSA10-
Map∆C3 were immunoblotted with anti-Map. Far Western blot with purified His-NHERF2 
followed by detection with anti-NHERF2 shows that NHERF2 is able to interact with Map 
but not Map∆C3. 
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In order to confirm the Map-binding domains of NHERF1 and 2, purified His-NHERF1, His-
NHERF2 and MBP-fusions of their PDZ and EBD were adsorbed on ELISA plates and 
incubated with MBP-Map. Map could interact with His-NHERF1 and its PDZ1 (Figure 3.3 
A) as well as His-NHERF2 and its PDZ1 (Figure 3.3 B). Signals obtained for full length 
NHERF1 and NHERF2 were higher than for isolated PDZ1 domains. This might be due to the 
different conformations of the full length and truncated NHERFs. 
 
 
Figure 3.3: Map interacts with PDZ1 of NHERF1 and NHERF2 by ELISA 
A: Purified His-NHERF1 and MBP fusions of its PDZ1, PDZ2 and EBD, as well as MBP, 
were immobilised at a concentration of 1 µM on ELISA plates and incubated with 2 µM of 
MBP-Map. Following incubation with anti-Map and anti-mouse HRP-conjugated antibodies, 
absorbance at 490 nm was measured. The signals obtained for NHERF1 and its PDZ1 were 
significantly higher than for MBP (control). Results are shown as mean ± SD. P-values of 
<0.05 (*) were considered as significant. 
B: Purified His-NHERF2 and MBP fusions of its PDZ1, PDZ2 and EBD, as well as MBP, 
were immobilised at a concentration of 1 µM on ELISA plates and incubated with 2 µM of 
MBP-Map. Following incubation with anti-Map and anti-mouse HRP-conjugated antibodies, 
absorbance at 490 nm was measured. The signals obtained for NHERF2 and its PDZ1 were 
significantly higher than for MBP (control). Results are shown as mean ± SD. P-values of 
<0.05 (*) were considered as significant. 
 
Taken together, using far Western blot and ELISA techniques, we confirmed that Map 
interacts with both PDZ domains of NHERF1 and NHERF2. 
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3.1.2. EspI interacts with NHERF1 and NHERF2 
A recent study using the PDZ domain array suggested that, besides Map, EspI might also be 
able to interact with NHERF1 and NHERF2 (Lee et al., 2008). In this screen, binding of the 
last 150 amino acids of EspI to PDZ domains of several proteins, among them NHERF1 
PDZ1 and NHERF2 PDZ2, were detected (Lee et al., 2008). In order to validate the 
interactions, we first analysed the binding of GST-EspIC150 to full length NHERF1 and 2. 
His-NHERF1 and His-NHERF2 were blotted and overlaid with purified GST-EspIC150 
(Figure 3.4 A). The overlay showed that EspIC150 is able to interact with both proteins. 
In order to confirm that EspI interacted with NHERF1 and 2 through its PDZ-binding motif, 
extracts of EPEC ΔespI expressing EspI and EspIΔC7 were blotted and overlaid with purified 
His-NHERF1 or His-NHERF2 (Figure 3.4 B). The overlay demonstrated that the last seven 
amino acids of EspI are essential for interaction with NHERF1 and NHERF2. 
PDZ domains of NHERF1 and NHERF2 as well as their EBD were then blotted and overlaid 
with purified GST-EspIC150. Following detection, EspI could interact with PDZ1 of 
NHERF1 and PDZ2 of NHERF2 (Figure 3.4 C and D). Interestingly, a weak signal was also 
obtained for NHERF1 PDZ2. 
Taken together, these results confirm that EspI interacts with NHERF1 and NHERF2, via 
PDZ1 and PDZ2 respectively. In addition, our data suggests that EspI might also be able to 
bind PDZ2 of NHERF1. Furthermore, NHERF1 and NHERF2 did not interact with EspI∆C7, 
thus confirming that their interaction relies on EspI PDZ-binding motif. 
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Figure 3.4: EspI interacts with PDZ1 and 2 of NHERF1 and PDZ2 of NHERF2 
A: Purified His-NHERF1, His-NHERF2, GST and GST-EspIC150 were blotted and overlaid 
with GST-EspIC150 followed by detection with anti-EspI. No cross-reactivity was detected 
by Western blot using anti-EspI. Equivalent loading of proteins was confirmed by Coomassie 
staining. EspIC150 interacts with NHERF1 and NHERF2. 
B: Bacterial extracts of EPEC ∆espI pSA10-EspI and ∆espI pSA10-EspI∆C7 were 
immunoblotted with anti-EspI. Far Western blot with purified His-NHERF1 and His-
NHERF2 followed by detection with anti-NHERF1 or anti-NHERF2 showed that NHERF1 
and NHERF2 were able to interact with EspI but not EspI∆C7. 
C: Purified MBP, GST-EspIC150, and MBP fusions of NHERF1 PDZ1, PDZ2 and EBD were 
blotted and overlaid with GST-EspIC150 followed by detection with anti-EspI. No cross-
reactivity was detected by Western blot using anti-EspI. Equivalent loading of proteins was 
confirmed by Coomassie staining. EspIC150 interacts with PDZ1 and 2 of NHERF1. 
D: Purified MBP fusions of NHERF2 PDZ1, PDZ2 and EBD, as well as purified GST and 
GST-EspIC150 were blotted and overlaid with GST-EspIC150 followed by detection with 
anti-EspI. No cross-reactivity was detected by Western blot using anti-EspI. Equivalent 
loading of proteins was confirmed by Coomassie staining. EspI interacts with PDZ2 of 
NHERF2 (black arrow). 
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3.1.3. NleH1 interacts with NHERF2 
Similar to Map and EspI, NleH1 possesses a C-terminal PDZ-binding motif. In order to 
identify putative NleH1 binding partners, we performed a PDZ array, probing the blotted PDZ 
domains with a GST-fusion protein of the last 150 amino acids of NleH1 (Figure 3.5 A and 
B). The array revealed several PDZ domains, including PDZ2 of NHERF2, which were bound 
specifically by GST-NleH1C150 but not GST (Figure 3.5). 
 
Figure 3.5: NleH1 interacts with PDZ2 of NHERF2 on PDZ array 
A: PDZ protein array overlaid with purified GST and detected with anti-GST antibodies. PDZ 
domains are listed in appendix 5. 
B: PDZ protein array overlaid with purified GST-NleH1C150 and detected with anti-GST 
antibodies. PDZ domains are listed in appendix 5. NleH1C150 interacts specifically with 
PDZ2 of NHERF2 and other PDZ domains. 
This experiment was performed by Erin Garcia in Dr Randy Hall’s laboratory, Emory 
University Atlanta. 
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In order to confirm the interaction between NleH1 and NHERF2, purified His-NHERF1, His-
NHERF2 and GST were blotted and overlaid with GST-NleH1 (Figure 3.6 A). In line with the 
results of the PDZ array, NleH1 was only detected in the overlay of NHERF2 but not 
NHERF1. 
This data was further strengthened by a reverse overlay experiment. Overlaid NHERF2 bound 
to blotted NleH1C150 and the positive control His-EspI but not to GST (Figure 3.6 B), 
confirming the interaction of NHERF2 and NleH1 and indicating that the last 150 amino acids 
of NleH1 are indeed sufficient to interact with NHERF2. The role of the PDZ-binding motif 
for the interaction could not be assessed in this study as GST and His-tagged NleH1∆C4 
constructs were found to be unstable and thus could not be purified. 
In order to identify the PDZ domains targeted by NleH1, MBP fusions of NHERF2 PDZ and 
EBD domains were blotted and overlaid with GST-NleH1 (Figure 3.6 C). Following 
detection, NleH1 could only interact with full length NHERF2 but not its isolated domains, 
indicating that, in this experiment, PDZ domains per se are not sufficient to maintain 
interaction with NleH1. 
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Figure 3.6: NleH1 interacts with NHERF2 by gel overlay 
A: Purified His-NHERF1, His-NHERF2, GST-NleH1 and GST were blotted and overlaid 
with GST-NleH1 followed by detection with anti-NleH antibodies. Anti-His Western blot 
confirmed equivalent loading of NHERF proteins and anti-NleH Western blot showed little 
cross-reactivity of the antibody for blotted proteins. NleH1 could interact with NHERF2 
(black arrow) but not NHERF1 by overlay. 
B: Purified His-NHERF2, GST, GST-NleH1C150 and His-EspI were transferred onto PVDF 
membrane and either overlaid with purified His-NHERF2 followed by detection with anti-
NHERF2 or immunoblotted with anti-GST and anti-NHERF2. NHERF2 interacted with His-
EspI and GST-NleH1 (black arrow). 
C: Purified His-NHERF2, MBP fusions of NHERF2 PDZ1, PDZ2 and EBD, as well as 
purified MBP were blotted and overlaid with GST-NleH1 followed by detection with anti-
NleH. No cross-reactivity was detected by Western blot using anti-NleH. Equivalent loading 
of proteins was confirmed by Coomassie staining. NleH1 interacts with His-NHERF2 but not 
the MBP fusions of its PDZ domains. 
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3.1.4. Discussion 
In this section, we analysed the binding of three EPEC PDZ-binding motif-containing 
effectors Map, EspI and NleH1 to NHERF proteins. Screens performed before this work 
identified NHERF1 and NHERF2 as putative Map and EspI binding partners (Lee et al., 
2008; Simpson et al., 2006). Moreover, in a new PDZ array screen, we identified NHERF2 as 
a new host cell partner of NleH1. Using different biochemical approaches, we established that 
Map and EspI interact with both full length NHERF1 and NHERF2, whereas NleH1 only 
binds NHERF2. However, detailed analysis of the binding domains involved in the interaction 
revealed differences in the specificities for the NHERF PDZ-binding domains targeted by the 
three effectors. 
Previous studies using EspI C-terminal domain on the PDZ array led to the discovery of 
multiple cellular partners, among which NHERF1 and NHERF2 (Lee et al., 2008). As 
interaction of Map with NHERF1 has been previously reported (Simpson et al., 2006) and 
NleH1 possesses a C-terminal PDZ-binding motif, we decided to use the PDZ array to 
discover new cellular partners for these two effector proteins. MapC50 could interact with 
PDZ1 and 2 of NHERF1 and 2 as well as PDZ3 of NHERF3. NleH1 could interact with a 
variety of PDZ domains and most importantly with PDZ2 of NHERF2. 
Following identification of cellular partners through PDZ interaction, we aimed at confirming 
the interaction between full length proteins. To do so, we used two techniques: far Western 
blot and ELISA. The buffer conditions differ between these techniques, far Western blot 
being considered more stringent than ELISA due to the presence of SDS. 
Using far Western blot, we confirmed the interaction between Map and EspI with NHERF1 
and 2 as well as interaction between NleH1 and NHERF2. For Map and EspI, the interaction 
was mediated by their C-terminal PDZ-binding motif. Interaction between EspI and MBP 
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fusions of NHERF1 and 2 PDZ domains matched the results obtained by PDZ array. 
However, interaction of Map with PDZ2 of NHERF1 and PDZ1 of NHERF2 could not be 
observed as on the PDZ array. Similarly, NleH1 could not interact with PDZ2 of NHERF2 by 
far Western blot, probably due to the highly stringent conditions of the experiment. 
Study of the interaction between EspI and NleH1 by ELISA could not be achieved as both 
proteins displayed some affinity for the negative control MBP. Nevertheless, ELISA 
experiments showed that Map could interact with NHERF1 and 2 as well as their respective 
PDZ1 domain. However, the interaction of Map with their PDZ2 domains, as observed by 
PDZ array, could not detected by ELISA. 
Interestingly, MapC50 could also interact with PDZ3 of NHERF3, an interaction that was not 
detected in the Y2H screen performed by Dr N. Simpson in our laboratory. NHERF3 is not 
expressed in HeLa cells (LaLonde et al., 2010) and was thus absent from the cDNA library 
used for the Y2H screen. NHERF3 appears to be a good candidate for future studies on Map 
biology. However, EspI and NleH1 do no interact with PDZ domains from this protein and we 
thus decided to focus our research on NHERF1 and NHERF2. 
Even though NHERF1 and NHERF2 share 51 % identity on the amino acid level, NleH1 
interacted specifically with NHERF2. However, qualitative analysis of our far Western blot 
assays suggests that NleH1 has reduced affinity for NHERF2 than Map or EspI. NleH1 could 
interact with the full length protein but not its isolated domains, indicating that other NHERF2 
domains might be required for interaction. The role of NleH1 PDZ-binding motif in the 
interaction with NHERF2 could not be addressed by far Western blot as GST- or His-tagged 
NleH1∆C4 were not stable in bacteria. 
NHERF1 and 2 usually interact with proteins carrying a C-terminal motif displaying a serine 
or threonine (S/T) in position -2, any amino acid in position -1 and an hydrophobic residue in 
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position 0. However, some of their cellular partners do not follow these criteria (K or V in 
position -2, F or M in position 0) (Shenolikar et al., 2004), indicating that NHERF1 and 2 
PDZ domains can accommodate different PDZ-binding motifs. In the PDZ array, Map TRL 
motif targeted solely PDZ domains from NHERFs, EspI TRV motif interacted mainly with 
PDZ1 of NHERF1 and PDZ2 of NHERF2, while NleH1 (SKI) only bound PDZ2 of 
NHERF2. Taken together, these results indicate that the amino acid sequence and 
composition of the PDZ-binding motif play a critical role in the specificity of interaction 
between effectors and given PDZ domains. In the context of infection, the three translocated 
proteins could thus potentially compete for the same binding site on NHERF2. 
In this chapter, we confirmed that effector proteins Map, EspI and NleH1 interact with 
different NHERF proteins, with NHERF2 as a common target. The next step of this study will 
focus on getting a cellular model to investigate the relevance of these interactions in the 
context of infection. 
 
3.2. Analysis of NHERF1 and NHERF2 expression and generation of 
HeLa-NHERF1 and HeLa-NHERF2 stable cell lines 
In order to investigate the cellular microbiology of diarrhoeagenic Escherichia coli infections 
in vitro, several model cell lines (i.e. HeLa, Caco2 and Swiss 3T3) are routinely used. These 
cell lines originate from different mammalian tissues which display significant differences in 
their proteomes and phenotypes upon infection. As endogenous expression of NHERF 
proteins was shown to vary between different tissues (Ingraffea et al., 2002; Yun et al., 1997), 
the expression profiles and localisation of NHERFs in the standard model cell lines was 
characterised, which lead to the decision to generate HeLa stable cell lines expressing 
NHERF1 and NHERF2 to facilitate this study.  
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3.2.1. Characterisation of NHERF expression and localisation in model 
cell lines 
3.2.1.1. Generation of an anti-NHERF2 antibody 
Human NHERF2 was cloned into pET28a vector using primers NHERF2-Fw and NHERF2-
Rv to generate an expression vector for the expression of a N-terminally His-tagged protein. 
The construct was transformed into the E. coli BL21 star strain, followed by overnight 
expression of the protein and cell lysis. The recombinant protein was purified from cleared 
supernatants by Fast Protein Liquid Chromatography (FPLC), followed by SDS PAGE 
analysis of the FPLC eluted fractions which showed the presence of a protein of the expected 
size of 45 kDa with little contamination by other bacterial proteins (Figure 3.7 A). The 
collected fractions had a protein concentration ranging from 0.1 to 1 mg/ml. The most 
concentrated fractions (1-9) were pooled and dialysed against PBS pH 7.5 and sent for rabbit 
immunisation at Covalab laboratories (Harrogate, UK). After 89 days of immunisation, the 
rabbit serum was collected and tested for reactivity by Western blot (Figure 3.7 B). The serum 
showed specific affinity for NHERF2 and little cross-reactivity for NHERF1 or bacterial 
lysate. 
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Figure 3.7: Generation of anti-NHERF2 antibodies and cross-reactivity control. 
A: Purification of recombinant His-NHERF2. His-NHERF2 was purified by FPLC and eluted 
fractions were subjected to SDS-PAGE and Coomassie staining. Nine elution fractions 
showed a band at the expected size of the His-NHERF2 protein (45 kDa) and contained 
hardly any impurities from other bacterial proteins. 
B: Specificity control of the rabbit anti-NHERF2 serum. Purified His-NHERF1 and His-
NHERF2 were blotted with rabbit anti-NHERF2 serum (3
rd
 bleed). Equivalent loading of 
proteins was confirmed by Coomassie staining. The generated anti-NHERF2 antibody 
specifically binds to NHERF2 and putative degradation products. Little or no cross-reactivity 
was observed with NHERF1 or bacterial proteins. 
 
3.2.1.2. Expression profile of NHERF1 and 2 in model cell lines 
Commercial rabbit anti-NHERF1 antibody and rabbit anti-NHERF2 serum (3.2.1.1) were 
used to detect the expression levels of endogenous proteins in HeLa, Swiss 3T3 and Caco2 
cells by Western blot (Figure 3.8). NHERF1 could be detected in HeLa cells and even higher 
levels could be detected in Caco2 cells but no NHERF1 could be detected in Swiss 3T3. 
Interestingly, the NHERF1 band appears as a doublet in Caco2 cells, indicating a possible 
alternative splicing or post-transcriptional modification of the protein. According to the 
manufacturer’s protocol, the anti-NHERF1 antibody should detect both human and mouse 
NHERF1, strongly suggesting a lack of expression rather than a lack of detection of NHERF1 
in Swiss cell lysates. 
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The study was repeated using anti-NHERF2 antibodies and identical amounts of cell lysate as 
used for NHERF1. The anti-NHERF2 Western blot revealed that HeLa cells express NHERF2 
at levels only just above the detection limit. As observed for NHERF1, Caco2 cells also 
expressed higher levels of NHERF2 compared to HeLa cells and NHERF2 could not be 
detected in Swiss 3T3 cells. 
 
 
Figure 3.8: Expression of NHERF1 and NHERF2 in HeLa, Swiss 3T3 and Caco2 cells 
Approximately 5 µg of cell extracts from HeLa, Swiss 3T3 and Caco2 cells were blotted and 
probed with anti-NHERF1 and anti-NHERF2 antibodies. Purified His-NHERF1 and His-
NHERF2 were blotted as controls. Equivalent protein loading was confirmed by Coomassie 
staining. HeLa and Caco2 cells, but not Swiss 3T3 cells, display detectable endogenous levels 
of NHERF1. Endogenous levels of NHERF2 were hardly detectable in HeLa and Caco2 cells 
(black arrows). The anti-NHERF2 serum showed a cross-reaction with a high molecular 
weight protein present in all cell lines. 
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3.2.1.3. Localisation of NHERF1 and 2 in model cell lines 
In order to confirm expression of NHERF1 and NHERF2, HeLa, Swiss 3T3 and Caco2 cells 
were grown on glass coverslips and processed for immunofluorescence. The generated rabbit 
anti-NHERF2 serum could not specifically detect NHERF2 by immunofluorescence, probably 
due to its cross-reactivity with a host cell protein as observed by Western blot (Figure 3.8). 
However, by using the commercial anti-NHERF1 antibody, it was shown that NHERF1 could 
be detected and partially colocalised with the actin cytoskeleton in HeLa and Caco2 cells 
(Figure 3.9). Interestingly, NHERF1 signal could also be observed in the nucleus of HeLa 
cells. This observation, which is unprecedented for HeLa cells, has been reported for 
NHERF1 in breast cancer cells (Cardone et al., 2007) and for NHERF2 in mouse pre-Sertoli 
cells (Thevenet et al., 2005). The presence of NHERF1 in the brush border of Caco2 cells has 
previously been reported (Donowitz et al., 2005), however, this study did not present 
experimental data concerning NHERF1 staining or colocalisation with the actin cytoskeleton. 
In Swiss 3T3 cells, the NHERF1 signal was equivalent to the fluorescent background level 
observed in samples not probed with anti-NHERF1. 
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Figure 3.9: NHERF1 colocalises with actin in HeLa and Caco2, but is not detected in Swiss 
3T3 cells 
Fluorescence microscopy of HeLa, Swiss 3T3 and Caco2 cells. NHERF1 was detected with 
anti-NHERF1 antibody (green) and actin was stained with Rhodamine phalloidin (red). 
NHERF1 displays partial colocalisation with actin in HeLa and Caco2 (white arrows) but was 
not detected in Swiss 3T3 cells. Scale bar = 10µm. 
 
3.2.2. Generation and characterisation of stable HeLa-NHERF1 and 
HeLa-NHERF2 cell lines 
The previous Western blot and immunofluorescence experiments (Figure 3.8 and 3.9) 
indicated that NHERF1 was expressed and could be detected in HeLa and Caco2 cells. 
Unfortunately, the anti-NHERF2 serum could not be used for immunofluorescence due to its 
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lack of specificity. In order to facilitate the analysis of NHERF proteins and reproducibility of 
experiments, it was decided to generate stable cells lines expressing tagged NHERF proteins. 
Even though Swiss 3T3 cells do not express interfering endogenous NHERFs and are 
commonly used for stable expression of recombinant proteins, these cells are derived from 
mouse fibroblasts and generally express a different proteomic profile to human cells. Caco2 
cells would have made an ideal model for NHERF studies as they differentiate into a 
monolayer resembling the intestinal epithelia and express detectable amounts of NHERF1 and 
2. Unfortunately these cells cannot be stably transfected. HeLa cells were considered a good 
compromise as they are derived from human cells, are very well characterised and can be 
easily transfected. Thus it was decided to generate HeLa cell lines stably expressing HA-
tagged NHERF1 and NHERF2. 
Plasmids pBKCMV-HA-NHERF1 and pBKCMV-HA-NHERF2 were transfected in HeLa 
cells to generate stable cell lines HeLa-NHERF1 and HeLa-NHERF2. Ninety six clones were 
isolated for each cell line. For HeLa-NHERF1, 48 clones were processed for 
immunofluorescence and 6 clones were found positive for HA-NHERF1 expression. 
Localisation of HA-NHERF1 was similar in all 6 clones and resembled that observed for 
endogenous NHERF1 (Figure 3.9). For HeLa-NHERF2, 60 clones were processed for 
immunofluorescence and 4 clones were found positive. HeLa-NHERF1 Clone B7 and HeLa-
NHERF2 Clone D6 had the highest expression levels and were chosen for all subsequent 
experiments. 
In all these clones, HA-NHERF1 and HA-NHERF2 showed a predominant localisation to the 
plasma membrane where they partially colocalised with actin (Figure 3.10 A). The expression 
levels of NHERF1, NHERF2 and the HA-tagged proteins in the stable cell lines were then 
controlled (Figure 3.10 B). As previously observed in Figure 3.9, it appeared that 
untransfected HeLa cells endogenously express NHERF1 but in contrast, NHERF2 can hardly 
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be detected (Figure 3.10 B). Interestingly, HeLa-NHERF1 cells seemed to express the same 
levels of NHERF1 as untransfected HeLa cells. However, anti-HA Western blot shows that 
the majority of NHERF1 in the stable cell line is HA-tagged (Figure 3.10 B). This indicates 
that in HeLa cells, levels of NHERF1 are tightly regulated and the stable cell line HeLa-
NHERF1 does not overexpress NHERF1. HA-NHERF2 could only be detected in HeLa-
NHERF2 cell extracts, confirming the observation that only the HA-tagged protein is 
expressed in the stable cell line (Figure 3.10 B). While recombinant His-tagged NHERF1 and 
NHERF2 appear to have the same molecular weight in SDS PAGE gels (Figures 3.7 and 3.8), 
HA-NHERF1 had a higher molecular weight than HA-NHERF2 in their respective stable cell 
line extracts. This can be explained by the fact that NHERF1, but not NHERF2, is 
phosphorylated in eukaryotic cells (Lamprecht and Seidler, 2006). 
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Figure 3.10: Analysis of HeLa-NHERF1 (clone B7) and HeLa-NHERF2 (clone D6) stable 
cell lines 
A: Fluorescence microscopy of HeLa, HeLa-NHERF1 and HeLa-NHERF2 cells. NHERF1 
and NHERF2 were detected with anti-HA antibody (green) and actin was stained with 
Rhodamine phalloidin (red). HA-NHERF1 and HA-NHERF2 can be detected in the cytoplasm 
and at the plasma membrane where they partially colocalise with the actin cytoskeleton. Scale 
bar = 10µm.  
B: Expression levels of NHERF proteins in HeLa, HeLa-NHERF1 and HeLa-NHERF2 cells. 
Cell extracts were blotted and probed with anti-NHERF1, anti-NHERF2 and anti-HA 
antibodies. Western blot using anti-tubulin confirmed equivalent loading of proteins. NHERF1 
is endogenously expressed in all cells; NHERF2 can only be detected in the HeLa-NHERF2 
stable cell line. Both NHERF1 and 2 were HA-tagged, but HeLa-NHERF1 expressed higher 
levels of its recombinant protein compared to HeLa-NHERF2. 
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3.2.3. Discussion 
In this section, the expression and localisation of endogenous NHERF1 and NHERF2 in 
frequently used model cell lines was characterised. New “tools”, including a NHERF2 
antibody and stable HeLa cell lines expressing HA-tagged NHERF1 and NHERF2 were 
generated and validated, in order to study these NHERF proteins during Escherichia coli 
infection. 
Overnight expression of His-NHERF2 using auto-inducible media allowed significant 
expression of the protein compared to classical methods of induction. His-NHERF2 was 
highly soluble thorough the FPLC purification process and the purified protein could be used 
for immunisation. The rabbit anti-NHERF2 serum raised using the recombinant protein was 
shown to be highly specific using Western blot. However, its use in immunofluorescence 
studies was limited due to the presence of high background levels. 
Endogenous NHERF1 and NHERF2 were detected by Western blot in HeLa and Caco2 cell 
extracts. In this experiment, Caco2 cells expressed more NHERF1 and NHERF2 than HeLa 
cells. Controversy over the expression of NHERF1 and NHERF2 in Caco2 cells has been 
exposed by three previous studies. While Northern blot analysis of Caco2 cells revealed the 
absence of mRNA corresponding to NHERF1 and NHERF2 (Yun et al., 1997), Western blot 
and immunofluorescence studies indicated that both NHERF proteins were present in this cell 
line (Lamprecht and Seidler, 2006; Yun et al., 2005). Our experiments concur with the 
Western blot and immunofluorescence data. 
In HeLa cells, NHERF1 levels were higher than NHERF2. Another study has previously 
shown that the expression levels of NHERF1 and NHERF2 were identical in HeLa cells (Oh 
et al., 2004). Discrepancies in endogenous NHERF2 expression between HeLa cells used in 
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our laboratory and the ones used in other laboratories could be due to growth conditions or 
passage number. 
The fact that mouse fibroblasts do not express NHERF1 and NHERF2 was previously 
observed in the cell line PS120 (Zizak et al., 1999; Yun et al., 1997). NHERF1 and NHERF2 
amino acid sequences possess 86% and 91% identity, respectively between human and mouse 
species (BLAST search, http://blast.ncbi.nlm.nih.gov/Blast.cgi). As a result of this high 
degree of identity, polyclonal antibodies raised against human NHERF2 would very likely 
cross-react with the mouse isoform. Our anti-NHERF1 and anti-NHERF2 antibodies could 
not detect NHERF1 or NHERF2 in Swiss 3T3 fibroblasts by Western blot or 
immunofluorescence, strongly suggesting that these proteins are either expressed but not 
detectable, or not expressed at all in Swiss 3T3 cells.  
In order to circumvent the limitations raised by Caco2 and Swiss 3T3 cell lines, it was 
decided to generate stable HeLa cells expressing HA-tagged NHERF1 and NHERF2 to 
further the investigations. 
In these cell lines, NHERF1 and NHERF2 staining at the plasma membrane resembled that 
observed in human sarcoma HT1080 cells, in human epithelial carcinoma A431 cells and in 
Madin Darny canine kidney (MDCK) cell lines (Theisen et al., 2007; DeMarco et al., 2002). 
By introducing a plasmid-borne copy of NHERF1 in HeLa cells, it was expected that the 
levels of NHERF1 expression in the cells would increase. Interestingly, the expression of 
NHERF1 appeared to be tightly regulated in HeLa cells and the levels observed in mock-
transfected cells were similar to that observed in cells carrying the pBK-CMV-HA-NHERF1 
vector. Endogenous NHERF2 could hardly be detected in HeLa cells. Following introduction 
of pBK-CMV-HA-NHERF2 in HeLa cells, levels of NHERF2 were significantly increased. 
The generated HeLa-NHERF2 cell line could thus be considered as an overexpressing one. 
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Taken together, these results indicate that stable expression of HA-tagged NHERF proteins in 
stable cell lines presents an economic and technical advantage compared to transient 
transfection, particularly as it allows a near-homogenous population of cells to express a 
protein of interest at stable levels and for a prolonged time. HeLa cells express only very low 
levels of endogenous NHERF2 protein and generation of a stable cell line will allow us to 
analyse the effects of NHERF2 in a very well characterised system without the interfering 
effects of endogenous protein(s). 
 
3.3. Modulation of effector function through NHERF2 interaction 
Map, EspI and NleH1 fulfil unrelated intracellular functions. Map provokes transient 
filopodia formation at the site of bacterial attachment before being targeted to the 
mitochondria, EspI is targeted to the Golgi apparatus where it inhibits vesicular transport and 
NleH1 is targeted to the endoplasmic reticulum and inhibits apoptosis. In this part of the 
project, the localisation of these effectors in HeLa-NHERF2 cells and how their interaction 
with NHERF2 affects their respective functions was investigated. 
3.3.1. Map colocalises with NHERF2 in HeLa-NHERF2 cells 
In order to analyse the Map-NHERF2 interaction in HeLa-NHERF2 cells, different Myc-
tagged constructs were engineered: full length Map, Map lacking its PDZ-binding motif 
(∆C3) and Map lacking its mitochondrial targeting sequence (∆N44). Map was first cloned in 
the mammalian expression vector pRK5 using primers Map-Fw2 and Map-Rv. The resulting 
plasmid was used as a template to generate Map∆C3 and Map∆N44 by inverse PCR using 
primer pairs Map∆C3-Fw/Map∆C3-Rv and Map∆N44-Fw/Map∆N44-Rv. 
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HeLa-NHERF2 cells were then transfected with pRK5-Map, pRK5-Map∆C3 and pRK5-
Map∆N44 and processed for immunofluorescence (Figure 3.11). Map, Map∆C3 and 
Map∆N44 were expressed in these cells and did not induce cytotoxicity as previously 
suggested (Kenny et al., 2002). Map, as previously described (Kenny and Jepson, 2000), and 
Map∆C3 were targeted to the mitochondria where they colocalised with the mitotracker 
marker. Map∆N44 exhibited a diffuse cytoplasmic localisation and, as expected, was not 
targeted to the mitochondria. Similar localisation was seen for all three Map derivatives in 
HeLa cells (data not shown). 
 
Figure 3.11: Map and Map∆C3, but not Map∆N44, localise to the mitochondria 
Fluorescence microscopy of HeLa-NHERF2 cells transfected with pRK5, pRK5-Map, pRK5-
Map∆C3 and pRK5-Map∆N44. Map proteins were detected using anti-Myc antibodies 
(green) and mitochondria were stained using mitotracker (red). Map and Map∆C3 colocalised 
with the mitochondria in transfected cells (white arrows). Map∆N44 had a diffuse localisation 
and did not colocalise with mitochondria. Scale bar = 10 µm. 
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Immunofluorescence was then used to investigate how ectopic expression of Map, Map∆C3 
and Map∆N44 affected the localisation of NHERF2 (Figure 3.12). In mock transfected cells, 
NHERF2 was mainly associated with the plasma membrane. Following transfection with 
pRK5-Map, NHERF2 was depleted from the plasma membrane and colocalised with Map in 
discrete structures, which, as observed in the previous experiment (Figure 3.11), corresponded 
to the mitochondria. In contrast, Map∆C3 failed to recruit NHERF2 to mitochondrial 
structures in transfected HeLa-NHERF2 cells. These results strongly suggests that (i) 
ectopically-expressed Map is able to recruit NHERF2 to the mitochondria, (ii) Map PDZ-
binding motif is required for interaction with NHERF2 and (iii) Map PDZ-binding motif is 
still available for interaction when Map is localised at the mitochondria. 
Map∆N44 did not localise to the mitochondria but partial colocalisation with NHERF2 was 
observed at the plasma membrane in actin projections corresponding to filopodia. Overall, 
Map and Map∆N44 colocalised with NHERF2 in two different compartments of the cell. 
Formation of filopodia was independent of Map MTS as previously described in other studies 
(Kenny et al., 2002). 
The induction of strong filopodia at the surface of the cells by ectopically-expressed Map was 
confirmed by scanning electron microscopy (SEM) (Figure 3.12). This phenotype was even 
more dramatic in HeLa-NHERF2 cells transfected with Map∆N44. In contrast, transfection of 
Map∆C3 did not induce increased levels of filopodia in these cells. Taken together, these 
results indicate that the PDZ-mediated binding of Map to NHERF2 influences the formation 
of filopodia. 
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Figure 3.12: Map and Map∆N44 colocalise with NHERF2 and induce filopodia following 
transfection 
Fluorescence microscopy and scanning electron microscopy (SEM) of HeLa-NHERF2 cells 
transfected with pRK5, pRK5-Map, pRK5-Map∆C3 or pRK5-Map∆N44. Map was detected 
with anti-Myc antibodies (purple), NHERF2 with anti-HA antibodies (green) and actin was 
labelled with Rhodamine phalloidin (red). Map and Map∆N44 colocalised with NHERF2 in 
mitochondrial structures (filled arrows) and in filopodia (open arrows), respectively. No 
colocalisation between NHERF2 and Map∆C3 was observed. Transfection of cells with 
pRK5-Map and pRK5-Map∆N44 induced strong filopodia, whereas such a phenotype was not 
observed with pRK5-Map∆C3. Scale bar = 10 µm. 
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3.3.2. Interaction of Map with NHERF2 modulates filopodia topology and 
dynamics during EPEC infection 
Transfection experiments confirmed that Map and NHERF2 interact in eukaryotic cells. 
These experiments also indicated that the interaction between these two proteins has dramatic 
effects on filopodia formation. Map-NHERF2 interaction and its effect on filopodia dynamics 
in the context of infection were therefore studied. 
HeLa-NHERF2 cells were infected with EPEC wild-type and EPEC ∆map mutant 
complemented with pSA10-Map or pSA10-Map∆C3 (Figure 3.13). Map∆N44 could not be 
used by infection as the translocation signal of Map is contained within the first 44 N-terminal 
amino acids (Kenny and Jepson, 2000). Infection of HeLa-NHERF2 for 30 minutes with 
EPEC wild-type led to development of moderate filopodia at the site of bacterial adherence 
(Figure 3.13 A and B). EPEC ∆map expressing Map∆C3 from pSA10 produced short 
filopodia at the site of bacterial adherence (Figure 3.13 A), which could not observed by SEM 
(Figure 3.13 B). EPEC ∆map expressing Map from pSA10 induced exaggerated filopodia, 
which were longer than those formed by EPEC wild-type and extended further around the 
adherent microcolony. Even though this phenotype was probably due to overexpression of 
Map, it strongly suggests that the interaction between Map and NHERF2 modulates the 
topology of filopodia during infection. Interestingly, recruitment of NHERF2 at the site of 
bacterial attachment was observed for all strains; this phenotype will be further described and 
analysed in chapter 3.4. 
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Figure 3.13: The interaction of Map with NHERF2 modulates filopodia topology during 
infection 
A: Fluorescence microscopy of HeLa-NHERF2 cells infected for 30 minutes with EPEC 
wild-type (wt) and EPEC ∆map mutant complemented with pSA10-Map or pSA10-Map∆C3. 
Actin was stained with Rhodamine phalloidin (red), NHERF2 was detected with anti-HA 
antibodies (green) and EPEC was detected with anti-O127 antibodies (cyan). Filopodia (open 
arrows) are formed at the site of adherent EPEC wt and ∆map pSA10-Map microcolonies 
(filled arrows) but not EPEC ∆map pSA10-Map∆C3. Scale bar = 10µm. 
B: Scanning electron microscopy of HeLa-NHERF2 cells infected with EPEC wild-type (wt) 
and EPEC ∆map complemented with pSA10-Map or pSA10-Map∆C3. Short filopodia were 
observed at the site of EPEC wt adhesion whereas exaggerated filopodia were observed at the 
site of EPEC ∆map pSA10-Map adhesion. No filopodia were observed with EPEC ∆map 
expressing Map∆C3. Scale bar = 5 µm. 
 
Filopodia are an early transitory phenomenon which are down-regulated during EPEC 
infection (Berger et al., 2009; Kenny et al., 2002). Consequently, the dynamics of filopodia 
formation and withdrawal in EPEC wild-type-infected HeLa and HeLa-NHERF2 cells were 
investigated. At all time points of infection, it was observed that more HeLa-NHERF2 cells 
displayed filopodia at the site of bacterial attachment than HeLa cells (Figure 3.14 A). This 
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phenotype suggests that expression of NHERF2 in HeLa cells plays a role in filopodia 
stabilisation. 
In order to investigate the role of PDZ-mediated NHERF2-Map interaction in filopodia 
persistence, HeLa and HeLa-NHERF2 cells were infected with EPEC Δmap expressing Map 
or Map∆C3. In both cell lines, filopodia induced by EPEC Δmap expressing Map∆C3 
withdrew much faster than those induced by the mutant strain expressing full length Map 
(Figure 3.14 B). Importantly, approximately 80 % of HeLa-NHERF2 cells infected with 
EPEC Δmap expressing Map displayed filopodia after 90 minutes of infection while only 20 
% of HeLa cells displayed such a phenotype (Figure 3.14 B). Taken together these results 
suggest that, in our HeLa-NHERF2 model, the interaction Map-NHERF2 stabilises filopodia 
during infection. 
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Figure 3.14: The interaction Map-NHERF2 modulates filopodia dynamics during infection 
A: Quantification of infected HeLa (black bars) and HeLa-NHERF2 (white bars) cells 
displaying filopodia following infection with wild-type EPEC. Down-regulation of filopodia 
was delayed in HeLa cells expressing HA-NHERF2. One hundred infected cells were counted 
in three independent experiments. Results are shown as mean ± SD. P-values of <0.05 (*) 
were considered as significant. 
B: Quantification of infected HeLa and HeLa-NHERF2 cells displaying filopodia following 
infection with EPEC Δmap complemented with pSA10-Map or pSA10-Map∆C3. EPEC 
Δmap complemented with pSA10-Map, but not pSA10-Map∆C3, was able to maintain 
filopodia over time in NHERF2-expressing HeLa cells. One hundred infected cells were 
counted in three independent experiments. Results are shown as mean ± SD. P-values of 
<0.05 (# for HeLa cells, § for HeLa-NHERF2 cells) were considered as significant 
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3.3.3. EspI interacts with NHERF2 in HeLa-NHERF2 cells 
According to recent studies (Lee et al., 2008) and the results presented in chapter 3.1.2, EspI 
can interact with several eukaryotic proteins, including NHERF2. In order to confirm the 
interaction between EspI and NHERF2 in vivo, HeLa-NHERF2 cells were transfected with 
GFP fusions of EspI and EspI∆C7 (Kindly provided by Prof. Elizabeth Hartland, Melbourne 
University). Both EspI and EspI∆C7 were targeted to the Golgi apparatus where they 
colocalised with the Golgi marker GM130 as previously reported (Lee et al., 2008) (Figure 
3.15). EspI, but not EspI∆C7, colocalised with NHERF2 at the plasma membrane, suggesting 
that EspI and NHERF2 interact in vivo and that this interaction is mediated by EspI PDZ-
binding motif. 
 
Figure 3.15: EspI colocalises with NHERF2 by transfection 
Fluorescence microscopy of HeLa-NHERF2 cells transfected with pGFP-C2, pGFP-C2-EspI 
and pGFP-C2-EspI∆C7. NHERF2 was detected with anti-HA antibodies (red) and Golgi 
apparatus was stained with anti-GM130 antibodies (cyan). Both EspI and EspI∆C7 (green) 
localised at the Golgi apparatus (open arrows). Partial colocalisation of HA-NHERF2 and 
EspI, but not EspI∆C7, was observed at the plasma membrane (filled arrows). Scale bar = 
10µm. Plasmids were kindly provided by Dr Elizabeth Hartland (Melbourne University). 
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To further confirm that EspI and NHERF2 interact during the course of infection, HeLa-
NHERF2 cells were infected with EPEC ΔespI and ΔespI complemented with pSA10-EspI or 
pSA10-EspIΔC7 for 1 h. HA-NHERF2 was immunoprecipitated from cell extracts using anti-
HA antibodies coated beads and samples were analysed by Western blot for presence of EspI 
(Figure 3.16). EspI and EspIΔC7 were found in HeLa-NHERF2 cell extracts infected with 
their respective strains, indicating that the proteins were properly translocated. EspI, but not 
EspIΔC7, could be co-immunoprecipitated with HA-NHERF2. This result strongly suggests 
that, in the course of infection, EspI interacts with NHERF2, and that interaction is mediated 
by the last 7 amino acids of EspI. 
 
 
Figure 3.16: EspI co-immunoprecipitates with NHERF2 
HA-NHERF2 was immunoprecipitated with anti-HA-coated beads from HeLa-NHERF2 cells 
infected for 1 hour with EPEC ΔespI mutant and ΔespI mutant complemented with pSA10-
EspI or pSA10-EspIΔC7. Equivalent protein loading was confirmed by anti-NHERF2 
Western blots. Anti-EspI Western blots reveal equivalent levels of EspI and EspI∆C7 in the 
whole cell extracts and the presence of EspI, but not EspI∆C7, in HA-NHERF2 
immunoprecipitated samples. 
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3.3.4. NHERF2 modulates the transport of EspI to the Golgi 
Several studies demonstrated that EspI traffics from the site of bacterial attachment to the 
Golgi apparatus during EPEC infection (Lee et al., 2008; Gruenheid et al., 2004). However, 
the mechanisms implicated in its transport from the membrane to the Golgi remain unknown. 
Consequently, how the interaction with NHERF2 affected the transport dynamics of EspI in 
HeLa and HeLa-NHERF2 cells was investigated by immunofluorescence (Figure 3.17 A). 
After 30 min of infection of HeLa cells with EPEC ∆espI expressing EspI, EspI was mainly 
found at the site of bacterial adherence. However, under the same infection conditions in 
HeLa-NHERF2 cells, EspI was located at the site of bacterial adherence and in perinuclear 
structures (Figure 3.17 A). Due to antibody incompatibility, Golgi markers could not be used 
in this immunofluorescence experiment. However, a control experiment confirmed that EspI 
only accumulates in structures corresponding to the Golgi apparatus (Figure 3.18 A). These 
results suggest that EspI transport to the Golgi apparatus was accelerated in cells expressing 
NHERF2. In order to quantify the effect of NHERF2 expression on the transport rate of EspI 
to the Golgi apparatus, HeLa and HeLa-NHERF2 cells were infected with EPEC ∆espI 
expressing EspI and the presence of EspI at the Golgi in infected cells was quantified by 
immunofluorescence microscopy at different time points (Figure 3.17 B). At early time points 
(15 and 30 minutes), more HeLa-NHERF2 cells showed EspI staining at the Golgi compared 
to normal HeLa cells. 
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Figure 3.17: EspI transport to the Golgi apparatus is accelerated in HeLa-NHERF2 cells 
A: Fluorescence microscopy of HeLa and HeLa-NHERF2 cells infected for 30 minutes with 
EPEC ∆espI pSA10-EspI. NHERF2 was detected with anti-HA antibodies (green), EspI was 
stained with anti-EspI antibodies (red) and DNA was counter-stained with Hoechst 33342 
(cyan). EspI was detected at the site of bacterial attachment in HeLa and HeLa-NHERF2 cells 
(open arrows), but increased EspI staining in perinuclear structures corresponding to the Golgi 
apparatus was only observed in HeLa-NHERF2 cells (filled arrows). Scale bar = 10 µm. 
B: Quantification of EPEC ΔespI pSA10-EspI infected HeLa (black bars) and HeLa-NHERF2 
(white bars) cells in which EspI mainly localised to the Golgi apparatus. Increased EspI 
localisation at the Golgi apparatus was observed in HeLa-NHERF2 cells compared to HeLa 
cells following 15 and 30 minutes of infection. Fifty infected cells were counted in three 
independent experiments. Results are shown as mean ± SD. P-values of <0.01 (*) were 
considered as significant. 
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In order to investigate the role of EspI PDZ-binding motif in the transport process, HeLa-
NHERF2 cells were infected with EPEC ∆espI expressing EspI or EspI∆C7. After 30 min of 
infection, EspI was detected at the site of bacterial attachment and at the Golgi while EspI∆C7 
was only detected at the site of bacterial attachment (Figure 3.18 A). In order to quantify the 
role of NHERF2 and the EspI PDZ-binding motif in EspI transport, HeLa and HeLa-NHERF2 
cells were infected with EPEC ∆espI expressing EspI and EspI∆C7 (Figure 3.18 B). Golgi 
staining of EspI∆C7 was much lower after 30, 60 and 90 min of infection compared to EspI in 
both HeLa and HeLa-NHERF2 cell lines. Taken together, these results suggest that EspI 
interacts with NHERF2 through its PDZ-binding domain and that interaction accelerates 
transport of EspI to the Golgi apparatus. 
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Figure 3.18: The PDZ-binding motif of EspI is required for its transport to the Golgi 
A: Fluorescence microscopy of HeLa-NHERF2 cells infected for 30 minutes with EPEC 
∆espI and EPEC ∆espI complemented with pSA10-EspI or pSA10-EspI∆C7. Golgi apparatus 
was stained with anti-GM130 antibodies (green), EspI was stained with anti-EspI antibodies 
(red) and DNA was counter-stained with Hoechst 33342 (cyan). EspI is detected at the site of 
EPEC ∆espI pSA10-EspI and EPEC ∆espI pSA10-EspI∆C7 adherence (open arrows). EspI, 
but less EspI∆C7, colocalised with the Golgi apparatus after 30 min of infection (filled 
arrows). Scale bar = 10µm. 
B: Quantification of EspI Golgi localisation in HeLa and HeLa-NHERF2 cells infected with 
EPEC ∆espI complemented with pSA10-EspI or pSA10-EspI∆C7. EspI∆C7 shows reduced 
localisation to the Golgi compared to EspI in both cell lines. Fifty infected cells were counted 
in three independent experiments. Results are shown as mean ± SD. P-values of <0.05 (# for 
HeLa cells, § for HeLa-NHERF2 cells) were considered as significant. 
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3.3.5. NHERF1 silencing induces Golgi apparatus disassembly but does 
not inhibit EspI transport to the Golgi apparatus  
Upon infection with EPEC, it was observed that EspI transport to the Golgi was accelerated in 
cells expressing NHERF2. However in HeLa cells, in which endogenous NHERF2 could 
hardly be detected, EspI was still transported to the Golgi apparatus (Figure 3.18 B). It was 
hypothesised that EspI transport could be mediated through interaction with NHERF1. Since 
our HeLa-NHERF1 cell line did not overexpress NHERF1 compared to HeLa cells (Chapter 
3.2.2), we decided to investigate EspI transport to the Golgi in HeLa cells transfected with 
interfering RNA directed against NHERF1. 
To set up the optimal conditions for NHERF1 silencing, HeLa cells were transfected with 
either NHERF1-interfering RNA (NHERF1i) or non-interfering RNA (scramble) and 
NHERF1 expression was analysed by Western blot (Figure 3.19 A). NHERF1 silencing could 
be observed as early as 24 h post-transfection, and the protein could hardly be detected after 
43 h post-transfection. NHERF1 levels remained constant in cells treated with scramble RNA 
(Figure 3.19 A). Upon transfection with NHERF1i, an increased number of cells with a 
dispersed Golgi apparatus was observed, while transfection with scramble RNA led to little 
Golgi dispersion. Following quantification by immunofluorescence, it was observed that 
NHERF1i induced Golgi apparatus dispersion in significantly more HeLa cells than scramble 
RNA (Figure 3.19 B). Apoptosis and microtubule disruption can trigger Golgi dispersion 
(Mukherjee et al., 2007; Cole et al., 1996). However, nucleus and microtubule networks were 
similar in scramble and NHERF1i-treated cells, indicating that Golgi dispersion was not due 
to apoptosis or microtubules disruption (Figure 3.19 C).  
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Figure 3.19: RNA interference of NHERF1 provokes disruption of the Golgi apparatus 
A: Cell extracts of HeLa cells transfected with NHERF1-interfering RNA (NHERF1i) or 
scramble RNA were collected at different time points, blotted and probed with anti-NHERF1. 
Western blot using anti-tubulin antibodies confirmed equivalent loading of proteins. 
Expression of NHERF1 is significantly diminished after 43 hours of interference. 
B: Quantification of HeLa cells displaying a dispersed Golgi apparatus after 43 hours of 
transfection with NHERF1i or scramble RNA. Golgi dispersion was observed by 
immunofluorescence microscopy using anti-GM130 antibodies. RNA interference of 
NHERF1 induces an increased dispersion of the Golgi apparatus in HeLa cells compared to 
scramble RNA-treated HeLa cells. One hundred infected cells were counted in three 
independent experiments. Results are shown as mean ± SD. P-values of <0.05 (*) were 
considered as significant. 
C: Fluorescence microscopy of HeLa cells transfected for 43 hours with NHERF1i or 
scramble RNA. Tubulin was detected with anti-tubulin antibodies (green), Golgi apparatus 
was stained with anti-GM130 antibodies (red) and DNA was counter-stained with Hoechst 
33342 (cyan). NHERF1 RNA interference induces dispersion of the Golgi apparatus (white 
arrows), while this organelle maintains a compact structure in scramble RNA-treated HeLa 
cells. Microtubule network and nucleus morphology were similar in cells transfected with 
NHERF1i or scramble RNA. Scale bar = 10 µm. 
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The fact that NHERF1 silencing induced Golgi apparatus dispersion impeded the 
quantification of cells displaying EspI staining at the Golgi. Nevertheless, we wanted to 
determine whether NHERF1 silencing inhibited EspI targeting to the Golgi apparatus. HeLa 
cells treated with NHERF1i and scramble RNA were infected for 1 h with EPEC ∆espI 
complemented with pSA10-EspI and were then processed for immunofluorescence (Figure 
3.20). Partial colocalisation of EspI and GM130 was observed in cells treated with NHERF1i 
and scramble RNA, suggesting that, even if NHERF1 plays a role in maintaining integrity of 
the Golgi apparatus, its silencing did not inhibit EspI transport to this organelle. 
 
 
Figure 3.20: RNA interference of NHERF1 does not abolish EspI transport to the Golgi 
Fluorescence microscopy of HeLa cells transfected for 43 hours with NHERF1-interfering 
RNA (NHERF1i) or non-interfering RNA (scramble) and infected for 1 h with EPEC ∆espI 
complemented with pSA10-EspI. Golgi apparatus was stained with anti-GM130 antibodies 
(green), EspI was stained with anti-EspI antibodies (red) and DNA was counter-stained with 
Hoechst 33342 (cyan). EspI colocalised with the Golgi apparatus in HeLa cells either treated 
with NHERF1i or treated with scramble RNA (white arrows). Scale bar = 10 µm. 
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Implication of NHERF1 in EspI transport to the Golgi could not be assessed using 
immunofluorescence studies as NHERF1 could not be overexpressed in HeLa cells and its 
silencing led to Golgi dispersion. Nevertheless, our results do not exclude the possibility that 
NHERF1 actually participates in EspI transport. Indeed, EspI lacking its PDZ-binding motif 
showed decreased Golgi localisation in HeLa cells. 
 
3.3.6. NleH1 interacts with NHERF2 in HeLa-NHERF2 cells  
In this study, NleH1 was identified as the third EPEC effector that is able to bind NHERF2 
(Chapter 3.1.3). In order to investigate the interaction between NleH1 and NHERF2 in cells, 
HeLa-NHERF2 cells were transfected with pRK5, pRK5-NleH1 or pRK5-NleH1∆C4 (Figure 
3.21). NleH1 was mainly detected at the plasma membrane where it partially colocalised with 
NHERF2. Contrary to the His- and GST-tagged constructs (Chapter 3.1.3), NleH1∆C4 did not 
show any signs of instability when expressed in HeLa-NHERF2 cells and was mainly 
detected in the perinuclear region. However, the protein did not colocalise with NHERF2, 
indicating that the interaction is mediated via the NleH1 PDZ-binding motif. 
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Figure 3.21: NleH1 colocalises with NHERF2 by transfection 
Fluorescence microscopy of Hela-NHERF2 cells transfected with pRK5, pRK5-NleH1 or 
pRK5-NleH1∆C4. NHERF2 was detected with anti-HA antibodies (green) and NleH1 was 
detected with anti-Myc antibodies (red). NleH1, but not NleH1∆C4, partially colocalised with 
NHERF2 at the plasma membrane (white arrows). Scale bar = 10 µm. 
 
The interaction between NleH1 and NHERF2 during EPEC infection was then investigated. 
EPEC ∆∆nleH (carrying the double mutations ∆nleH1 ∆nleH2) was transformed with pSA10-
NleH1 or pSA10-NleH1∆C4 (Scott Robinson, unpublished data). NleH1 was expressed and 
secreted by EPEC ∆∆nleH complemented with pSA10-NleH1 (Figure 3.22 A). On the 
contrary, NleH1∆C4 seemed to hardly be expressed in the bacteria, which might be due to the 
instability already observed for the His- and GST-tagged constructs (Chapter 3.1.3). However, 
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some NleH1∆C4 could be secreted by EPEC ∆∆nleH complemented with pSA10- NleH1∆C4 
(Figure 3.22 A). HeLa-NHERF2 cells were infected for one hour with EPEC ∆∆nleH or the 
complemented strains and HA-NHERF2 was immunoprecipitated from cell extracts using 
anti-HA coated beads. While NleH1∆C4 could not be detected in cell extracts or in the 
immunoprecipitated samples, probably due to its low secretion levels, NleH1 was present in 
HeLa-NHERF2 cell extracts and immunoprecipitated samples, demonstrating that NleH1 
interacts with NHERF2 during infection (Figure 3.22 B). 
 
 
 
Figure 3.22: NleH1, but not NleH1∆C4, is stable and co-immunoprecipitates with NHERF2 
A: Bacterial extracts and secreted proteins from EPEC ∆∆nleH, EPEC ∆∆nleH complemented 
with pSA10-NleH1 or pSA10-NleH1∆C4 were blotted and probed with anti-NleH antibodies. 
NleH1 is detected in the bacterial extract and supernatant of EPEC ∆∆nleH pSA10-NleH1 
(black arrows). NleH1∆C4 could be detected in the supernatant but not in the bacterial extract 
of EPEC ∆∆nleH pSA10-NleH1∆C4, suggesting that the protein is not stable inside bacteria. 
B: HA-NHERF2 was immunoprecipitated with anti-HA-coated beads from HeLa-NHERF2 
cells infected for 1 hour with EPEC ∆∆nleH and EPEC ∆∆nleH complemented with pSA10-
NleH1 or pSA10-NleH1∆C4. Equivalent loading of proteins was monitored by anti-NHERF2 
Western blots. Anti-NleH Western blots reveals presence of NleH1 in whole cell extracts and 
HA-NHERF2 immunoprecipitated samples (black arrows). NleH1∆C4 could not be detected 
in cell extracts or immunoprecipitated samples. 
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3.3.7. The interaction NleH1-NHERF2 inhibits NleH1 anti-apoptotic 
activity 
NleH1 has an anti-apoptotic activity and thus prevents caspase-3 activation, nuclear 
condensation and cell detachment during EPEC infection (Hemrajani et al., 2010). 
In order to investigate the effect of NHERF2 expression on NleH1-mediated caspase-3 
inhibition, HeLa and HeLa-NHERF2 cells were transfected with pRK5-NleH1 or pRK5-
NleH1ΔC4 and treated 4 h with the pro-apoptotic, global kinase inhibitor, staurosporine. 
Following immunofluorescence staining, cells displaying caspase-3 activation were analysed 
and quantified (Figure 3.23 A and B). 
HeLa and HeLa-NHERF2 cells transfected with pRK5 displayed similar levels of activated 
caspase-3, indicating that NHERF2 expression per se did not prevent staurosporine-induced 
apoptosis. Frequent and strong activation of caspase-3 was observed in HeLa cells transfected 
with pRK5 or pRK5-NleH1ΔC4, but not in pRK5-NleH1 transfected cells after staurosporine 
treatment (Figure 3.23 A and B). This confirmed the anti-apoptotic activity of NleH1 and 
indicated that NleH1 PDZ-binding motif plays an important role in its activity. Most 
importantly, HeLa-NHERF2 cells transfected with pRK5 or pRK5-NleH1 showed similar 
levels and occurrence of caspase-3 activation, suggesting that the interaction of NleH1 with 
NHERF2 antagonises its anti-apoptotic activity. 
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Figure 3.23: NHERF2 antagonises the anti-apoptotic activity of NleH1 on activation of 
caspase-3 
A: Fluorescence microscopy of HeLa and HeLa-NHERF2 cells transfected with pRK5 
(Mock), pRK5-NleH1 or pRK5-NleH1ΔC4 and treated for 4 hours with 1 µM STS. NHERF2 
was stained with anti-HA antibodies (red), NleH1 with anti-Myc antibodies (green) and 
activated caspase-3 was detected with anti-cleaved caspase-3 antibodies (white). All cells 
presented high levels of activated caspase-3, except HeLa cells expressing NleH1. Mutation 
of NleH1 PDZ-binding motif and NHERF2 expression inhibit NleH1 anti-apoptotic activity. 
Scale bar = 10 µm. 
B: HeLa and HeLa-NHERF2 cells were transfected with pRK5 (black bars), pRK5-NleH1 
(white bars) or pRK5-NleH1ΔC4 (gray bars) before being treated with 1 µM STS for 4 hours. 
Caspase-3 activation was observed by immunofluorescence microscopy using anti-Myc, anti-
NHERF2 and anti-cleaved caspase-3 antibodies. Cells expressing NHERF2 and NleH1 were 
more often positive for caspase-3 activation than HeLa cells expressing NleH1. One hundred 
transfected cells were counted for activated caspase-3 signal in three independent 
experiments. Results are shown as mean ± SD. P-values of <0.05 (*) were considered as 
significant. 
 
In order to confirm the data obtained for the caspase-3 activation assay, a series of analogue 
experiments were performed that monitored nuclear condensation which is another marker for 
apoptosis. 
HeLa and HeLa-NHERF2 cells were transfected with pRK5, pRK5-NleH1 or pRK5-
NleH1ΔC4 and treated for 4 hours with staurosporine. Cells displaying nuclear condensation 
were quantified by immunofluorescence (Figure 3.24 A and B). HeLa cells expressing NleH1, 
but not NleH1ΔC4, showed lower levels of nuclear condensation, which indicates that the last 
4 amino acids are important for the anti-apoptotic activity of the protein. Transfection of 
HeLa-NHERF2 cells with pRK5-NleH1ΔC4 resulted in the same phenotype as in normal 
HeLa cells. HeLa-NHERF2 cells transfected with pRK5-NleH1 displayed diminished nuclear 
condensation, but the levels were significantly higher than those observed in HeLa cells 
expressing NleH1. Taken together, these results confirm that the NleH1 PDZ-binding motif is 
important for the anti-apoptotic role of the protein and that interaction with NHERF2 might 
counteract NleH1 anti-apoptotic function. 
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Figure 3.24: NHERF2 antagonises the anti-apoptotic activity of NleH1 on nuclear 
condensation 
A: Fluorescence microscopy of HeLa and HeLa-NHERF2 cells transfected with pRK5 
(Mock), pRK5-NleH1 or pRK5-NleH1ΔC4 and treated for 4 hours with 1µM STS. NHERF2 
was stained with anti-HA antibodies (green), NleH1 with anti-Myc antibodies (red) and DNA 
was counter-stained with Hoechst 33342 (cyan). All cells presented high levels of nuclear 
condensation (white arrows), except HeLa cells expressing NleH1, indicating that deletion of 
NleH1 PDZ-binding motif and NHERF2 expression inhibit its anti-apoptotic activity. Scale 
bar = 10 µm. 
B: HeLa and HeLa-NHERF2 cells were transfected with pRK5 (black bars), pRK5-NleH1 
(white bars) or pRK5-NleH1ΔC4 (gray bars) before being treated with 1µM STS for 4 hours. 
Nuclear condensation was observed by immunofluorescence microscopy using anti-Myc and 
anti-NHERF2 antibodies and Hoechst 33342 staining. Immunofluorescence analysis revealed 
that cells expressing NHERF2 and NleH1 were more often positive for nuclear condensation 
than HeLa cells expressing NleH1. One hundred transfected cells were counted for nuclear 
condensation in three independent experiments. Results are shown as mean ± SD. P-values of 
<0.05 (*) were considered as significant. 
 
3.3.8. Discussion 
In this section, we investigated how the interaction between NHERF2 and Map, EspI and 
NleH1 affects their respective functions. 
Map possesses three domains which have each been associated with specific functions: the 
first N-terminal 44 amino acids contain a T3SS secretion signal and a MTS responsible for 
targeting Map to the mitochondria (Kenny and Jepson, 2000), the central WxxxE-containing 
motif is involved in Cdc42 activation and filopodia formation (Bulgin et al., 2010; Huang et 
al., 2009) and the last C-terminal 3 amino acids are involved in the interaction with NHERF1 
(Simpson et al., 2006). 
In chapter 3.1.1, NHERF2 was identified as a Map host cell partner. We then aimed to 
confirm the Map-NHERF2 interaction by transfection. Interestingly, transfection of Map into 
HeLa-NHERF2 cells modified the cellular localisation of NHERF2. From this data, it can be 
assumed that ectopically-expressed Map had a higher affinity for mitochondrial proteins than 
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for NHERF2, thus depleting the protein from the cytoplasm and concentrating it at the 
mitochondria. This phenotype was not observed when cells were transfected with pRK5-
Map∆C3, further confirming that Map PDZ-binding motif mediates the interaction with 
NHERF2. Deletion of Map MTS abolished its targeting to the mitochondria and led to 
increased filopodia at the surface of HeLa-NHERF2 cells. 
Even though transfection of Map in HeLa-NHERF2 cells highlighted a possible difference in 
its affinity for NHERF2 and mitochondrial proteins, the presence of NHERF2 at the 
mitochondria was not observed during infection with EPEC expressing Map, suggesting that 
Map-dependent recruitment of NHERF2 to the mitochondria might not be physiological. 
Several studies have shown that Map is present at the site of bacterial attachment at early time 
points of infection (Simpson et al., 2006) and then accumulates at the mitochondria at later 
time points (Kenny and Jepson, 2000). The dynamics of Map transport from the bacterial 
attachment site to the mitochondria during infection could not be investigated in our study due 
to technical limitations in Map detection by immunofluorescence. Moreover, our attempts to 
co-immunoprecipitate Map with NHERF2 were unsuccessful, probably due to the high 
insolubility of Map. 
In the context of EPEC infection, we observed that Map PDZ-binding motif was essential to 
maintain filopodia at the site of bacterial attachment. Furthermore, expression of NHERF2 in 
HeLa cells stabilised filopodia formation at the site of bacterial adhesion. The presence of 
NHERF2 at the site of bacterial attachment thus plays a role in retaining Map and delaying its 
transport to the mitochondria. In addition, localisation of Map GEF activity underneath 
adherent bacteria could stabilise filopodia formation through localised activation of Cdc42. 
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Since approximately 37% of human and mouse GEFs possess a PDZ-binding motif (Garcia-
Mata and Burridge, 2007), Map PDZ-binding motif could thus be considered as an additional 
level of mimicry to host GEFs. 
Similarly to Map, EspI localisation shifts from the site of bacterial attachment to an 
intracellular organelle during the course of EPEC infection (Lee et al., 2008; Gruenheid et al., 
2004). Interaction of EspI with the Sec23/24 complex leads to inhibition of vesicular transport 
between the ER and the Golgi apparatus, where EspI accumulates (Kim et al., 2007). 
However, little is known about the mechanisms of EspI transport inside eukaryotic cells. 
Comparing HeLa and HeLa-NHERF2 cells infected with EPEC expressing EspI, we observed 
that EspI transport to the Golgi was accelerated in cells overexpressing NHERF2. Even 
though the role of NHERF2 in endocytic sorting of proteins is not fully understood, it could 
facilitate EspI transport to intracellular compartments. However, NHERF2 was not essential 
for the transport of EspI as the effector protein still accumulated in Golgi structures in HeLa 
cells, in which NHERF2 could hardly be detected. 
Lee and co-workers identified several PDZ-containing proteins, such as NHERF1 and 
SNX27, as potential EspI partners (Lee et al., 2008). These proteins, which have been shown 
to participate in the endocytic recycling of the GPCR 5-HT4(a) (Joubert et al., 2004), could 
potentially participate in the transport of EspI to the Golgi apparatus. 
The role of NHERF1 in EspI transport could not be addressed by immunofluorescence 
analysis, since its silencing in HeLa cells led to dispersion of the Golgi apparatus. Indeed, this 
is the first time that NHERF1 is reported to be involved in Golgi integrity. Golgi integrity has 
been shown to rely on protein kinase A (PKA) and protein kinase D (PKD) localised activity 
(Mavillard et al., 2010; Czondor et al., 2009; Bejarano et al., 2006). NHERF1 plays an 
important role in localising protein kinases (Kunkel et al., 2009; Weinman et al., 2000). We 
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can thus speculate that NHERF1 either plays a role at the Golgi apparatus or is involved in a 
regulatory cascade stabilising the Golgi structure. Even though EspI is not directly involved in 
Golgi disruption, as observed by infection, interaction with NHERF1 and 2 could accelerate 
its transport to the organelle. 
Finally, EspI∆C7 failed to be actively transported to the Golgi apparatus, indicating that the 
PDZ-binding domain is essential for EspI transport. Moreover, EspI∆C7 remained mainly 
localised underneath adherent bacteria, strongly suggesting the presence of non-PDZ domain-
containing partner at the site of bacterial attachment. 
During the course of EPEC infection, NleH1 interacts with the ER-associated protein Bax 
inhibitor 1 (BI-1) to inhibit apoptosis (Hemrajani et al., 2010). As NleH1 was able to interact 
with NHERF2 in our in vitro assays (Chapter 3.1.3), we wanted to investigate the effect of the 
interaction on its anti-apoptotic activity. 
Ectopically-expressed NleH1 colocalised with NHERF2 at the plasma membrane of HeLa-
NHERF2 cells. Furthermore, NleH1 anti-apoptotic activity observed in HeLa cells was 
strongly diminished when the protein was expressed in HeLa-NHERF2 cells. We can 
hypothesise that NHERF2 delays or inhibits the interaction of NleH1 with BI-1, and as a 
result, abolishes its anti-apoptotic activity. 
In addition, NleH1 lacking its PDZ-binding motif also lost its anti-apoptotic activity, strongly 
suggesting that additional PDZ-containing host cell proteins might play a role in the activity 
of NleH1 or facilitate its association with BI-1. 
Taken together, our results demonstrated that three different T3SS effectors with distinct 
functions bind PDZ-containing scaffold protein NHERF2. We hypothesise that interaction 
with NHERFs modulates timing and location of their respective activities during infection. 
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3.4. Recruitment of NHERFs by A/E pathogens 
This study has shown that interaction of NHERF2 with effector proteins resulted in 
modification of their respective phenotypes. The next objective was to investigate the 
distribution of NHERF proteins during diarrhoeagenic E. coli infection. Accumulation of 
NHERF1 at the site of EPEC attachment was first described by Simpson and co-workers in 
2006 (Simpson et al., 2006). In order to determine whether NHERF1 or NHERF2 recruitment 
is a common phenotype triggered by several diarrhoeagenic E.coli or whether it is restricted to 
EPEC, the HeLa-NHERF1 and HeLa-NHERF2 cell lines generated previously were used to 
investigate the possible recruitment and mechanism of recruitment of NHERF1 and NHERF2 
upon infection with different diarrhoeagenic E. coli strains. Both the HeLa-NHERF1 and the 
HeLa-NHERF2 cell lines demonstrated similar phenotypes throughout this study and 
therefore the representative data obtained for HeLa-NHERF2 will be described in this chapter. 
3.4.1. NHERF2 is recruited by different diarrhoeagenic Escherichia coli 
HeLa-NHERF2 cells were infected with EPEC (strain E2348/69), EHEC (strain TUV93-0), 
DAEC (strain C1845) and EAEC (strain 042) as described in chapter 2.5 and NHERF2 
recruitment was analysed by immunofluorescence microscopy. NHERF2 was recruited at the 
site of bacterial attachment by EPEC, EHEC and DAEC but not EAEC (Figure 3.25). EPEC 
microcolonies induced strong NHERF2 recruitment while EAEC clusters did not. EHEC and 
DAEC, which exhibited a diffuse pattern of adhesion, triggered NHERF2 recruitment only 
around single adherent bacteria.  
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Figure 3.25: Recruitment of NHERF2 by diarrhoeagenic Escherichia coli strains 
Representative fluorescence microscopy of uninfected HeLa-NHERF2 cells and HeLa-
NHERF2 cells infected with EPEC E2348/69, EHEC TUV93-0, EAEC 042 or DAEC C1845. 
NHERF2 was stained with anti-HA antibodies (green), DNA was counter-stained with 
Hoechst 33342 (red). EPEC, EHEC and DAEC recruit NHERF2 (filled arrows). EAEC failed 
to recruit NHERF2 at the site of bacterial adhesion (open arrows). Scale bar = 10µm. 
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3.4.2. The mechanisms of NHERF recruitment by EPEC 
3.4.2.1. EPEC recruits NHERF2 independently of the T3SS and BFP 
The mechanism of NHERF recruitment by EPEC was consequently investigated. In order to 
investigate the role of the adhesion factors intimin, BFP and the EspA filament in the 
recruitment of NHERFs by EPEC, HeLa-NHERF2 cells were infected with EPEC wild-type, 
the T3SS-deficient mutant ∆escN, which is unable to secrete EspA, the intimin mutant ∆eae 
and a bundle-forming pilus-deficient ∆bfp strain (Figure 3.26). EPEC wild-type formed actin 
pedestals and recruited NHERF2 to the site of bacterial attachment. EPEC ∆escN 
demonstrated decreased adherence compared to EPEC wild-type and did not form actin 
pedestals. However, EPEC ∆escN induced diffuse recruitment of actin and NHERF2 
underneath adherent bacteria. EPEC ∆eae provoked diffuse actin polymerisation and 
recruitment of NHERF2. EPEC ∆bfp did not form microcolonies as shown for EPEC wild-
type, but was able to trigger pedestal formation and NHERF2 recruitment to the site of 
bacterial attachment. Taken together, these results indicate that EPEC is able to recruit 
NHERF2 independently of the T3SS, the adhesin intimin or the bundle-forming pilus. 
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Figure 3.26: Recruitment of NHERF2 by EPEC is T3SS, intimin and BFP-independent 
Fluorescence microscopy of HeLa-NHERF2 cells infected with EPEC wild-type (wt), ∆escN 
mutant, ∆eae mutant and ∆bfp mutant. NHERF2 was detected with anti-HA antibodies 
(green), EPEC strains were stained with anti-O127 antibodies (cyan) and actin was stained 
with Rhodamine phalloidin (red). EPEC wt and ∆bfp form pedestals at the site of bacterial 
attachment while the ∆eae mutant triggers diffuse actin recruitment. The T3SS, the adhesin 
intimin and the bundle forming pilus are not required to recruit NHERF2 at the site of 
bacterial adhesion (white arrows). Scale bar = 10µm. 
 
3.4.2.2. Role of ezrin in the NHERF2 recruitment triggered by EPEC 
NHERF2 was shown to be recruited concomitantly with filamentous actin underneath 
adherent EPEC ∆escN (Figure 3.26). NHERF2 can be linked to the actin network through 
interaction with ezrin (Chapter 1.2.1). In order to investigate whether ezrin-mediated binding 
of NHERF2 to the actin cytoskeleton is implicated in its recruitment by EPEC ∆escN, HeLa-
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NHERF2 cells were transfected with KS-pCV6 plasmids encoding VSVG-tagged ezrin or an 
ezrin mutant lacking its N-terminal domain (ezrin∆Nt) (Plasmids were kindly provided by 
Prof. Alain Servin, CNRS UMR 510, France). This N-terminal domain mutant acts as a 
dominant negative protein that uncouples endogenous ezrin from the actin cytoskeleton 
(Algrain et al., 1993). Following infection with EPEC ∆escN, NHERF2, as well as VSVG-
ezrin and VSVG-ezrin∆Nt, were recruited to the site of EPEC ∆escN adhesion (Figure 3.27). 
These results show that ezrin and ezrin∆Nt can be recruited by EPEC through a T3SS-
independent mechanism. Furthermore, the data indicates that NHERF2 recruitment by EPEC 
∆escN does not occur through an ezrin-mediated interaction with the actin cytoskeleton. 
 
Figure 3.27: Ezrin-coupling to the actin cytoskeleton is not required for NHERF2 recruitment 
by EPEC ∆escN 
Fluorescence microscopy of HeLa-NHERF2 cells transfected with VSVG-ezrin (A) or 
VSVG-ezrin∆Nt (B), uninfected or infected with EPEC ∆escN. NHERF2 was detected with 
anti-HA antibodies (green), ezrin and ezrin∆Nt were detected with anti-VSVG antibodies 
(red) and DNA was counter-stained with Hoechst 33342 (cyan). NHERF2, as well as ezrin 
and ezrin∆Nt were recruited to the site of EPEC ∆escN adhesion (white arrows). Scale bar = 
10µm. 
Plasmids were kindly provided by Prof. Alain Servin, CNRS UMR 510, France. 
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3.4.2.3. NHERF2∆EBD is recruited by TirEPEC 
The requirement of the EBD of NHERF2 in the recruitment of NHERF2 underneath adherent 
EPEC was next investigated. Full length NHERF2 and NHERF2∆EBD (lacking the last 36 C-
terminal amino acids) were amplified by PCR using primers NHERF2-Fw2 and NHERF2-
Rv2 or NHERF2∆EBD-Rv and cloned into pRK5 to generate pRK5-NHERF2 and pRK5-
NHERF2∆EBD. Western blot analysis indicated that both proteins were expressed in 
transfected HeLa cells (Figure 3.28 A). EPEC wild-type, but not ∆escN, was able to recruit 
NHERF2∆EBD at the site of bacterial attachment (Figure 3.28 B). This indicates that EPEC 
recruits NHERF2∆EBD by a T3SS-dependent mechanism. 
Upon translocation, Tir is inserted into the host plasma membrane and is clustered underneath 
adherent EPEC. In order to determine the implication of TirEPEC in the T3SS-dependent 
recruitment of NHERF2∆EBD, HeLa cells transfected with pRK5-NHERF2∆EBD were 
infected with EPEC ∆tir. This showed that EPEC ∆tir could not recruit NHERF2∆EBD 
(Figure 3.28 B). Recruitment of NHERF2∆EBD could be restored by complementation of 
EPEC ∆tir with pSA10-TirEPEC, thus confirming the importance of Tir for NHERF2∆EBD 
recruitment. 
Tir acts as a platform for localised actin polymerisation and recruits proteins involved in this 
process. In order to investigate the role of Tir-mediated actin polymerisation in 
NHERF2∆EBD recruitment, HeLa cells transfected with PRK5-NHERF2∆EBD were infected 
with EPEC TirAA, an EPEC strain encoding a chromosomal Y454A Y474A (TirAA) double 
tyrosine mutation which is incapable of triggering actin polymerisation and formation of actin 
pedestals. This strain was able to recruit NHERF2∆EBD, indicating that Tir but not pedestal 
formation is essential for NHERF2∆EBD recruitment. 
134 
 
 
Figure 3.28 
135 
 
Figure 3.28: Recruitment of NHERF2∆EBD by EPEC is Tir-dependent but actin 
polymerisation-independent 
A: Cell extracts of HeLa cells transfected with pRK5 (Mock), pRK5-NHERF2 or pRK5-
NHERF2∆EBD were blotted and probed with anti-NHERF2 and anti-Myc antibodies. 
Western blot using anti-tubulin antibodies confirmed equivalent loading of proteins. 
Endogenous NHERF2 is not detectable in HeLa cells and deletion of NHERF2 EBD induces 
a shift in protein size. Both constructs are expressed and Myc-tagged. 
B: Fluorescence microscopy of HeLa cells transfected with pRK5-NHERF2∆EBD and 
infected with EPEC wild-type (wt), ∆escN mutant, ∆tir mutant, ∆tir mutant complemented 
with pSA10-TirEPEC and EPEC carrying chromosomally encoded mutations Y454A and 
Y474A in Tir (TirAA). NHERF2∆EBD was detected with anti-Myc antibodies (green), EPEC 
strains were stained with anti-O127 antibodies (cyan) and actin was stained with Rhodamine 
phalloidin (red). EPEC ∆escN and ∆tir mutants were unable to recruit NHERF2∆EBD. EPEC 
wt and ∆tir complemented with pSA10-TirEPEC could recruit NHERF2∆EBD, as could EPEC 
TirAA, indicating that recruitment is Tir-dependent but pedestal formation-independent. Scale 
bar = 10µm. 
 
Taken together, these results suggest that EPEC can use two alternative pathways to recruit 
NHERF2: (i) a T3SS-independent pathway (shown by recruitment of NHERF2 to EPEC 
∆escN) and (ii) a T3SS-dependent pathway (dependent on translocated Tir). Tir-elicited actin-
polymerisation was not required for the second pathway and required the NHERF2 N-
terminal PDZ domains. 
 
3.4.3. NHERF2 recruitment by EHEC is Tir-dependent but actin 
polymerisation-independent 
EHEC is able to recruit NHERF2 to the site of bacterial adherence (Figure 3.25). In order to 
investigate the implication of the T3SS and T3SS effectors in NHERF2 recruitment, different 
EHEC mutants were investigated in the HeLa-NHERF2 infection model. EHEC ∆escN did 
not adhere to cells under the experimental conditions, which impeded the analysis of 
NHERF2 recruitment by this strain. In contrast, EHEC ∆tir was able to adhere to HeLa-
NHERF2 although at a reduced level compared to EHEC wild-type. Immunofluorescence 
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experiments and analysis of Z-stack pictures shows that EHEC wild-type was almost 
completely surrounded by NHERF2, while adherent EHEC ∆tir did not recruit NHERF2 
(Figure 3.29 A).  
In order to confirm the role of Tir in NHERF2 recruitment, HeLa-NHERF2 cells were 
transfected with HN-Tir and HN-Tir∆Nt (Campellone et al., 2002). HN-Tir is a modified 
version of wild-type TirEHEC in which the first transmembrane domain (residues 256-276) is 
replaced by the membrane-spanning domain of the Newcastle Disease Virus envelope protein 
(sequence: IAILLLTVMTLAISAAALAYSM). This modification reduces the generation of 
exaggerated cytoplasmic actin filaments triggered by ectopic expression of Tir (Campellone et 
al., 2002). As a result, ectopically-expressed HN-Tir displays an increased potential for 
membrane targeting and a higher complementation rate than ectopically-expressed wild-type 
TirEHEC. HN-Tir and HN-Tir∆Nt were amplified from pHM6-HN-Tir (Kindly provided by 
Prof. John Leong) using primers Tir-Fw or Tir∆Nt-Fw and Tir-Rv, and cloned into pRK5. 
Infection of mock-transfected HeLa-NHERF2 cells with EHEC ∆tir did not lead to pedestal 
formation or NHERF2 recruitment. Infection of HN-Tir-transfected HeLa-NHERF2 cells with 
EHEC ∆tir induced formation of pedestals and restored recruitment of NHERF2 underneath 
adherent bacteria (Figure 3.29 B). Infection of HN-Tir∆Nt-transfected HeLa-NHERF2 cells 
with EHEC ∆tir lead to the formation of elongated pedestals in which NHERF2 was recruited, 
indicating that the Tir N-terminal domain is not required for NHERF2 recruitment. 
137 
 
 
Figure 3.29 
 
 
 
 
138 
 
Figure 3.29: Recruitment of NHERF2 by EHEC depends on the C-terminus of Tir 
A: Fluorescence microscopy of HeLa-NHERF2 cells infected with EHEC wild-type (left) and 
EHEC ∆tir (right). Z-stack images were deconvoluted and an orthoview was created to show 
the depth of the cell. NHERF2 was detected with anti-HA antibodies (green) and EHEC was 
stained with anti-O157 antibodies (red). White bars indicate where the orthogonal sections of 
the image have been folded out (zx and zy sections). The bottom of the cells is at the edge of 
field (right and upper panels). Recruitment of NHERF2 is observed at the site of EHEC wild-
type (open arrows) but not EHEC ∆tir (filled arrows) adhesion. M: merge, scale bar = 10 µm. 
B: Fluorescence microscopy of HeLa-NHERF2 cells transfected with pRK5 (i), pRK5-HN-
Tir (ii) or pRK5-HN-Tir∆Nt (iii), and infected with EHEC ∆tir. NHERF2 was detected with 
anti-HA antibodies (green) and HN-Tir was stained with anti-Myc antibodies (blue). Actin 
was stained with Rhodamine phalloidin (red) and DNA was counterstained with Hoechst 
33342 (cyan). Enlarged insets of cyan, blue, red and green channels are displayed on the right 
of each picture. EHEC ∆tir does not recruit NHERF2 but its recruitment is restored by ectopic 
expression of HN-Tir and HN-Tir∆Nt, indicating that Tir N-terminal domain is not required 
for NHERF2 recruitment. Scale bar = 10 µm. 
 
These experiments indicate that NHERF2 recruitment is reliant on the C-terminus of TirEHEC. 
This region of TirEHEC contains the NPY motif required to recruit TccP, N-WASP and the 
Arp2/3 complex which are essential for actin polymerisation and pedestal formation. In order 
to investigate the implication of actin polymerisation on EHEC-mediated NHERF2 
recruitment, HeLa cells transfected with pRK5-NHERF2 were infected with EHEC wild-type, 
∆tir mutant, ∆tccP mutant and ∆tir mutant complemented with pSA10-TirEHEC or with 
pSA10-TirEHEC Y458A (Figure 3.30 A). NHERF2 was recruited by all strains except EHEC ∆tir, 
indicating that actin polymerisation and pedestal formation are not essential for NHERF2 
recruitment. 
TirEPEC could recruit NHERF2 independently of its EBD domain (Figure 3.28). In order to 
determine whether the EBD of NHERF2 was required for recruitment by TirEHEC, HeLa cells 
were transfected with pRK5-NHERF2∆EBD and infected with EHEC wild-type, ∆tir mutant, 
∆tccP mutant and ∆tir mutant complemented with pSA10-TirEHEC (Figure 3.30 B). All strains, 
with the exception of EHEC ∆tir, recruited NHERF2∆EBD. Taken together, these results 
suggest that TirEHEC can recruit NHERF2 independently of the EBD and actin polymerisation. 
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Figure 3.30: NHERF2 recruitment by EHEC is independent of actin polymerisation and 
NHERF2 EBD 
A: Fluorescence microscopy of HeLa cells transfected with pRK5-NHERF2 and infected with 
EHEC wt, ∆tir, ∆tccP and ∆tir complemented with pSA10-TirEHEC or with pSA10-TirEHEC 
Y458A. NHERF2 was detected with anti-Myc antibodies (green), EHEC strains were stained 
with anti-O157 antibodies (cyan) and actin was stained with Rhodamine phalloidin (red). 
EHEC wild-type (wt), ∆tccP, ∆tir complemented with pSA10-TirEHEC or pSA10-TirEHEC 
Y458A, but not EHEC ∆tir, are able to recruit NHERF2 at the site of bacterial adhesion. Scale 
bar = 10 µm. 
B: Fluorescence microscopy of HeLa cells transfected with pRK5-NHERF2∆EBD and 
infected with EHEC wild-type, ∆tir, ∆tccP and ∆tir complemented with pSA10-TirEHEC. 
NHERF2∆EBD was detected with anti-Myc antibodies (green) and EHEC strains were 
stained with anti-O157 antibodies (cyan). EHEC wild-type (wt), ∆tccP and ∆tir 
complemented with pSA10-TirEHEC, but not EHEC ∆tir, are able to recruit NHERF2∆EBD at 
the site of bacterial adhesion. Scale bar = 10 µm. 
 
It was observed that Tir tyrosine 458, which plays an important role in the actin 
polymerisation pathway subverted by TirEHEC, was not involved in NHERF2 recruitment. In 
order to identify other critical residues for NHERF2 recruitment (Chapter 1.1.3.3), HeLa-
NHERF2 cells were infected with EHEC ∆tir complemented with pSA10-TirEPEC, TirEPEC P17-
22A, TirEPEC R521A, TirEHEC P17-22A, TirEHEC S436-7A, TirEHEC Y490A, TirEHEC Y519A, TirEHEC R529A, and 
TirEHEC Y458A R529A (Figure 3.31). All these Tir mutants were engineered by Dr A. Mousnier in 
our laboratory (unpublished data). 
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Figure 3.31 
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Figure 3.31: NHERF2 recruitment by TirEHEC is independent of residues P17-22, S436-7, 
Y490, Y519 and Y529. 
Fluorescence microscopy of HeLa-NHERF2 cells infected with EHEC ∆tir complemented 
with pSA10-TirEPEC, TirEPEC P17-22A, TirEPEC R521A, TirEHEC P17-22A, TirEHEC S436-7A, TirEHEC Y490A, 
TirEHEC Y519A, TirEHEC R529A, and TirEHEC Y458A R529A. NHERF2 was detected with anti-HA 
antibodies (green) and EHEC was stained with anti-O157 antibodies (cyan). All constructs 
were able to recruit NHERF2 at the site of bacterial adhesion. Scale bar = 10 µm. 
 
Bacteria expressing each of the constructs were able to recruit NHERF2 at the site of bacterial 
attachment. Taken together these results indicate that: (i) TirEHEC can be substituted by 
TirEPEC, (ii) the PPR regions of TirEPEC and TirEHEC are not involved in NHERF2 recruitment, 
(iii) serine residues S436 and 437, which can be phosphorylated (Bommarius et al., 2007), are 
not required for NHERF2 recruitment by TirEHEC and (iv) residues R521 and R529, which are 
potentially implicated in the respective GAP activities of TirEPEC and TirEHEC (Brandt et al., 
2009; Kenny et al., 2002), do not play a role in NHERF2 recruitment. 
Taken together, these results strongly suggest that NHERF2 is recruited by TirEHEC 
independently of NHERF2 EBD and actin polymerisation. The C-terminal domain of Tir is 
sufficient to trigger recruitment of NHERF2. Segments in the C-terminal domains of TirEPEC 
and TirEHEC share up to 64% identity (Campellone et al., 2006) and it is therefore tempting to 
speculate that TirEPEC and TirEHEC possess a common domain involved in NHERF2 
recruitment. 
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3.4.4. Recruitment of NHERF3 by EPEC and EHEC 
Using the PDZ array, it was shown that Map could interact with PDZ3 of NHERF3 (Chapter 
3.1.1). Since PDZ domains of NHERF1 and 2 share between 32% and 44% identity with 
PDZ3 of NHERF3, the recruitment of NHERF3 by EPEC and EHEC and the potential 
implication of Tir was consequently investigated. 
HeLa cells were transfected with pcDNA-Myc-NHERF3 and infected with different EPEC 
strains. In uninfected cells, NHERF3 was generally detected in the cytoplasm and in 
perinuclear regions. EPEC wild-type, but not the ∆escN or ∆tir mutants, was able to recruit 
NHERF3 to the site of bacterial attachment (Figure 3.32). Complementation of EPEC ∆tir 
with pSA10-TirEPEC restored the capacity of the strain to recruit NHERF3 at the site of 
bacterial attachment. In order to investigate the importance of pedestal formation in NHERF3 
recruitment, HeLa cells expressing NHERF3 were infected with EPEC carrying 
chromosomally-encoded mutations Y454A and Y474A in Tir (TirAA). Following 
immunofluorescence staining, NHERF3 was still shown to be recruited to the site of bacterial 
adhesion, indicating that actin polymerisation is not required to induce such a phenotype. 
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Figure 3.32: EPEC recruits NHERF3 independently of pedestal formation 
Fluorescence microscopy of HeLa cells transfected with pcDNA-Myc-NHERF3 and infected 
with EPEC wild-type (wt), ∆escN mutant, ∆tir mutant, ∆tir mutant complemented with 
pSA10-TirEPEC and EPEC carrying chromosomally-encoded mutations Y454A and Y474A in 
Tir (TirAA). NHERF3 was detected with anti-Myc antibodies (green), EPEC strains were 
stained with anti-O127 antibodies (cyan) and actin was stained with Rhodamine phalloidin 
(red). EPEC ∆escN and ∆tir mutants were unable to recruit NHERF3. EPEC wild-type, ∆tir 
mutant complemented with pSA10-TirEPEC and EPEC TirAA could recruit NHERF3 (white 
arrows), indicating that recruitment is Tir-dependent but pedestal formation-independent. 
Scale bar = 10 µm. 
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The recruitment of NHERF3 by the EHEC strains was next investigated (Figure 3.33). EHEC 
wild-type, but not the ∆tir mutant, was able to recruit NHERF3 to the site of bacterial 
attachment. Upon complementation of EHEC ∆tir with pSA10-TirEHEC or pSA10-TirEHEC 
Y458A, recruitment of NHERF3 was restored, indicating that Tir, but not actin polymerisation, 
is required for such a phenotype. 
 
Figure 3.33: NHERF3 recruitment by EHEC is Tir-dependent and actin polymerisation 
independent 
Fluorescence microscopy of HeLa cells transfected with pcDNA-Myc-NHERF3 and infected 
with EHEC wild-type (wt), ∆tir and ∆tir complemented with pSA10-TirEHEC or pSA10-
TirEHEC Y458A. NHERF3 was detected with anti-Myc antibodies (green) and EHEC strains 
were stained with anti-O157 antibodies (cyan). EHEC ∆tir mutant was unable to recruit 
NHERF3. EHEC wild-type and ∆tir complemented with pSA10-TirEHEC or pSA10-TirEHEC 
Y458A were able to recruit NHERF3 (white arrows), indicating that recruitment is Tir-
dependent and actin polymerisation independent. Scale bar = 10 µm. 
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3.4.5. Recruitment and modulation of NHERF1 and NHERF2 expression 
by Citrobacter rodentium 
The ability of EPEC and EHEC to recruit NHERF1, NHERF2 and NHERF3 to the site of 
bacterial attachment was observed in vitro. In order to analyse whether this phenotype also 
occurs in vivo, mice were infected with C. rodentium, the mouse model pathogen of EPEC 
and EHEC. Localisation of NHERF1 and 2 was investigated by immunofluorescence in colon 
sections from uninfected mice and mice infected for 9 days with C. rodentium as described in 
chapter 2.7.2. In the uninfected mice colon, NHERF1 and 2 were enriched in the microvilli 
constituting the brush border (Figure 3.34). Both proteins were also found in the lamina 
propria. 
Upon infection with C. rodentium, NHERF1 and NHERF2 were strongly recruited to the site 
of bacterial attachment. Moreover, NHERF1 and 2 could not be detected in the lamina propria 
in infected samples, indicating that the proteins were not only recruited but could also be 
redistributed in adjacent tissues. Implication of Tir in recruitment of NHERF1 and 2 could not 
be investigated in vivo since the C. rodentium ∆tir mutant is not able to colonise the mouse 
gut (Crepin et al., 2010). 
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Figure 3.34: Citrobacter rodentium recruits NHERF1 and NHERF2 in vivo 
Fluorescence microscopy of mice colon sections uninfected or infected with Citrobacter 
rodentium. NHERF1 and NHERF2 were stained with anti-NHERF1 and anti-NHERF2 
antibodies (green) and Citrobacter rodentium was detected with anti-intimin β antibodies 
(red). NHERF1 and 2 are enriched in the colon brush border (filled arrows) and lamina 
propria (black arrows). Citrobacter rodentium induces re-organisation of NHERF1 and 2 and 
recruits both proteins at the site of bacterial adhesion (open arrows). Scale bar = 50 µm. 
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Increased NHERF1 and 2 staining at the sites of C. rodentium attachment could be due to 
recruitment of the two proteins, but could also be due to upregulation of the expression of the 
proteins during the course of infection. Two independent studies suggested that NHERF1 
levels in the gut could be modulated during C. rodentium infection. A recent study comparing 
transcriptional patterns in colons from susceptible FVB and resistant SW mice infected with 
C. rodentium reported that NHERF1 was down-regulated in susceptible mice upon infection 
(Borenshtein et al., 2008). This study concluded that down-regulation of NHERF1 could 
correspond to a defence mechanism aimed at reducing ion loss in the intestinal lumen. 
In our laboratory, Dr James Collins and Dr Valérie Crépin lead proteomic profiling 
experiments on jejunal samples from C57 BL6 mice, which are considered resistant to C. 
rodentium pathology and morbidity (unpublished data). Comparing infected and uninfected 
mice, they reported that NHERF1 expression is potentially upregulated during the course of 
Citrobacter rodentium infection. Interestingly, proteomic levels of NHERF2 were not altered 
during C. rodentium infection. 
Results from these two studies cannot be directly compared since different mice lineages 
(FVB and SW versus C57 BL6) and different organs (colon versus jejunum) were analysed 
using different techniques (transcriptomics versus proteomics) but they do highlight the fact 
that NHERF1 levels are altered during C. rodentium infection. 
Taken together, these results indicate that C. rodentium not only recruits, but also modulates 
NHERFs expression during infection. 
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3.4.6. Discussion 
In this section, we investigated the recruitment of NHERF proteins by EPEC and EHEC, 
using EAEC and DAEC as controls. In an initial screen, it was observed that NHERF1 and 2 
were recruited underneath adherent EPEC, EHEC and DAEC, but not EAEC prototypical 
strains. Unlike EPEC or EHEC, DAEC strains do not possess a T3SS and induce clustering of 
the DAF receptor via the Dr adhesin. The Dr mutant of DAEC strain IH11128 was still able to 
recruit NHERF1 and NHERF2 (data not shown), suggesting that this phenotype is probably 
due to another adhesion factor present on the surface of DAEC strains. The fact that EAEC 
could not recruit NHERF1 or 2 indicates that NHERF proteins are not universal targets of 
diarrhoeagenic E. coli. 
The mechanisms by which NHERFs are recruited to the bacterial attachment sites were 
consequently investigated. The major EPEC adhesion factors are BFP, EspA filaments and 
intimin. Mutation of these factors did not abolish recruitment of NHERF1 and NHERF2. 
However, these adhesion factors could cross-complement each other for NHERF recruitment. 
It would thus be interesting to create EPEC mutants carrying multiple deletions (i.e. EPEC 
∆escN ∆eae) and observe how these affect recruitment of NHERFs. 
EPEC was observed to recruit NHERF2 using two mechanisms. The first was T3SS 
independent, highlighted by the ability of the EPEC T3SS secretion mutant ∆escN to still 
recruit NHERF2. However, even though this strain was unable to form pedestals, it provoked 
diffuse actin recruitment underneath adherent bacteria, which was reported previously (Vidal 
and Navarro-Garcia, 2008). As ezrin links NHERF2 to the actin cytoskeleton, its role in 
NHERF2 recruitment to the site of bacterial attachment was determined. Using ezrin∆Nt to 
uncouple NHERF2 from the actin cytoskeleton, we observed that NHERF2 was still recruited 
by EPEC ∆escN. Recruitment of NHERF2 through this pathway could be due to other 
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proteins from the ERM family or mediated by host membrane-anchored molecules. Indeed, 
EPEC is capable of recruiting membrane receptor protein CD44, which interacts with ERM 
proteins (Hirao et al., 1996; Tsukita et al., 1994), and polyphosphatidylinositol (PIP) 
molecules (Sason et al., 2009; Rescher et al., 2004). PIPs have multiple functions in the cell: 
they anchor signalling molecules to the plasma membrane (Heo et al., 2006), restructure the 
actin cytoskeleton and participate in vesicle dynamics (Skwarek and Boulianne, 2009; 
Raucher et al., 2000). Several studies identified PDZ domains as novel modules interacting 
with the phosphatidylinositol isoform PI(4,5)P2 (Sugi et al., 2008; Zimmermann, 2006; 
Zimmermann et al., 2002). The fact that EPEC recruits PI(4,5)P2 to the site of bacterial 
adhesion in a T3SS-independent manner (Sason et al., 2009) opens two possibilities for the 
T3SS-independent recruitment of NHERF2: the first would consist of a direct interaction 
between NHERF2 and PI(4,5)P2 and the second could be indirectly mediated by a linking 
protein such as annexin 2 which also interacts with PI(4,5)P2 (Rescher et al., 2004). 
The second pathway of NHERF2 recruitment by EPEC was discovered using 
NHERF2∆EBD. EPEC wild-type, but not ∆escN, was able to recruit NHERF2∆EBD, 
indicating that a T3SS protein was involved in NHERF2∆EBD recruitment. Tir was then 
identified as the sole translocated protein required for NHERF2∆EBD recruitment. This 
second pathway was identical in EHEC as TirEHEC was responsible for recruitment of 
NHERF2 and NHERF2∆EBD. In addition, using transfection, the TirEHEC C-terminal domain 
was demonstrated to be sufficient to recruit NHERF2. Transfection experiments using HN-
Tir∆Ct would thus confirm this observation. 
Finally, pedestal formation was not required for NHERF2∆EBD recruitment by both EPEC 
and EHEC, suggesting that proteins involved in actin polymerisation do not participate in 
NHERF2∆EBD accumulation underneath adherent bacteria. 
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Interaction assays showed that Tir and NHERF2 do not interact directly by far Western blot 
(data not shown), indicating that a linker protein or complex is probably required for 
NHERF2∆EBD recruitment. Taken together, these observations led us to set up a model for 
NHERF2 recruitment by EPEC and EHEC (Figure 3.35). 
 
 
Figure 3.35: Model for NHERF2 recruitment by EPEC and EHEC 
EPEC is capable of recruiting NHERF2 independently of its T3SS and the host cell protein 
ezrin. T3SS-independent recruitement of NHERF2 is likely to rely on the presence of an 
unknown host partner (question mark). Both EPEC and EHEC indirectly recruit 
NHERF2∆EBD via Tir. The potential linker between NHERF2∆EBD and Tir is represented 
by a circled question mark. 
P.M.: plasma membrane, cyto: host cell cytoplasm. 
 
NHERF3 PDZ3 shares high identity with NHERF1 and 2 PDZ domains. As this protein is a 
potential binding partner of Map, the potential for it to be recruited by EPEC and EHEC was 
investigated. NHERF3 was recruited in a Tir-dependent and actin polymerisation-independent 
manner by both EPEC and EHEC. As TirEPEC and TirEHEC do not possess a C-terminal PDZ-
binding motif, these results suggest that they indirectly recruit PDZ-containing proteins. In a 
recent study, TirEPEC has been shown to play a role in recruitment of the PDZ-containing 
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protein Shank 3 (Huett et al., 2009). Even though the implication of Shank 3 PDZ domain 
was not assessed in this study, it suggests that Tir can recruit several PDZ domain-containing 
proteins. 
Finally, the potential for NHERF1 and 2 to elicit a similar recruitment phenotype in vivo 
during infection with C. rodentium was analysed. In uninfected mouse colon sections, both 
NHERF1 and 2 were enriched in the brush border. This localisation is slightly different to that 
observed in mouse proximal tubules sections, where NHERF1 was mainly localised in the 
brush border and NHERF2 was found at the base of the microvilli (Wade et al., 2003). 
Infection with C. rodentium led to an increased signal for NHERF1 and 2 at the site of 
bacterial attachment. This high signal could either be due to the recruitment of NHERF 
proteins to the site of bacterial adherence, or the increased expression of NHERFs in the 
colon, or ultimately the combination of both. C. rodentium has also been shown to recruit 
Nck, N-WASP and IRTKS in vivo (Crepin et al., 2010)). These proteins play an important 
role in the scaffolding of complexes involved in actin polymerisation. The role of NHERF1 
and 2 during infection has not yet been established, but they could be exploited by C. 
rodentium to play a role in fine tuning the activity of effector proteins in vivo in order to 
ensure a successful colonisation. 
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4. Discussion 
The human gut is a complex organ with multiple functions including electrolyte exchange, 
digestion and absorption of nutrients and water. The commensal microflora and intestinal host 
cells co-exist in a well controlled balance which plays an important role in the function of the 
gut. In contrast, diarrhoeagenic E. coli, such as EPEC and EHEC, provoke cellular damages to 
the intestinal epithelium and disturb the homeostasis of the gut, ultimately causing the typical 
symptoms of diarrhoea. 
In the last decade, research on the molecular mechanisms used by EPEC and EHEC to 
colonise cells and elicit disease mainly focused on the identification of individual T3SS 
effector targets and host cell factors involved in actin pedestal formation. These efforts 
revealed that several EPEC and EHEC effectors interacted with one or more host cell 
partners, sometimes with different subcellular localisations and antagonistic functions (Dean 
and Kenny, 2009; Garmendia et al., 2005). Furthermore, to date more than 25 host cell 
proteins have been detected in the pedestal of EPEC and EHEC (Goosney et al., 2001). 
However, while the function of some SH2 and SH3 domain-containing proteins, such as Nck, 
have been characterised during infection, the role of PDZ domain-containing proteins, such as 
NHERF1, ZO-1, ZO-2 and Shank 3 (Huett et al., 2009; Hanajima-Ozawa et al., 2007; 
Simpson et al., 2006), is yet to be characterised. Similarly, spatial and temporal coordination 
of effectors and the resulting effects on the host cell biology remains relatively unexplored. 
Regulation of effector proteins has been shown to occur at different levels during infection. 
On the bacterial level, sequential transcription of groups of effectors occurs during different 
stages of Shigella infection (Schroeder and Hilbi, 2008), while the affinity for chaperones 
appears to dictate the sequence of effector translocation in Yersinia and EPEC (Mills et al., 
2008; Birtalan et al., 2002). In addition, the host cell machinery can be exploited to modulate 
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the localisation and activity of selected effectors: TirEPEC is able to trigger strong actin 
polymerisation only when phosphorylated by host kinases (Phillips et al., 2004; Kenny, 1999) 
and the Salmonella effector proteins SifA and SopA are lipidated and ubiquitinated, 
respectively, by the host cell machinery (Zhang et al., 2005; Boucrot et al., 2003). 
In this study, we investigated how EPEC and EHEC exploit the adaptor proteins NHERF1 
and NHERF2 to regulate the activity and localisation of various effector proteins. The 
recruitment of NHERF1 to EPEC pedestals (Simpson et al., 2006) was confirmed, and the 
ability of both EPEC and EHEC to recruit NHERF2 and NHERF3 was discovered. EPEC and 
EHEC were able to recruit these NHERF proteins in a Tir-dependent way while EPEC could 
also recruit NHERF1 and NHERF2 in a T3SS-independent manner. Differential protein 
recruitment mechanisms used by EPEC and EHEC have previously been reported (Goosney 
et al., 2001). T3SS-independent recruitment of NHERF1 and NHERF2 by EPEC resembled 
that of CD44 and calpactin, which was reported to occur in a Tir-independent manner, 
suggesting that these proteins are present underneath adherent bacteria before translocation of 
effectors. 
 
The role of Tir as a platform for focal actin polymerisation during EPEC and EHEC infection 
has been extensively studied in vitro (Whale et al., 2007; Campellone and Leong, 2003). 
Moreover, Tir is also able to cluster adaptor proteins such as ezrin or α-actinin independently 
of actin polymerisation (Goosney et al., 2001), indicating that its function extends beyond that 
of pedestal formation. As no direct interaction between Tir and NHERFs has been 
demonstrated, Tir-dependent recruitment of NHERF proteins could occur through interaction 
with one of these adaptor proteins. Ongoing research in the laboratory suggests that 
membrane-bound annexin 2 could potentially link Tir to NHERF2. 
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Although NHERFs are recruited to the pedestal, they are not required for pedestal formation 
as this phenomenon occurs in NHERF-deficient cells, such as mouse fibroblasts (Gruenheid et 
al., 2001). On the other hand, the importance of NHERF recruitment at the site of bacterial 
attachment assumes full meaning in the context of PDZ-binding effectors. This work 
confirmed that Map and EspI can interact with NHERF1 and NHERF2, and identified NleH1 
as a new interacting partner of NHERF2. Interaction of NHERF2 with Map, EspI and NleH1 
led to stabilisation of filopodia, accelerated transport to the Golgi and inhibition of anti-
apoptotic activity, respectively. 
The interaction of Map with NHERF2 is transient and Map is ultimately transported to the 
mitochondria by an unknown mechanism. Interestingly, among all the PDZ domains present 
on the PDZ array, Map only interacted with NHERF proteins. NHERF1, NHERF2 and 
NHERF3 have an increased localisation at the plasma membrane, while NHERF4 is present 
in intracellular compartments (Donowitz et al., 2005). Endogenous GTPases, such as the Map 
target Cdc42, are posttranscriptionally lipidated at their C-terminal end, leading to increased 
localisation in membranous compartments (Roberts et al., 2008). Instead of enhancing its 
GEF activity, NHERF proteins could rather localise and maintain Map activity at the plasma 
membrane, leading to stable Cdc42 activation and filopodia formation at the site of bacterial 
attachment. 
Similarly to Map, EspI localisation at the site of bacterial attachment is transient and the 
effector protein eventually traffics to the Golgi apparatus. Overexpression of NHERF2 led to 
accelerated localisation of EspI to the Golgi. As NHERFs are recruited to the site of bacterial 
attachment, an inhibition of transport and accumulation of EspI at the pedestal would be 
expected. This contradiction could be reconciled in a model where the presence of NHERFs 
underneath adherent bacteria is dynamic. Therefore, bacteria would not sequester NHERFs at 
the site of attachment but rather redirect their flux. 
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The process by which NHERF2 triggers the accelerated transport of EspI to the Golgi 
apparatus is not clear. As no direct endocytic route exists between the plasma membrane and 
the Golgi, it is assumed that NHERF2 brings EspI to an intermediate compartment, such as 
early endosomes, where EspI is then transported to the Golgi by another unknown partner. 
Implication of NHERF1 in endocytic recycling of the β2 adrenergic receptor has been 
described in previous studies (Cao et al., 1999). Therefore, further study of EspI trafficking 
would help to better understand the role of NHERF2 in endocytosis. 
As with Map, EspI interacted with NHERF1 and NHERF2 proteins on the PDZ array, but 
unlike Map, it also interacted with PDZ domains from other proteins. The relevance of these 
interactions during infection has not yet been clarified. However, it is tempting to speculate 
that NHERFs might replace/block another auxillary PDZ-mediated interaction of EspI at the 
plasma membrane and promote accelerated trafficking to the Golgi where EspI fulfils its main 
function. 
The data presented in this study on the effect of NHERF2 on the activity of NleH1 provides 
an indication for a similar competition scenario. NleH1 interacted with several PDZ domains 
from different proteins on the PDZ array. In the model cell line used in this study, interaction 
with NHERF2 strongly diminished its anti-apoptotic activity. As the NleH1 PDZ-binding 
motif was also essential for this activity, it can be postulated that interaction with another 
PDZ domain-containing protein is required for this activity. In this case, NHERF2 would 
compete with this unknown partner for NleH1, with the result of the competition being a 
reduced anti-apoptotic response. An analysis on other proteins identified by PDZ array is 
currently underway in our laboratory (Robinson S., unpublished data). 
Other PDZ-binding motif-containing effector proteins, such as NleH2, could potentially 
interact with NHERF proteins. Even though NleH2 possesses the same PDZ-binding motif as 
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NleH1 and shares the same anti-apoptotic activity, their anti-inflammatory activities are 
different (Gao et al., 2009). As NleH2 differs from NleH1 by the insertion of a central 10 
amino acid sequence, it would be interesting to investigate whether NleH2 interacts with 
NHERF2 and whether this interaction modulates its anti-inflammatory activity. 
Using biochemical methods, it was observed that Map, EspI and NleH1 display different 
selectivity for NHERF proteins: Map interacts with NHERF1, NHERF2 and NHERF3, EspI 
interacts with NHERF1 and NHERF2, and NleH1 can only interact with NHERF2. As a 
result, all three effector proteins could compete for interaction with NHERF2. A major 
determinant for competition is the amino acid sequence of their C-terminus and its capacity to 
interact with discrete PDZ domains. However, competition between effectors during infection 
would not only depend on the concentration of the host NHERF2 but also on the 
concentration and timing of translocated proteins. Alternatively, effector proteins could 
interact with different PDZ domains on the same NHERF molecule. A recent study showed 
that overexpression of EspI did not affect Map-dependent filopodia formation, thus favouring 
the second hypothesis (Thanabalasuriar et al., 2010). Further experiments, such as Biacore 
analysis, could be used to determine the affinity of these effectors for the different PDZ 
domains of NHERF proteins or other PDZ-containing interaction partners. These would give 
an indication on the sequence of events occurring after translocation of PDZ-binding effector 
proteins. 
 
Based on these results, we propose a model in which NHERF1 and NHERF2 are exploited by 
EPEC and EHEC to form a cellular hub for effector sorting (Figure 4.1). 
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Figure 4.1: Model of exploitation of NHERF1 and NHERF2 by EPEC 
1: NHERF1 and NHERF2 are recruited to the site of bacterial attachment, possibly through 
Tir and an unknown protein linker. Interaction with Map C-terminus stabilises filopodia 
formation at the site of bacterial attachment. 
2: Interaction of EspI with NHERF1 and NHERF2 accelerates its transport rate to intracellular 
compartments and ultimately to the Golgi apparatus. 
3: By retaining NleH1 at the plasma membrane, NHERF2 delays its targeting to the ER, thus 
diminishing its anti-apoptotic activity. 
P.M.: Plasma membrane; cyto: host cell cytoplasm; T3SS: Type 3 secretion system. 
 
It can be concluded from the in vitro experiments that, rather than participating in activation 
of actin polymerisation pathways, NHERFs participate in spatial and temporal localisation of 
EPEC and EHEC effector proteins. 
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A very interesting challenge will be to analyse the consequences of effector-NHERF 
interactions in vivo, especially on colonisation dynamics and development of diarrhoea in the 
infected mammalian gut. To this end, initial experiments using the Citrobacter rodentium 
mouse model were performed. C. rodentium shares the same colonisation strategy and has a 
largely overlapping effector protein repertoire with EPEC and EHEC. Previous studies 
demonstrated that host adaptor proteins Nck, N-WASP and IRTKS, which are found at EPEC 
pedestals, are also recruited by C. rodentium in vivo (Crepin et al., 2010; Girard et al., 2009). 
In line with in vitro observations, NHERF1 and NHERF2 were also recruited by C. 
rodentium. 
NHERF proteins have different patterns of expression in the gut: NHERF1 and 3, but not 
NHERF2, are enriched in the small intestine (Ingraffea et al., 2002; Kocher et al., 1998) while 
NHERF1 and NHERF2 are expressed equally in the colon (Yun et al., 1997). This strongly 
suggests that the composition of NHERF proteins at the site of C. rodentium attachment could 
vary within the intestine. C. rodentium colonises mainly the large intestine (Hemrajani et al., 
2008). Even though tissue tropism of A/E pathogens is highly dependent on the intimin 
subtype (Mundy et al., 2007), activities of the NHERF-binding effectors could vary in the 
intestine and NHERF proteins could thus influence the colonisation of certain areas of the gut. 
One particular phenotype which might be affected by the different NHERF expression 
patterns and the subsequent different effector activities is the disruption of tight junctions. 
Map targets NHERF1, NHERF2 and NHERF3 which ensures it has several NHERF partners 
in different sections of the gut. As increased activation of Cdc42 induces redistribution of 
tight junction proteins (Bruewer et al., 2004), the interaction of Map with NHERFs could 
participate in the tight junction disruption activity of Map (Dean and Kenny, 2004). Similarly 
to Map, EspI also participates in tight junction disruption (Thanabalasuriar et al., 2010). 
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NHERF1 and NHERF2 would therefore be expected to promote this phenomenon by 
accelerating EspI transport to the Golgi. 
EPEC colonises the small and large intestine (Mundy et al., 2007; Tzipori et al., 1995). As 
NleH1 only interacts with NHERF2 in vitro and NHERF2 is predominantly expressed in the 
large intestine, it can be speculated that NHERF2-mediated inhibition of apoptosis is stronger 
in the large intestine. In this context, the deleterious effects of EPEC would be accentuated in 
the colon and would lead to an increased shedding of bacteria. 
Effector proteins with PDZ-binding motifs could also compete with endogenous NHERF 
partners. Map and NleG8, a putative T3SS effector protein from C. rodentium, possess a C-
terminal DTRL motif identical to that of CFTR. Many studies highlighted the importance of 
the CFTR PDZ-binding motif in the interaction with NHERF proteins and in trafficking and 
anchoring of the ion transporter (Swiatecka-Urban et al., 2002; Moyer et al., 2000; Moyer et 
al., 1999). Provided that bacterial effectors participate in dissociation of CFTR from 
NHERFs, this would lead to decreased recycling of the protein and therefore reduced chloride 
secretion. EPEC and C. rodentium have been shown to affect chloride transport by down-
regulating the Cl
-
/OH
-
 exchanger Dra in Caco2 cells and in mice, respectively (Borenshtein et 
al., 2009; Gill et al., 2007). As Dra is one of the cellular partners of NHERF2 (Lamprecht et 
al., 2002), it would be interesting to investigate the effect of NHERF2 recruitment and 
effector interaction on Dra activity. 
Alternatively, upregulation of NHERF1 and recruitment of NHERF1 and NHERF2 could play 
a role in alteration of ion transport. Recruitment of NHERFs to the site of bacterial 
attachment, possibly via Tir, would increase the localisation of protein kinases, such as PKA 
and PKC, underneath attached bacteria. As increased activity of protein kinases and 
stimulated chloride secretion upon EPEC infection have been observed (Collington et al., 
161 
 
1998; Crane and Oh, 1997), these physiological changes would inhibit NHE3, through 
increased endocytosis, and activate CFTR by phosphorylation, leading to chloride excess in 
the lumen and water movement. The unbalanced activity of ion channels could ultimately 
contribute to the typical symptoms in diarrhoea. 
A key experiment to determine the implication of NHERF1 and NHERF2 in the pathology of 
Citrobacter rodentium would be to study its infection dynamics in NHERF deficient mice. 
NHERF1 -/- and NHERF2 -/- mice have been engineered in different laboratories (Broere et 
al., 2007; Morales et al., 2004; Shenolikar et al., 2002). Deletion of NHERF1 led to smaller 
microvilli in the colon (but not in the small intestine), reduced jejunal fluid absorption and 
reduced CFTR activation in the small intestine (Broere et al., 2009; Broere et al., 2007). 
Deletion of NHERF2 did not lead to significant morphologic alteration of organs (Broere et 
al., 2007). We can hypothesise that, in NHERF1 -/- mice, the reduced jejunal surface and 
fluid absorption would reduce the colonisation of C. rodentium in the small intestine. In the 
colon, expression of NHERF2 would complement the absence of NHERF1. However, in 
NHERF2 -/- mice, NleH1 anti-apoptotic activity would not be inhibited in the colon, probably 
leading to decreased cell shedding and increased colonisation. The dynamics of C. rodentium 
colonization and A/E lesion formation in these transgenic mice would provide valuable 
information on the implication of NHERFs in the process of infection. 
Finally, exploitation of NHERF proteins by A/E pathogens could be implicated in tumour 
formation. Colonic infection with C. rodentium triggers hyperproliferation of epithelial cells, 
also called hyperplasia, and promotes chemically induced tumours (Luperchio and Schauer, 
2001; Newman et al., 2001). Recent studies have shown that NHERF1 and NHERF2 interact 
with the tumour suppressor PTEN to regulate cell proliferation (Georgescu, 2008; Takahashi 
et al., 2006) and NHERF1 is overexpressed in the majority of oestrogen receptor-positive 
breast tumours (Georgescu et al., 2008). Overexpression of NHERF1 and recruitment of 
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NHERF1 and NHERF2 during C. rodentium infection could thus play a role in the formation 
of colon tumours. 
In this study, we identified a novel regulatory mechanism by which recruitment of NHERF 
proteins to the attachment site of A/E pathogens forms a distribution hub for PDZ-binding 
effector proteins. This mechanism is exploited for membrane retention (Map), trafficking 
(EspI) and regulation of anti-apoptotic activity (NleH1). Thus, differential binding to 
NHERFs and to their different PDZ domains provides a mechanism to fine tune activity of 
effector proteins. Future studies will focus on the validation of this model during host-
pathogen interaction in vivo and its impact on electrolyte transport. 
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Appendix 1 
Strains Description Reference 
E2348/69 Wild-type EPEC O127:H6 (Levine et al., 1978) 
ICC192 E2348/69 ΔescN (Garmendia et al., 2004) 
ICC225 E2348/69 Δtir (Berger et al., 2009) 
ICC202 E2348/69 Δmap (Simpson et al., 2006) 
ICC248 E2348/69 ΔespI (Marches et al., 2008) 
ICC303 E2348/69 ΔΔnleH (Hemrajani et al., 2010) 
JPN15 E2348/69 Δbfp (Hicks et al., 1998) 
CVD206 E2348/69 Δeae 
(Donnenberg and Kaper, 
1991) 
ICC307 EPEC TirAA, EPEC expressing genomic TirY454A Y474A A. Wong 
TUV93-0 EHEC EDL933 O157:H7 stx1- stx2- ATCC 
ICC187 TUV93-0 ΔescN (Garmendia et al., 2004) 
KC5 TUV93-0 Δtir 
(Murphy and Campellone, 
2003) 
ICC185 TUV93-0 ΔtccP (Garmendia et al., 2004) 
042 EAEC O44:H18 (Nataro et al., 1995) 
C1845 DAEC O75:NM (Bilge et al., 1989) 
IH11128 DAEC O75:H5:K (Vaisanen-Rhen, 1984) 
DR14 IH11128 ΔDr (Goluszko et al., 1997) 
ICC169 Wild-type Citrobacter rodentium 
(Schauer and Falkow, 
1993b) 
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Appendix 2 
Plasmid Description Source 
pBKCMV Mammalian expression vector Stratagen 
pBKCMV-HA-
NHERF1 
Derivative of pBKCMV encoding HA-tagged 
NHERF1 
Dr R. Hall 
pBKCMV-HA-
NHERF2 
Derivative of pBKCMV encoding HA-tagged 
NHERF2 
Dr R. Hall 
pcDNA-Myc-
NHERF3 
Derivative of pcDNA encoding Myc-tagged 
NHERF3 
Dr R. Hall 
pHM6-HN-Tir 
Derivative of pHM6 encoding HA tagged HN-Tir 
from EHEC EDL933 
(Campellone et al., 
2006) 
pRK5 N-terminal Myc-tag mammalian expression vector Clontech 
pRK5-NHERF2 Derivative of pRK5 encoding NHERF2 This study 
pRK5-
NHERF2ΔEBD 
Derivative of pRK5 encoding NHERF2ΔEBD 
This study 
pRK5-Map 
Derivative of pRK5 encoding Myc-tagged Map 
from EPEC E2348/69 
This study 
pRK5-MapΔC3 
Derivative of pRK5 encoding Myc-tagged 
MapΔC3 from EPEC E2348/69 
This study 
pRK5-MapΔN44 
Derivative of pRK5 encoding Myc-tagged 
MapΔN44 from EPEC E2348/69 
This study 
pRK5-NleH1 
Derivative of pRK5 encoding Myc-tagged NleH1 
from EPEC E2348/69 
K.S. Robinson 
pRK5-NleH1ΔC4 
Derivative of pRK5 encoding Myc-tagged 
NleH1ΔC4 from EPEC E2348/69 
K.S. Robinson 
pRK5-HN-Tir 
Derivative of pRK5 encoding Myc-tagged HN-Tir 
from EHEC EDL933 
This study 
pRK5-HN-TirΔNt 
Derivative of pRK5 encoding Myc-tagged HN-Tir 
from EHEC EDL933 
This study 
KS-pCV6-ezrin 
Derivative of KS-pCV6 encoding VSVG-tagged 
ezrin 
(Algrain et al., 1993) 
KS-pCV6-ezrinΔNt 
Derivative of KS-pCV6 encoding VSVG-tagged 
ezrinΔNt 
(Algrain et al., 1993) 
pEGFP-C2 C-terminal GFP-tag expression vector Clontech 
pEGFP-C2-EspI 
Derivative of pGFP-C2 encoding EspI from 
EPEC E2348/69 
Dr E. Hartland 
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pEGFP-C2-EspIΔC7 
Derivative of pGFP-C2 encoding EspIC7 from 
EPEC E2348/69 
Dr E. Hartland 
pSA10 pKK177-3 containing lacI 
(Schlosser-Silverman et 
al., 2000) 
pSA10-TirEPEC 
Derivative of pSA10 encoding Tir from EPEC 
E2348/69 
Dr C. Berger 
pSA10-TirEPEC P17-22A 
Derivative of pSA10 encoding Tir P17-22A from 
EPEC E2348/69 
Dr A. Mousnier 
pSA10-TirEPEC R521A 
Derivative of pSA10 encoding Tir R521A from 
EPEC E2348/69 
Dr A. Mousnier 
pSA10-TirEHEC 
Derivative of pSA10 encoding Tir from EHEC 
EDL933 
(Mousnier et al., 2008) 
pSA10-TirEHEC P17-22A 
Derivative of pSA10 encoding Tir P17-22A from 
EHEC EDL933 
Dr A. Mousnier 
pSA10-TirEHEC S436-7A 
Derivative of pSA10 encoding Tir S436-7A from 
EHEC EDL933 
Dr A. Mousnier 
pSA10-TirEHEC Y490A 
Derivative of pSA10 encoding Tir Y490A from 
EHEC EDL933 
Dr A. Mousnier 
pSA10-TirEHEC Y519A 
Derivative of pSA10 encoding Tir Y519A from 
EHEC EDL933 
Dr A. Mousnier 
pSA10-TirEHEC Y529A 
Derivative of pSA10 encoding Tir Y529A from 
EHEC EDL933 
Dr A. Mousnier 
pSA10-TirEHEC Y458A 
R529A 
Derivative of pSA10 encoding Tir Y458A R529A 
from EHEC EDL933 
Dr A. Mousnier 
pSA10-TirEHECY458A 
Derivative of pSA10 encoding Tir Y458A from 
EHEC EDL933 
(Mousnier et al., 2008) 
pSA10-Map 
Derivative of pSA10 encoding Map from EPEC 
E2348/69 
(Simpson et al., 2006) 
pSA10-Map∆C3 
Derivative of pSA10 encoding Map∆C3 from 
EPEC E2348/69 
(Simpson et al., 2006) 
pSA10-EspI 
Derivative of pSA10 encoding EspI from EPEC 
E2348/69 
This study 
pSA10-EspI∆C7 
Derivative of pSA10 encoding EspI∆C7 from 
EPEC E2348/69 
This study 
pSA10-NleH1 
Derivative of pSA10 encoding NleH1 from EPEC 
E2348/69 
(Hemrajani et al., 2010) 
pSA10-NleH1ΔC4 
Derivative of pSA10 encoding NleH1∆C4 from 
EPEC E2348/69 
Dr C. Hemrajani 
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pET28a His6-tag expression vector Novagen 
pET28a-NHERF1 Derivative of pET28a encoding His6-NHERF1 (Simpson et al., 2006) 
pET28a-NHERF2 Derivative of pET28a encoding His6-NHERF2 This study 
pET28a-EspI Derivative of pET28a encoding His6-EspI This study 
pMalc2X MBP-tag expression vector New England Biolabs 
pMalc2X-Map Derivative of pMalc2X encoding MBP-Map This study 
pMalc2X-N1-PDZ1 
Derivative of pMalc2X encoding MBP-PDZ1 of 
NHERF1 
This study 
pMalc2X-N1-PDZ2 
Derivative of pMalc2X encoding MBP-PDZ2 of 
NHERF1 
This study 
pMalc2X-N1-EBD 
Derivative of pMalc2X encoding MBP-EBD of 
NHERF1 
This study 
pMalc2X-N2-PDZ1 
Derivative of pMalc2X encoding MBP-PDZ1 of 
NHERF2 
This study 
pMalc2X-N2-PDZ2 
Derivative of pMalc2X encoding MBP-PDZ2 of 
NHERF2 
This study 
pMalc2X-N2-EBD 
Derivative of pMalc2X encoding MBP-EBD of 
NHERF2 
This study 
pGEX-KG GST-tag expression vector GE Healthcare 
pGEX-3X GST-tag expression vector GE Healthcare 
pGEX-KG-NleH1 Derivative of pGEX-KG encoding GST-NleH1 K.S. Robinson 
pGEX-KG-
NleH1C150 
Derivative of pGEX-KG encoding GST-
NleH1C150 
K.S. Robinson 
pGEX-3X-MapC50 Derivative of pGEX-3X encoding GST-MapC50 Dr E. Hartland 
pGEX-3X-EspIC50 Derivative of pGEX-3X encoding GST-EspIC50 (Lee et al., 2008) 
 
192 
 
Appendix 3 
Name Sequence (restriction sites in bold) 
NHERF2-Fw 5’-CTTAAAGCTAGCATGGCCGCGCCGGAG-3’ 
NHERF2-Rv 5’-GGGTTTGAATTCTCAGAAGTTGCTGAAG-3’ 
NHERF2-Fw2 5’-CGGGATCCGCCGCGCCGGAGCCGC-3’ 
NHERF2-Rv2 5’-CCCAAGCTTTCAGAAGTTGCTGAAGATTTC-3’ 
NHERF2dEBD-
Rv 
5’- CCCAAGCTTTCAGGCCGCCGTGGGGCTC-3’ 
N1PDZ1-Fw 5’-GAGTCTAGACTCTGCTGCCTGGAGAAGGGTC-3’ 
N1PDZ1-Rv 5’-CCCCAAGCTTTCACTCGGGGTCGACCACCAGCAGGCGCACGGC-
3’ 
N1PDZ2-Fw 5’-GAGTCTAGACGGCTCTGTACCATGAAGAAGGGC-3’ 
N1PDZ2-Rv 5’-CCCCAAGCTTTCATTCCCTGTCCACCACCAGCAGCTTGGTCTC-3’ 
N1EBD-Fw 5’-GAGTCTAGAACTGACGAGTTCTTCAAGAAATG-3’ 
N1EBD-Rv 5’-CCCCAAGCTTTCAGAGGTTGCTGAAGAGTTCGTTTTTC-3’ 
N2PDZ1-Fw 5’-CCGGAATTCCTGTGCCGCTTGGTGCGCG-3’ 
N2PDZ1-Rv 5’-ATTTCTGCAGTCACTGGTCCACCACCAGCAGCCGAG-3’ 
N2PDZ2-Fw 5’-CCGGAATTCCGGCTCTGCCACCTGCGAAAG-3’ 
N2PDZ2-Rv 5’-ATTTCTGCAGTCAGGGGTCCACGACCAGCAGCCGGG-3’ 
N2EBD-Fw 5’-CGGAATTCGAGACAGATGAACACTTCAAGCGGCTTC-3’ 
N2EBD-Rv 5’-GTTAAACTGCAGTCAGAAGTTGCTGAAGATTTC-3’ 
Tir-Fw 5’-GCGGGATCCCCTATTGGTAATCTTGGTCATAATC-3’ 
Tir∆Nt-Fw 5’ GCGGGATCCTCAACTTCCAGCCTTCGTTCAGATCC-3’ 
Tir-Rv 5’-CGCGGATCCTTAGACGAAACGATGCGATCCCGG-3’ 
Map-Fw1 5’-TTTGAATTCGGAGCAAATGTTTAGTCCAACGGCAAT -3’ 
Map-Fw2 5’-TTTGAATTCGGAGCAATGTTTAGTCCAACGGCAAT -3’ 
Map-Rv 5’-CCAATGCATTGGTTCTGCAGCTACAGCCGAGTATCCTGCA-3’ 
MapΔC3-Fw 5’-TAGCTGCAGAAGCTTGGCCG-3’ 
MapΔC3-Rv 5’-ATCCTGCACATTGTCTGCAATC-3’ 
MapΔN44-Fw 5’-TCGAACCTTATGATTAATCATGG-3’ 
MapΔN44-Rv 5’-TTGCTCCGAATTCGCGACC-3’ 
EspI-Fw1 5’-GGAATTCATGAACATTCAACCGATCGTAACATCCGG-3’ 
EspI-Fw2 5’-GGGGATCCAACATTCAACCGATCGTAACATCC-3’ 
EspI-Fw3 5’-CGGAATTCATGAACATTCAACCGATCG-3’ 
EspI-Rv1 5’-AGGGCCCGGGTTAGACTCTTGTTTCTTGGATTATATCAACGG-3’ 
EspI-Rv2 5’-CGGAATTCTTAGACTCTTGTTTCTTGGATTATATC-3’ 
EspI-Rv3 5’-CGGGATCCTTAGACTCTTGTTTCTTGG-3’ 
EspIΔC7-Rv1 5’-AGGGCCCGGGTTAATCAACGGTATCAACATAATTTGATGG-3’ 
EspIΔC7-Rv3 5’- CGGGATCCTTAATCAACGGTATCAACATAATTTGATGG-3’ 
NleH1-Fw1 5’-GCGGATCCGCGCTATCACCATCTTCTGTAAATTTG-3’ 
NleH1-Rv1 5’-GCGAAGCTTCTAAATTTTACTTAATACCACAC-3’ 
NleH1ΔC4-Rv 5’-CTGCAGTTTCGACTATACCACACTAATAAGATCTTG-3’ 
NleH1-Fw2 5’-GACTCCATGGGTCTATCACCATCTTCTGTAAATTTG-3’ 
NleH1c150-Fw 5’-GACTCCATGGGTTATGTTATTGGCAAAGGGGGTA-3’ 
NleH1-Rv2 5’-GCGAAGCTTCTAAATTTTACTTAATACCACAC-3’ 
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Appendix 4 
Antibody* Dilution Source 
 Western 
blot 
ELISA Cyto 
immunostaining 
Histo 
immunostaining 
 
R α-NHERF1 1/5000  1/50 1/50 AbCam 
R α-NHERF2 1/5000  1/100 1/50 This study 
M α-His 1/3000 1/5000   Novagen 
M α-GM130   1/200  BD Biosciences 
R α-EspI 1/2000  1/200  Dr E. Hartland 
M α-Map 1/2000 1/5000   (Simpson et al., 
2006) 
R α-NleH 1/3000    Dr C. Hemrajani 
M α-HA   1/200  Invitrogen 
R α-HA 1/2000  1/200  Sigma 
M α-Myc   1/200  Upstate 
R α-Myc 1/2000  1/200  Millipore 
R α-O127   1/1000  VLA 
G α-O157   1/500  Fitzgerald Industries 
International 
C α-intimin β    1/50 Dr Fairbrother 
M α -HA HRP 1/1000    Roche 
M α- β-tubulin 1/1000  1/200  DHSB 
R α-VSVG   1/200  Sigma 
R α-GST 1/2000    Invitrogen 
R α-cleaved 
caspase-3 
  1/100  Cell Signalling 
Technology 
D α-M Cy2, 
Cy3, Cy5 
  1/200 1/200 Jackson laboratories 
D α-R 
AMCA, Cy2, 
Cy3, Cy5 
  1/200 1/200 Jackson laboratories 
D α-M HRP 1/5000 1/5000   Dako 
D α-R HRP 1/5000    Dako 
* R= rabbit, M= mouse, D= donkey, C= chicken, HRP= horse radish peroxydase, HA= 
hemagglutinin 
194 
 
Appendix 5 
 
Position PDZ domain Position PDZ domain Position PDZ domain Position PDZ domain 
A1 MAGI-1 PDZ1 C1 INADL PDZ6 E1 RHOPHILIN-2 G1 PDZK1 PDZ4 
A2 MAGI-1 PDZ2 C2 SAP97 PDZ1+2 E2 
HARMONIN 
PDZ1 
G2 PDZK2 PDZ1 
A3 MAGI-1 PDZ3 C3 SAP97 PDZ3 E3 
HARMONIN 
PDZ2 
G3 PDZK2 PDZ2 
A4 
MAGI-1 
PDZ4+5 
C4 SAP102 PDZ1+2 E4 NEURABIN PDZ G4 PDZK2 PDZ3 
A5 MAGI-2 PDZ1 C5 SAP102 PDZ3 E5 
SPINOPHILIN 
PDZ 
G5 PDZK2 PDZ4 
A6 MAGI-2 PDZ2 C6 
CHAP110 
PDZ1+2 
E6 α1 SYNTROPHIN G6 LNX1 PDZ1 
A7 MAGI-2 PDZ3 C7 CHAP110 PDZ3 E7 β1 SYNTROPHIN G7 LNX1 PDZ2 
A8 MAGI-2 PDZ4 C8 E6TP1 PDZ E8 β2 SYNTROPHIN G8 LNX1 PDZ3 
A9 MAGI-2 PDZ5 C9 ERBIN PDZ E9 γ1 SYNTROPHIN G9 LNX1 PDZ4 
A10 MAGI-3 PDZ1 C10 ZO-1 PDZ1 E10 γ2 SYNTROPHIN G10 LNX2 PDZ1 
A11 MAGI-3 PDZ2 C11 ZO-1 PDZ2 E11 PAPIN1 G11 LNX2 PDZ2 
A12 MAGI-3 PDZ3 C12 ZO-1 PDZ3 E12 MUPP1 PDZ1 G12 LNX2 PDZ4 
B1 MAGI-3 PDZ4 D1 ZO-2 PDZ1 F1 MUPP1 PDZ6 H1 PTPN4 PDZ 
B2 MAGI-3 PDZ5 D2 ZO-2 PDZ2 F2 MUPP1 PDZ7 H2 
RHO-GEF 
PDZ 
B3 NHERF1 PDZ1 D3 ZO-2 PDZ3 F3 MUPP1 PDZ8 H3 RA-GEF PDZ 
B4 NHERF1 PDZ2 D4 ZO-3 PDZ1 F4 MUPP1 PDZ10 H4 ENIGMA PDZ 
B5 NHERF2 PDZ1 D5 ZO-3 PDZ2 F5 MUPP1 PDZ12 H5 LARG PDZ 
B6 NHERF2 PDZ2 D6 ZO-3 PDZ3 F6 MUPP1 PDZ13 H6 MAST205 PDZ 
B7 
PSD-95 
PDZ1+2 
D7 C2PA PDZ F7 PTPN13 PDZ1 H7 PTPN3 PDZ 
B8 PSD-95 PDZ3 D8 GIPC PDZ F8 PTPN13 PDZ3 H8 SHANK1 PDZ 
B9 PDZ-GEF1 PDZ D9 MALS1 PDZ F9 PTPN13 PDZ4+5 H9 
TAMALIN 
PDZ 
B10 CAL PDZ D10 MALS3 PDZ F10 PDZK1 PDZ1 H10 PAR-3 PDZ1 
B11 nNOS PDZ D11 DENSIN-180 F11 PDZK1 PDZ2 H11 PAR-3 PDZ2 
B12 INADL PDZ5 D12 RHOPHILIN-1 F12 PDZK1 PDZ3 H12 PAR-3 PDZ3 
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Appendix 6 
Binding to Na(+) /H(+) exchanger regulatory factor 2 (NHERF2) affects trafficking and 
function of the enteropathogenic Escherichia coli type III secretion system effectors Map, 
EspI and NleH. 
Martinez E, Schroeder GN, Berger CN, Lee SF, Robinson KS, Badea L, Simpson N, Hall RA, 
Hartland EL, Crepin VF, Frankel G. 
Cellular Microbiology, 2010 Jul 6 
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(NHERF2) affects trafficking and function of the
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Summary
Enteropathogenic Escherichia coli (EPEC) strains
are diarrhoeal pathogens that use a type III secre-
tion system to translocate effector proteins into
host cells in order to colonize and multiply in the
human gut. Map, EspI and NleH1 are conserved
EPEC effectors that possess a C-terminal class I
PSD-95/Disc Large/ZO-1 (PDZ)-binding motif. Using
a PDZ array screen we identified Na+/H+ exchanger
regulatory factor 2 (NHERF2), a scaffold protein
involved in tethering and recycling ion channels in
polarized epithelia that contains two PDZ domains,
as a common target of Map, EspI and NleH1. Using
recombinant proteins and co-immunoprecipitation
we confirmed that NHERF2 binds each of the effec-
tors. We generated a HeLa cell line stably express-
ing HA-tagged NHERF2 and found that Map, EspI
and NleH1 colocalize and interact with intracellular
NHERF2 via their C-terminal PDZ-binding motif.
Overexpression of NHERF2 enhanced the forma-
tion and persistence of Map-induced filopodia,
accelerated the trafficking of EspI to the Golgi and
diminished the anti-apoptotic activity of NleH1. The
binding of multiple T3SS effectors to a single
scaffold protein is unique. Our data suggest that
NHERF2 may act as a plasma membrane sorting
site, providing a novel regulatory mechanism to
control the intracellular spatial and temporal effec-
tor protein activity.
Introduction
Enteropathogenic Escherichia coli (EPEC) strains are
Gram-negative pathogenic bacteria frequently associated
with infantile diarrhoea in non-industrial countries (Chen
and Frankel, 2005; Croxen and Finlay, 2010). During the
course of infection, EPEC adheres intimately to the
surface of enterocytes and provokes microvillus efface-
ment, leading to the formation of characteristic attaching
and effacing (A/E) lesions (Knutton et al., 1987). The
ability to form A/E lesions is associated with the LEE
pathogenicity island (McDaniel et al., 1995), which
encodes gene regulators, the adhesin intimin, a type III
secretion system (T3SS), chaperones and effector pro-
teins (Garmendia et al., 2005). In addition, EPEC strains
express a diverse number of non-LEE-encoded effectors
(Iguchi et al., 2009).
Following translocation, the effector proteins are tar-
geted to different cellular compartments and subvert
numerous cellular processes to sustain colonization and
multiplication (Garmendia et al., 2005). Map, EspI (also
known as NleA) and NleH1 are conserved effectors and
major EPEC virulence factors (Simpson et al., 2006;
Hemrajani et al., 2008; Lee et al., 2008). NleH1 inhibits
NF-kB-dependent transcription through an N-terminal
interaction with ribosomal protein S3 (RPS3) (Gao et al.,
2009) and prevents apoptosis through a C-terminal inter-
action with Bax inhibitor-1 (Hemrajani et al., 2010). EspI is
targeted to the Golgi apparatus where it interacts with the
Sec23/24 complex and inhibits COPII-mediated vesicular
transport between the endoplasmic reticulum and the
Golgi apparatus (Kim et al., 2007; Lee et al., 2008). As a
result, EspI contributes to the disruption of cellular tight
junctions (Thanabalasuriar et al., 2010). Map is targeted
to the mitochondria via an N-terminal mitochondrial
targeting sequence where it disrupts the mitochondrial
Received 18 May, 2010; revised 22 June, 2010; accepted 28 June,
2010. *For correspondence. E-mail g.frankel@imperial.ac.uk; Tel.
+44 20 7594 5253; Fax +44 20 7594 3069.
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cellular microbiology
membrane potential (Kenny and Jepson, 2000;
Papatheodorou et al., 2006). At early time points Map
induces formation of transient filopodia at the bacterial
attachment sites (Kenny and Jepson, 2000) via its
guanine exchange factor (GEF) activity for the Rho-
GTPase Cdc42 (Huang et al., 2009). Moreover, via its
C-terminus, which comprises a class I PSD-95/Disc
Large/ZO-1 (PDZ)-binding motif (TRL), Map binds PDZ 1
of Na+/H+ exchanger regulatory factor 1 (NHERF1) (Alto
et al., 2006; Simpson et al., 2006). PDZ domains are
protein–protein recognition domains of about 90 amino
acids, which are widely represented in the human
genome (Tonikian et al., 2008). PDZ-binding motifs com-
prise a consensus S/T-X-F sequence (where X is any
amino acid and F is any hydrophobic residues (Songyang
et al., 1997). Importantly, PDZ binding motifs are also
found at the C-termini of NleH1 and EspI (SKI and TRV
respectively). Whereas no mammalian partner was thus
far associated with the PDZ-binding motif of NleH1, a
previous report demonstrated that EspI binds a number of
PDZ-containing proteins, including NHERF1 and
NHERF2 (Lee et al., 2008).
NHERF proteins (NHERF1 to 4) are present in abun-
dance in the mammalian small intestine and colon (Donow-
itz et al., 2005) where they have a central role in trafficking,
membrane retention, dimerization and regulation of ion
channels and membrane proteins (Shenolikar and
Weinman, 2001; Shenolikar et al., 2004). NHERF1 and 2
are closely related (51% amino acid identity) and the only
members in the NHERF protein family which possess two
PDZ domains and a C-terminal ezrin/radixin/moesin
(ERM) binding domain (EBD) (Reczek et al., 1997; Yun
et al., 1998). The EBD domain links NHERF1 and 2 to the
actin cytoskeleton thereby forming a scaffold for highly
organized multimeric signalling complexes (reviewed in
Lamprecht and Seidler, 2006). More than 30 binding part-
ners have been reported for NHERF1 and 2 (Shenolikar
et al., 2004), some are shared by more than one NHERF
isoform (Yun et al., 1998; Sun et al., 2000), while others
are NHERF isoform-specific (Shenolikar et al., 2004).
In this paper we report the binding of three T3SS effec-
tor proteins (Map, EspI and NleH1) to a single eukaryotic
target (NHERF2). We show that NHERF2 influences the
trafficking and function of EspI, Map and NleH1, suggest-
ing that it functions as a distribution hub at the plasma
membrane.
Results
Map, EspI and NleH1 bind NHERF2
Previous reports have demonstrated that Map interacts
with NHERF1 (Alto et al., 2006; Simpson et al., 2006),
and a global PDZ array screen indicated that EspI might
bind NHERF1 and NHERF2 (Lee et al., 2008). In this
study we screened target proteins, which are recognized
by the PDZ-motifs of Map and NleH1 using the PDZ
array. Overlaying a fusion consisting of the last 50 amino
acids of Map and GST (GST-MapC50) on the PDZ-
domain array confirmed that Map binds PDZ1 of
NHERF1 (Fig. 1A). In addition, we found that Map inter-
acted with PDZ2 of NHERF1 and both PDZ domains of
NHERF2 (Fig. 1A). NHERF2 was also identified as inter-
action partner of Map by a yeast two-hybrid screen
using full-length Map as bait and HeLa cDNA library as
a prey (data not shown). Overlaying a fusion consisting
of the last 150 amino acids of NleH1 and GST (GST-
NleH1C150) (a GST-NleH1C50 fusion was unstable) on
the PDZ-domain protein array revealed that NleH1
bound PDZ2 of NHERF2, although this interaction
appeared weaker than either Map:NHERF2 or EspI:N-
HERF2 (Fig. 1A) (Lee et al., 2008).
In order to confirm and characterize the interaction of
Map, EspI and NleH1 with NHERF2, we constructed and
purified His-NHERF2 and MBP fusions of NHERF2 PDZ1,
PDZ2 and EBD, which were immobilized on a membrane
and overlaid with purified MBP-Map, His-EspI and GST-
NleH1. Detection of bound proteins with effector-specific
antiserum revealed that Map, EspI and NleH1 interacted
with full-length NHERF2 (Fig. 1B). Map and EspI, but not
NleH1, also bound the purified PDZ2 domain of NHERF2
(Fig. 1B). Although Map interacted with PDZ1 of NHERF2
on the PDZ array, neither Map nor EspI bound the purified
PDZ1 or EBD domains (Fig. 1B). These results show that
despite some differences between binding to the arrayed
and fusion proteins, NHERF2 is targeted by Map, EspI and
NleH1.
In a reciprocal experiment full-length Map, EspI and
NleH1 were overlaid with His-NHERF2, which confirmed
the interactions (Fig. 1C, D and E). This binding was
dependent on the PDZ-binding motifs of Map and EspI as
NHERF2 did not bind the C-terminally truncated effectors
MapDC3 (Fig. 1C) or EspIDC7 (Fig. 1D). Unfortunately,
due to protein instability of NleH1DC4, the role of the PDZ
binding motif of recombinant NleH1 in binding NHERF2
could not be investigated.
NHERF2 co-immunoprecipitates EspI and NleH1 and
colocalizes with Map, EspI and NleH1
Once we confirmed the interaction between NHERF2
and Map, EspI and NleH1 using recombinant proteins,
we aimed to confirm the interaction by coimmunoprecipi-
tation. Towards this end we generated a stable HeLa
cell line constitutively expressing HA-tagged NHERF2
(HeLa–NHERF2). Immunofluorescence microscopy
using anti-HA antibodies revealed that NHERF2 local-
ized mainly at the plasma membrane (data not shown),
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in a pattern similar to that reported in un-polarized epi-
thelial cells like A431 or HT1080 cells, which express
NHERF2 endogenously (Theisen et al., 2007). The
HeLa–NHERF2 cells were infected for 1 h with EPEC
Dmap and EPEC Dmap expressing full-length Map or
MapDC3; EPEC DespI and EPEC DespI expressing full-
length EspI or EspIDC7; and EPEC DnleH and EPEC
DnleH expressing full-length NleH1 or NleH1DC4. We
were unable to co-immunoprecipitate NHERF2 and full-
length Map or MapDC3 (data not shown). Probing
infected cell extracts with anti-EspI and anti NleH1
revealed that while both full-length EspI and EspIDC7
were found in equal amounts, NleH1DC4 was unstable
(Fig. 2A and B). Following cell lysis the supernatants
were subjected to co-immunoprecipitation with anti-HA
antibodies. While NHERF2 did not co-immunoprecipitate
EspIDC7 (Fig. 2A) and NleH1DC4 (Fig. 2B), both full-
length EspI (Fig. 2A) and NleH1 (Fig. 2B) were
co-immunoprecipitated.
In order to determine if the effectors colocalize with
NHERF2, HeLa–NHERF2 cells were transfected with
pRK5 (Fig. 3) or pRK5 expressing myc-tagged Map,
MapDC3, NleH1 and NleH1DC4 as well as pGFP-EspI
and pGFP-EspIDC7. Analysing the transfected cells by
immunofluorescence revealed that Map colocalized with
mitochondria (Fig. S1) and NHERF2 (Fig. 3). Plasma
membrane-associated EspI and NleH1 colocalized
with NHERF2 (Fig. 3). We observed no colocalization
of NHERF2 and MapDC3, EspIDC7 or NleH1DC4
(Fig. S2).
Fig. 1. A. PDZ-domain protein arrays were overlaid with purified GST-MapC50, GST-NleH1C150 or GST followed by detection with anti-GST
antibodies. MapC50 interacts with PDZ1 and 2 domains of NHERF1 and NHERF2 whereas NleH1C150 interacts only with the PDZ2 domain
of NHERF2.
B. Purified His-NHERF2, MBP-PDZ1, MBP-PDZ2, MBP-EBD and MBP were transferred onto PVDF membrane and overlaid with purified
MBP-Map followed by detection with anti-Map, His-EspI followed by detection with anti-EspI or GST-NleH1 followed by detection with
anti-NleH. Equivalent protein loading was confirmed by Coomassie staining. Map, EspI and NleH1 interact with His-NHERF2, but only Map
and EspI interacted with MBP-PDZ2 (black arrows).
C and D. Bacterial extracts of EPEC Dmap overexpressing Map and MapDC3 (C) or EPEC DespI overexpressing EspI and EspIDC7 (D) were
transferred onto PVDF membrane and overlaid with purified His-NHERF2 followed by detection with anti-NHERF2 or immunoblotted with an
anti-Map or anti-EspI antibody. NHERF2 was able to interact with Map and EspI but not MapDC3 or EspIDC7.
E. Purified His-NHERF2, GST, GST-NleH1 and His-EspI were transferred onto PVDF membrane and overlaid with purified His-NHERF2
followed by detection with anti-NHERF2 or immunoblotted with anti-GST. NHERF2 interacted with His-EspI and GST-NleH1 (black arrow).
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Fig. 2. A. HA-NHERF2 was immunoprecipitated with anti-HA from HeLa–NHERF2 cells infected for 1 h with the indicated EPEC strains.
Equivalent protein loading was confirmed by anti-NHERF2 Western blots. Anti-EspI Western blot reveals equivalent levels of EspI and
EspIDC7 in the whole-cell extract and the presence of EspI, but not EspIDC7, in HA-NHERF2 immunoprecipitated sample.
B. HA-NHERF2 was immunoprecipitated with anti-HA from HeLa–NHERF2 cells infected for 1 h with the indicated EPEC strains. Equivalent
loading of proteins was monitored by anti-NHERF2 Western blots. Anti-NleH1 Western blot reveals presence of NleH1 in whole-cell extracts
(left panel), which was immunoprecipitated with HA-NHERF2 sample (right panel).
Fig. 3. Fluorescence microscopy of
HeLa–NHERF2 cells transfected with pRK5
(Mock), pRK5-map (Map), pEGFP-C2-espI
(EspI) and pRK5-nleH1 (NleH1). NHERF2
was detected with anti-HA (green) and
effectors Map and NleH1 were stained with
anti-myc (red). Green GFP signal was
converted to red for EspI. Map colocalizes
with NHERF2 (open arrows), while partial
colocalizations of EspI and NleH1 with
NHERF2 are observed at the plasma
membrane (plain arrows). Scale bar = 10 mm.
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NHERF2 modulates Map-induced filopodia dynamics
We investigated the effect of NHERF2 expression on
Map-induced filopodia. First, HeLa and HeLa–NHERF2
were transfected with pRK5 expressing myc-tagged
Map or MapDC3 and examined by scanning electron
microscopy. This revealed that ectopic expression of Map
resulted in filopodia formation in both cell lines, although
the length and complexity of filopodia were more promi-
nent on the HeLa–NHERF2 cells (Fig. 4A). Relatively
small and sporadic filopodia were observed in either cell
line ectopically expressing MapDC3 (Fig. 4A). Next HeLa
and HeLa–NHERF2 cells were infected with EPEC
wild-type and the dynamics of filopodia formation and
withdrawal was quantified by counting infected cells with
filopodia over time. This revealed that at each time point
more HeLa–NHERF2 cells with filopodia were observed
compared with HeLa cells (Fig. 4B).
To investigate whether persistence of filopodia was
due to the PDZ-mediated Map–NHERF2 interaction, the
number of cells with filopodia was quantified following
infection of HeLa and HeLa–NHERF2 cells with EPEC
Dmap expressing Map or MapDC3. Upon infection with
EPEC Dmap expressing full-length Map, the fraction of
infected HeLa–NHERF2 cells with filopodia was higher
and decreased much slower compared with infected
HeLa cells (Fig. 4C). This is consistent with the pheno-
type observed for infection with wild-type EPEC
(Fig. 4B). In contrast, no difference in numbers of cells
with filopodia or the kinetics of filopodia withdrawal was
found between HeLa–NHERF2 and HeLa cells infected
with EPEC Dmap expressing MapDC3 (Fig. 4C). These
results suggest that the expression of NHERF2 in HeLa
cells modulates Map-induced filopodia formation and
persistence, which is dependent on the PDZ-mediated
Map–NHERF2 interaction.
NHERF2 accelerates trafficking of EspI to the Golgi
During the early stages of EPEC infection, localization of
EspI shifts from the site of bacterial adhesion to the
Golgi apparatus, and this trafficking is enhanced by its
PDZ binding motif (Lee et al., 2008). In order to inves-
tigate the possible role of NHERF2 in trafficking of EspI
to the Golgi, HeLa and HeLa–NHERF2 cells were
infected for 15, 30, 60 and 90 min with EPEC DespI
expressing EspI. The number of infected cells with EspI
colocalizing with the Golgi protein GM130 was quantified
by immunofluorescence microscopy (Fig. 5A). At 15 and
30 min post infection, significantly more HeLa–NHERF2
cells showed EspI staining at the Golgi apparatus com-
pared with HeLa cells (Fig. 5A). To determine the impor-
tance of the EspI–NHERF2 interaction for trafficking of
the protein to the Golgi apparatus, HeLa–NHERF2 cells
were infected for 15, 30, 60 and 90 min with EPEC
DespI expressing EspI or EspIDC7 (Fig. 5A). Golgi
staining of EspIDC7 was significantly lower after 30
(Fig. 5A and B), 60 and 90 min post infection compared
with cells infected with EPEC DespI expressing EspI
(Fig. 5A).
Taken together, these results suggest that following
translocation EspI interacts with NHERF2 via its PDZ-
binding motif, which accelerates trafficking of EspI to the
Golgi apparatus.
NHERF2 antagonises the anti-apoptotic activity
of NleH1
NleH1 interacts with Bax inhibitor-1, which protects the
cell against various apoptotic stimuli (Hemrajani et al.,
2010; Robinson et al., 2010). We investigated the impact
of NHERF2 expression on the anti-apoptotic activity of
NleH1. Low translocation levels of NleH1DC4 prevented
an analysis of the importance of the PDZ-binding motif
during infection. To circumvent this, we ectopically
expressed NleH1 and NleH1DC4 in HeLa or HeLa
NHERF2 cells, which were treated with the pro-apoptotic
compound staurosporine (STS). The number of trans-
fected apoptotic cells, marked by caspase-3 activation or
nuclear condensation, was quantified by immunofluores-
cence counting. Significantly fewer HeLa cells trans-
fected with pRK5-NleH1 displayed caspase-3 activation
(Fig. 6A and B) or nuclear condensation (Fig. 6C) com-
pared with pRK5-transfected HeLa cells or cells trans-
fected with pRK5-NleH1DC4. Mock-transfected HeLa–
NHERF2 cells displayed a similar phenotype as normal
HeLa cells, showing that NHERF2 expression per se
neither promotes nor prevents STS-induced apoptosis
(Fig. 6B and C). Expression of NHERF2 did not influ-
ence the phenotype of cells expressing NleH1DC4.
However, the inhibition of caspase-3 cleavage (Fig. 6A
and B) and nuclear condensation (Fig. 6C) by NleH1
was significantly abolished in cells expressing
HA-NHERF2 compared with the HeLa cell control. Taken
together, these results show that even though the anti-
apoptotic activity of NleH1 depends on its PDZ-binding
motif, the interaction with NHERF2 is not the trigger for
its anti-apoptotic signalling. The data rather suggest that
NHERF2 counteracts the anti-apoptotic activity of
NleH1, possibly by direct competition for its PDZ binding
site or interference with its intracellular trafficking and
localization.
Discussion
NHERF proteins are known to orchestrate intracellular
protein trafficking, protein localization and cell signalling;
regulation of ion transporters being the best-studied
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example. NHERFs, which are modular proteins compris-
ing several protein–protein interaction domains, function
as scaffolds for the assembly of multiprotein complexes
at the plasma membrane. In particular, NHERFs are
involved in tethering plasma membrane localized trans-
porters such as NHE3, the apical form of the Na+/H+
exchanger and CFTR, a cAMP-regulated Cl-channel, to
the underlying actin cytoskeleton. NHERF1 and 2 bind the
Fig. 4. A. Scanning electron microscopy of Hela and HeLa–NHERF2 cells transfected with pRK5 (Mock), pRK5-map or pRK5-mapDC3.
Transfection of cells with pRK5-map induced filopodia in both cell lines; however, filopodia formed on HeLa–NHERF2 were longer and more
complex. Only sparse filopodia formation was observed upon transfection with pRK5-mapDC3. Scale bar = 10 mm.
B. Quantification of infected HeLa (black bars) and HeLa–NHERF2 (white bars) cells displaying filopodia following infection with wild-type
EPEC. Downregulation of filopodia is delayed in HeLa cells expressing HA-NHERF2. One hundred infected cells were counted in three
independent experiments. Results are shown as mean  SD. P-values of < 0.05 (*) were considered as significant.
C. Quantification of infected HeLa and HeLa–NHERF2 cells displaying filopodia following infection with EPEC Dmap overexpressing Map or
MapDC3. EPEC Dmap overexpressing Map, but not MapDC3, maintains filopodia over time in HeLa–NHERF2 cells compared with HeLa cells.
One hundred infected cells were counted in three independent experiments. Results are shown as mean  SD. P-values of < 0.05 (# for Map
versus MapDC3 in HeLa cells, § for Map versus MapDC3 in HeLa–NHERF2 cells) were considered as significant.
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transporters via their PDZ domains and actin-associated
ERM proteins via their C-terminal EBD (Brone and Egg-
ermont, 2005), thus linking the actin cytoskeleton to the
plasma membrane (Bretscher et al., 2000). The assign-
ment of individual functions to NHERF1 or 2 has proven to
be difficult due to high homology and widely overlapping
interactomes. Localization studies have shown that, in
polarized Caco-2 cells, NHERF1 is predominantly found
in the brush border (BB) whereas NHERF2 has some BB
localization but is mainly found in the inter-microvillar
clefts below the BB (Donowitz et al., 2005). The differen-
tial subcellular localization and tissue distribution of
NHERFs might determine functional specificity and
account for the observation from studies with knockout
mice that NHERF1–3 are not functionally redundant.
(Seidler et al., 2009). Despite their central position in
diverse signalling processes, the role of NHERF proteins
as versatile targets for bacterial effector proteins has not
been fully investigated.
Although fulfilling unrelated intracellular functions Map,
EspI and NleH1 share two common post-translocation
features, binding to NHERF2 and trafficking to an intrac-
ellular membranous compartment. Map is targeted to the
mitochondria (Kenny and Jepson, 2000), EspI to the Golgi
(Gruenheid et al., 2004) and NleH1 to the endoplasmic
reticulum (ER) (Hemrajani et al., 2010). A PDZ array
screen indicated that Map, EspI and NleH1 bind NHERF2.
Using recombinant Map, EspI and NleH1 and a stable
NHERF2 cell line revealed that all three effectors interact,
in a PDZ binding motif-dependent manner, with NHERF2.
Moreover, all three effectors colocalized with NHERF2
in HeLa–NHERF2 cells, and EspI and NleH1 were
co-immunoprecipitated with NHERF2 from infected cells.
Our efforts to co-immunoprecipitate Map and NHERF2
Fig. 5. A. Quantification of EspI Golgi
localization in HeLa and HeLa–NHERF2 cells
infected with EPEC DespI expressing EspI
or EspIDC7. Increased EspI localization at
the Golgi apparatus was observed in
HeLa–NHERF2 cells compared with HeLa
cells following 15 and 30 min of infection (*).
EspIDC7 shows reduced localization to the
Golgi compared with EspI in both cell lines
(# for HeLa cells, § for HeLa–NHERF2 cells).
Fifty infected cells were counted in three
independent experiments. Results are shown
as mean  SD. P-values of < 0.05 (* for HeLa
versus HeLa–NHERF2 in EPEC DespI
overexpressing EspI infected cells, # for EspI
versus EspIDC7 in HeLa cells and § for EspI
versus EspIDC7 in HeLa–NHERF2 cells) were
considered as significant.
B. Fluorescence microscopy of
HeLa–NHERF2 infected for 30 min with EPEC
DespI and EPEC DespI expressing EspI or
EspIDC7. EspI was stained with anti-EspI
(red), Golgi apparatus was stained with
anti-GM130 (green) and DNA was
counterstained with Hoechst 33342 (cyan).
EspI is detected at the bacterial attachment
sites (open arrows); however, Reduced
colocalization with the Golgi was observed for
cells infected with EPEC DespI expressing
EspIDC7 (plain arrows). Scale bar = 10 mm.
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were not successful. The fact that expression of NHERF2
in HeLa cells modulated the intracellular trafficking and/or
activity of all three effectors suggests that NHERF2 might
form a molecular hub at the plasma membrane from which
the effectors are distributed to their final destinations.
Map acts as a Rho-guanine nucleotide exchange factor
(GEF) for Cdc42 (Huang et al., 2009), but is unique in the
family of WxxxE motif proteins in possessing a PDZ-
binding motif at the C-terminus (Alto et al., 2006; Bulgin
et al., 2010). Approximately 37% of human and mouse
GEFs also possess a PDZ binding motif and there is
increasing evidence that PDZ-based interactions are
important for GEF function, and aid targeting of the GEF
to a subcellular location (Garcia-Mata and Burridge,
2007). Here removal of the C-terminal PDZ motif
abolished the interaction of Map with NHERF2 and led to
Fig. 6. A. Fluorescence microscopy of HeLa and HeLa–NHERF2 cells transfected with pRK5 or pRK5-nleH1 and treated for 4 h with 1 mM
STS. HA-NHERF2 was stained with anti-HA (red), NleH1 with anti-myc (green) and activated caspase-3 was detected with anti-cleaved
caspase-3 (white). Expression of NleH1 in HeLa cells inhibited activation of caspase-3 whereas expression of NleH1 in HeLa–NHERF2 cells
did not. Scale bar = 10 mm.
B and C. HeLa and HeLa–NHERF2 cells were transfected with pRK5 (black bars), pRK5-nleH1 (white bars) or pRK5-nleH1DC4 (grey bars)
before treated with 1 mM STS for 4 h. Capsase-3 activation and nuclear condensation in transfected cells were observed by
immunofluorescence microscopy using anti-myc, anti-cleaved caspase-3 (B) and Hoechst 33342 DNA staining (C). Immunofluorescence
analysis revealed that cells expressing HA-NHERF2 and NleH1 were more often positive for caspase-3 activation and nuclear condensation
than HeLa cells expressing NleH1. One hundred transfected cells were counted for activated caspase-3 or nuclear condensation in three
independent experiments. Results are shown as mean  SD. P-values of < 0.05 (*) were considered as significant.
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reduced filopodia formation and stability. Endogenous
GTPases are modified posttranscriptionally by the addi-
tion of a lipid moiety to the C-terminus (farnesyl, geranyl,
palmitoyl or methyl) (Roberts et al., 2008), which targets
them to different membranous compartments. We
suggest that the interaction of Map with the PDZ2 domain
of NHERF2 may transiently anchor Map at the apical
surface of an infected cell leading to filopodia formation
beneath adherent bacteria, before the effector is targeted
to the mitochondria.
EspI has been reported to inhibit COPII-dependent
vesicular transport between the ER and Golgi leading to
alterations in host cell protein secretion and tight junction
integrity (Kim et al., 2007; Thanabalasuriar et al., 2010).
EspI dynamics and trafficking upon translocation are still
poorly understood since the protein accumulates at the
Golgi apparatus and not at the ER, where COPII vesicles
are formed (Kim et al., 2007). Here we showed that the
interaction between EspI and NHERF2 is mediated
through the EspI C-terminal PDZ-binding motif, resulting in
an increased rate of trafficking of EspI to the Golgi. This
result is consistent with the potential role of NHERF2 in
recycling of endogenous membrane proteins (Donowitz
et al., 2005).
Recently, we found that NleH1 inhibits cell apoptosis
by interacting with Bax inhibitor-1 and decreasing acti-
vation of caspase-3, nuclear condensation and mito-
chondrial hyper permeabilization (Hemrajani et al., 2010;
Robinson et al., 2010). NleH1 also binds to ribosomal
protein 3 and reduces nuclear activity of NF-kB (Gao
et al., 2009). Similar to Map and EspI, we found that
NleH1 possesses a class I PDZ binding motif that regu-
lates its anti-apoptotic function. Although a recombinant
PDZ-binding motif mutant form of NleH1 could not be
purified because of protein instability, immunofluores-
cence of cells transfected with the PDZ motif mutant
demonstrated that the motif was critical to wild-type
function of NleH1 and its interaction with NHERF2.
However, the interaction with NHERF2 is not the trigger
for NleH1-mediated anti-apoptotic signalling; on the con-
trary, binding of NleH1 to NHERF2 inhibits anti-apoptotic
activity. This might represent a mechanism for the tem-
poral control of NleH1 anti-apoptotic function. In addi-
tion, NleH1-NHERF2 interaction might enable NleH1 in
general, or a fraction of the translocated protein, to
perform a secondary, yet unidentified, activity before or
in parallel to promoting cell survival.
The fact that three different T3SS effectors, which share
little sequence similarity and have distinct functions, bind
a single host cell scaffold protein is unprecedented. More-
over, while NleH1 binds NHERF2 only, EspI and Map bind
both NHERF1 and NHERF2. It is tempting to speculate
that EPEC and EHEC exploit endogenous BB-associated
NHERFs to regulate spatial and temporal intracellular traf-
ficking of Map, EspI and NleH1. Indeed, during infection of
mice with wild-type C. rodentium NHERF2 was exten-
sively recruited to the bacterial attachment sites (data not
shown).
T3SS effectors function in a co-ordinated manner. As
effectors from a single pathogen can complement or
antagonize each other, the timing and location of their
activity must be highly regulated. While timing of gene
expression and effector protein translocation provides a
regulatory mechanism at the bacterial level (Mills et al.,
2008), ubiquitination followed by proteasomal degrada-
tion (Kubori and Galan, 2003) and protein phosphoryla-
tion (Kenny, 1999) represent mechanisms, which are
exploited to control the activity of translocated effectors
within host cells. In this study we identified a novel regu-
latory mechanism by which recruitment of NHERFs to
the bacterial attachment site forms a distribution hub,
which is exploited for membrane retention (Map) or traf-
ficking (EspI). We propose that differential binding to
NHERF1 and/or NHERF2 and to their different PDZ
domains provides a mechanism to fine tune the activity
of the hub. We aim to exploit the C. rodentium model to
test this hypothesis in the context of host pathogen inter-
actions in vivo.
Experimental procedures
Bacterial strains and growth conditions
Escherichia coli strains used in this study are listed in Table 1.
Bacteria were cultured in Luria-Bertani (LB) medium or in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented
with ampicillin (100 mg ml-1) or kanamycin (50 mg ml-1) as
appropriate.
Plasmids
Plasmids and primers used in this study are listed in Tables 2 and
3. For cloning into the bacterial expression vector pSA10
(Schlosser-Silverman et al., 2000), espI, espIDC7 and nleH1DC4
were amplified from EPEC genomic DNA using primer pairs
EspI-Fw1 and EspI-Rv1, EspIDC7-Rv1 and NleH1-Fw1 and
NleH1DC4-Rv, respectively. For generation of (His)6-tagged pro-
teins, nherf2 was amplified from pBKCMV-HA-NHERF2 using
primers NHERF2-Fw and NHERF2-Rv and espI was amplified
from EPEC genomic DNA using primers EspI-Fw2 and EspI-Rv2;
both PCR products were cloned into pET28a(+) (Novagen). For
Table 1. List of strains.
Strain Description Origin
E2348/69 Wild-type EPEC O127:H6 Levine et al. (1978)
ICC202 E2348/69 Dmap Simpson et al. (2006)
ICC248 E2348/69 DespI Marches et al. (2008)
ICC303 E2348/69 DnleH1DnleH2
(named DnleH)
Hemrajani et al. (2010)
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Table 2. List of plasmids.
Description Origin
pBKCMV Mammalian expression vector Stratagene
pBKCMV-HA-NHERF2 pBKCMV encoding HA-tagged NHERF2 Dr R. Hall
pSA10 pKK177-3 containing lacI Schlosser-Silverman et al. (2000)
pRK5 N-terminal Myc-tag mammalian expression vector Clontech
pICC330 pSA10-map Simpson et al. (2006)
pICC331 pSA10-mapDC3 Simpson et al. (2006)
pICC507 pSA10-espI This study
pICC508 pSA10-espIDC7 This study
pICC443 pSA10-nleH1 Hemrajani et al. (2010)
pICC535 pSA10-nleH1DC4 This study
pICC509 pRK5-map, encoding myc-tagged Map This study
pICC510 pRK5-mapDC3, encoding myc-tagged MapDC3 This study
pICC512 pRK5-nleH1, encoding myc-tagged NleH1 This study
pICC513 pRK5-nleH1DC4, encoding myc-tagged NleH1DC4 This study
pEGFP-C2 Vector expressing fusions to the C-terminus of GFP Clontech
pGFP-EspI pEGFP-C2-espI encoding EspI This study
pGFP-EspI DC7 pEGFP-C2-espIDC7 encoding EspIDC7 This study
pET28a His6-tag expression vector Novagen
pICC332 pET28a-nherf1, encoding His6-NHERF1 Simpson et al. (2006)
pICC514 pET28a-nherf2, encoding His6-NHERF2 This study
pICC515 pET28a-espI, encoding His6-EspI This study
pMalc2X MBP-tag expression vector New England Biolabs
pICC516 pMalc2X-map, encoding MBP-Map This study
pICC517 pMalc2X-PDZ1, encoding MBP-PDZ1 of NHERF2 This study
pICC518 pMalc2X-PDZ2, encoding MBP-PDZ2 of NHERF2 This study
pICC519 pMalc2X-EBD, encoding MBP-EBD of NHERF2 This study
pGEX-KG GST-tag expression vector GE Healthcare
pGEX-3X GST-tag expression vector GE Healthcare
pICC520 pGEX-KG-nleH1, encoding GST-NleH1 This study
pICC521 pGEX-KG-nleH1C150, encoding GST-NleH1c150 This study
pGST-Map50 pGEX-3X-mapC50, encoding GST-MapC50 This study
Table 3. List of primers (restriction sites in
bold).Name Sequence
NHERF2-Fw 5′-CTTAAAGCTAGCATGGCCGCGCCGGAG-3′
NHERF2-Rv 5′-GGGTTTGAATTCTCAGAAGTTGCTGAAG-3′
PDZ1-Fw 5′-CCGGAATTCCTGTGCCGCTTGGTGCGCG-3′
PDZ1-Rv 5′-ATTTCTGCAGTCACTGGTCCACCACCAGCAGCCGAG-3′
PDZ2-Fw 5′-CCGGAATTCCGGCTCTGCCACCTGCGAAAG-3′
PDZ2-Rv 5′-ATTTCTGCAGTCAGGGGTCCACGACCAGCAGCCGGG-3′
EBD-Fw 5′-CGGAATTCGAGACAGATGAACACTTCAAGCGGCTTC-3′
EBD-Rv 5′-GTTAAACTGCAGTCAGAAGTTGCTGAAGATTTC-3′
Map-Fw1 5′-TTTGAATTCGGAGCAAATGTTTAGTCCAACGGCAAT -3′
Map-Fw2 5′-TTTGAATTCGGAGCAATGTTTAGTCCAACGGCAAT -3′
Map-Rv 5′-CCAATGCATTGGTTCTGCAGCTACAGCCGAGTATCCTGCA-3′
MapDC3-Fw 5′-TAGCTGCAGAAGCTTGGCCG-3′
MapDC3-Rv 5′-ATCCTGCACATTGTCTGCAATC-3′
MapC50-Fw 5′-GGATCCCCGATCCCATTACACGTTTTAAC-3′
MapC50-Rv 5′-GAATTCCTACAGCCGAGTATCCTGCAC-3′
EspI-Fw1 5′-GGAATTCATGAACATTCAACCGATCGTAACATCCGG-3′
EspI-Fw2 5′-GGGGATCCAACATTCAACCGATCGTAACATCC-3′
EspI-Fw3 5′-CGGAATTCATGAACATTCAACCGATCG-3′
EspI-Rv1 5′-AGGGCCCGGGTTAGACTCTTGTTTCTTGGATTATATCAACGG-3′
EspI-Rv2 5′-CGGAATTCTTAGACTCTTGTTTCTTGGATTATATC-3′
EspI-Rv3 5′-CGGGATCCTTAGACTCTTGTTTCTTGG-3′
EspIDC7-Rv1 5′-AGGGCCCGGGTTAATCAACGGTATCAACATAATTTGATGG-3′
EspIDC7-Rv3 5′-CGGGATCCTTAATCAACGGTATCAACATAATTTGATGG-3′
NleH1-Fw1 5′-GCGGATCCGCGCTATCACCATCTTCTGTAAATTTG-3′
NleH1-Rv1 5′-GCGAAGCTTCTAAATTTTACTTAATACCACAC-3′
NleH1DC4-Rv 5′-CTGCAGTTTCGACTATACCACACTAATAAGATCTTG-3′
NleH1-Fw2 5′-GACTCCATGGGTCTATCACCATCTTCTGTAAATTTG-3′
NleH1c150-Fw 5′-GACTCCATGGGTTATGTTATTGGCAAAGGGGGTA-3′
NleH1-Rv2 5′-GCGAAGCTTCTAAATTTTACTTAATACCACAC-3′
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generation of MBP fusion proteins, map was amplified from
pICC330 using primer pair Map-Fw2 and Map-Rv2, and PDZ1,
PDZ2 and the ezrin-binding domain (EBD) of NHERF2 were
PCR-amplified from pBKCMV-HA-NHERF2 using primer pairs
PDZ1-Fw and PDZ1-Rv, PDZ2-Fw and PDZ2-Rv, EBD-Fw and
EBD-Rv; all constructs were cloned into pMalc2X (New England
Biolabs). For generation of GST fusion proteins, nleH1 and
nleH1C150 (encoding the 150 C-terminal amino acids of NleH1)
were amplified from EPEC genomic DNA using primer pairs
NleH1-Fw2 or NleH1C150-Fw and NleH1-Rv2 respectively. Both
constructs were cloned into pGEX-KG. For mapC50, the region
encoding the 50 C-terminal amino acids of Map was amplified
from EPEC genomic DNA using primer pairs MapC50-Fw or
MapC50-Rv. The resulting fragment was cloned into the SmaI/
EcoRI sites of pGEX-3X. For transfection experiments, map,
nleH1 and nleH1DC4 were amplified from EPEC genomic DNA
using primer pairs Map-Fw1 and -Rv1, NleH1-Fw1 and NleH1-
Rv1 or NleH1DC4-Rv, respectively, and cloned into pRK5.
Plasmid pRK5-MapDC3 was generated by inverse PCR using
pRK5-Map as template. espI and espIDC7 were amplified from
EPEC genomic DNA using primer pairs EspI-Fw3 and EspI-Rv3
or EspIDC7-Rv3, respectively, and cloned into pGFP-C2. All con-
structs were verified by DNA sequencing.
Protein expression and purification
Genes cloned into pET28a, pMALc2X and pGEX vectors were
expressed in E. coli BL-21/DE3 star strain (Invitrogen) in pres-
ence of 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG) at
37°C as described previously (Crepin et al., 2005). His-tagged
proteins were purified using Ni2+ agarose His-Bind Resin Column
(Novagen), MBP-tagged proteins were purified on Amylose resin
(New England Biolabs) and GST-tagged proteins were purified
on glutathione-sepharose (GE Healthcare) using manufacturer’s
recommendations.
PDZ array screen
To assess the binding of the GST-MapC50 and NleH1C150
fusion proteins to the PDZ domain array, purified His-tagged PDZ
domain fusion proteins were spotted as previously described
(Fam et al., 2005; He et al., 2006) at 1 mg per bin onto Nytran
SuperCharge 96-grid nylon membranes (Schleicher & Schuell).
The membranes were allowed to dry overnight and then blocked
in ‘blot buffer’ (2% non-fat dry milk, 0.1% Tween-20, 50 mM NaCl,
10 mM Hepes, pH 7.4) for 30 min at room temperature. The
arrays were then overlaid with control GST, GST-MapC50 or
GST-NleH1C150 fusion proteins (100 nM in blot buffer) overnight
at 4°C. The overlaid arrays were washed three times for five
minutes each with 20 ml blot buffer, incubated with anti-GST
horseradish peroxidase (HRP)-conjugated antibody (Amersham,
1:4000) for 1 h at room temperature, washed again three times
for 5 min each with 20 ml blot buffer, and ultimately visualized via
chemiluminescence with the ECL kit from Pierce.
Yeast two-hybrid
Yeast two-hybrid screen using Map as prey and cDNA library as
bait was performed as described before (Simpson et al., 2006).
Western and far Western blot
Far Western blot was performed using 10 mg ml-1 of His-
NHERF2, His-EspI, MBP-Map or GST-NleH1 in Tris buffered
saline (TBS) 0.1% Tween20 with 1% skimmed milk followed by
Western blot detection as previously described (Simpson et al.,
2006). Western blots were performed following standard
methods using rabbit anti-NHERF2 (raised against purified
human His-NHERF2, Covalab), anti-EspI (Lee et al., 2008), anti-
NleH (raised against purified His-NleH1, Covalab), mouse anti-
Map (Immune Systems limited), anti-poly-Histidine (Sigma),
anti-GST (AbCam) and anti-HA HRP-conjugated (Roche) anti-
bodies. Goat anti-mouse and anti-rabbit IgG HRP conjugates
(Jackson laboratories) were used as secondary antibodies.
Transfection and generation of NHERF2 stable cell line
HeLa cells were routinely maintained in DMEM containing 10%
fetal calf serum (FCS) and 1 mM L-glutamine (Gibco) in a humidi-
fied atmosphere of 5% CO2 at 37°C. Transfection with pBKCMV,
pRK5 and pEGFP vectors and their derivatives was performed
using lipofectamin 2000 (Invitrogen) according to the manufac-
turer’s recommendations.
To generate the stable cell line, HeLa cells were grown to
confluence in 75-cm2 cell culture flasks and transfected with
pBKCMV-HA-NHERF2 using lipofectamin 2000 (Invitrogen) as
previously described (Oh et al., 2004). After 16 h, cells were
trypsinized and 2 ¥ 105 cells were sub-cultured in 100 mm Petri
dishes in DMEM media supplemented with 800 mg ml-1 geneticin
(Invitrogen). Cells were cultured for 10 days in the same Petri
dish with repeated change of media for selection of resistant
clones. Single clones were transferred to 96-well plates
(Nalgene) and grown to confluence. Clones were then trans-
ferred to 24-well plates and replicate 24-well plates containing
coverslips for expression analysis by immunofluorescence
microscopy. Positive clones were trypsinized, sub-cultured in
25 cm2 flasks and then stored at -80°C in DMEM supplemented
with 10% dimethylsulfoxide (DMSO). In this article, the stable cell
line is referred as HeLa–NHERF2.
Infection of HeLa cells
Cells were seeded onto glass coverslips 48 h prior to infection at
a 70% confluence and maintained in DMEM supplemented with
10% FCS at 37°C in 5% CO2. Three hours before infection, cells
were washed three times with PBS and the media replaced with
fresh DMEM without FCS. To prime bacteria for infection, DMEM
was inoculated with overnight cultures at a dilution of 1:50 of the
appropriate bacteria as previously described (Collington et al.,
1998). Recombinant protein expression was induced by addition
of 1 mM of IPTG 30 min prior to infection. Infections were carried
out at 37°C in 5% CO2 at a multiplicity of infection (MOI) of 100 for
each time point (15, 30, 60 or 90 min).
Co-Immunoprecipitation (Co-IP)
HeLa–NHERF2 cells were grown to confluence in 25 cm2 cell
culture flasks and infected for 1 h as described above. Cells were
washed 3 times with PBS and lysed in 500 ml of Co-IP buffer
[50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1% NP40, 0.5% sodium
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deoxycholate, 10% glycerol, protease inhibitors (Complete,
Roche)]. The lysate was transferred to a pre-chilled eppendorf
tube and centrifuged at 9200 g for 10 min at 4°C. The cleared
lysate was transferred to a fresh pre-chilled eppendorf tube con-
taining 15 ml of pre-equilibrated anti-HA agarose beads (Sigma)
and incubated on a spinning wheel for 2 h at 4°C. The suspension
was washed three times in Co-IP buffer followed by brief centrifu-
gation at 9200 g at 4°C after each wash. Bound proteins were
eluted using 80 ml of 100 mg ml-1 HA peptide (Sigma). Analysis of
the samples was performed by Western blot as described before.
Immunofluorescence staining and microscopy
Following infection or transfection, the coverslips were washed
three times in phosphate-buffered saline (PBS) and fixed with 3%
paraformaldehyde (PFA) for 20 min before being washed 3 more
times in PBS. The fixed cells were quenched for 20 min with PBS
50 mM NH4Cl, permeabilized for 4 min in PBS 0.25% Triton
X-100 and washed three times in PBS. The samples were
blocked for 1 h with PBS 5% bovine serum albumin (BSA) prior to
incubation with primary and secondary antibodies. The primary
mouse anti-HA (Covance) and anti-GM130 (BD transduction
laboratories) as well as rabbit anti-Myc (AbCam) and anti-cleaved
caspase-3 antibodies (Cell Signalling Technology) were used at a
dilution of 1:200. Rabbit anti-O127 (kindly provided by Dr Roberto
La Ragione, Veterinary Laboratory Agency, UK) was used at a
dilution of 1:500. The samples were incubated with the primary
antibody for 1 h, washed three times in PBS and incubated with
the secondary antibodies for 1 h. Donkey anti-rabbit IgG conju-
gated to a Cy3, Cy5 or AMCA fluorophore and donkey anti-
mouse IgG conjugated to Cy2, Cy3 or Cy5 fluorophores (Jackson
ImmunoResearch) were used at a 1:200 dilution. Mouse anti-Myc
FITC-conjugated antibody (Sigma) was used at a 1:100 dilution.
Actin was stained using Rhodamine phalloidin (Invitrogen) at a
1:500 dilution and DNA was stained using Hoechst 33342
(Molecular Probes). All dilutions were prepared in PBS containing
5% BSA. Following three washes in PBS, coverslips were
mounted on SuperFrost glass slides using Prolong Gold antifade
reagent (Invitrogen) and visualized with a Zeiss Axioimager
immunofluorescence microscope. All images were analysed
using the Axiovision Rel 4.5 software.
Apoptosis assay
For apoptosis studies, 1 mM staurosporine (STS) (Calbiochem)
was added to the media during 4 h and apoptotic cells (stained
either for nuclear condensation or caspase-3 activation) were
counted using immunofluorescence microscopy as described
(Hemrajani et al., 2010).
Scanning electron microscopy (SEM)
HeLa and HeLa–NHERF2 cells transfected with pRK5-Map or
pRK5-MapDC3 were washed three times with PBS and fixed with
3% glutaraldehyde in PBS. The samples were then washed with
PBS three times before being post fixed in 1% Osmium Tetroxide
for 1 h. Following three washes in PBS and 15 min dehydration in
graded ethanol solutions (50% to 100%), the samples were trans-
ferred to an Emitech K850 Critical Point drier and processed
according to the manufacturer’s instructions. The samples were
coated with gold/palladium using an Emitech Sc7620 minisputter
to a thickness of approximately 370 Å and examined at an
accelerating voltage of 20 kV using a Jeol JSM-6390 electronic
microscope.
Statistical analysis
Results are expressed as mean values  standard deviation. All
statistical tests were performed using the program Sigma Plot
version 11.0 using the parametric Student’s t-test. P < 0.05 was
considered as significant.
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Fig. S1. Fluorescence microscopy of HeLa–NHERF2 cells trans-
fected with pRK5 (Mock) and pRK5-map. Mitochondria were
detected with Mitotracker (red) and Map was detected with anti-
myc (green). Map colocalizes with the mitochondria. Scale
bar = 10 mm.
Fig. S2. Fluorescence microscopy of HeLa–NHERF2 cells trans-
fected with pRK5 (Mock), pRK5-mapDC3, pEGFP-C2-espIDC7
and pRK5-nleH1DC4. NHERF2 was detected with anti-HA
(green) and effectors Map and NleH1 were stained with anti-myc
(red). Green GFP signal was converted to red for EspI. Neither
effector colocalized with NHERF2. Scale bar = 10 mm.
Please note: Wiley-Blackwell are not responsible for the content
or functionality of any supporting materials supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
14 E. Martinez et al.
© 2010 Blackwell Publishing Ltd, Cellular Microbiology
